sartorius stedim biotech group reference document 2014 order intake sale revenue underlying ebitda margin1 million million 4426 4329 5002 4773 5539 5440 6149 5884 7221 6835 859 198 996 209 1170 215 1356 230 1605 235 financial schedule 800 200 26 analyst conference sfaf paris france march 5 2015 650 150 24 annual general shareholder meeting aubagne france april 7 2015 500 100 22 payment dividends1 april 14 2015 publication firstquarter figure 2015 april 20 2015 350 50 20 publication firsthalf figure 2015 july 22 2015 200 0 18 publication ninemonth figure 2015 october 20 2015 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 publication preliminary figure fiscal 2015 january 2016 order intake underlying ebitda million sale revenue underlying ebitda margin annual general shareholder meeting aubagne france april 5 2016 publication firstquarter figure 2016 april 2016 1 subject approval annual general shareholder meeting key figure figure given million according ifrs 2014 2013 2012 2011 2010 unless otherwise specified oder intake sale revenue earnings order intake 7221 6149 5539 5002 4426 contact sale revenue 6835 5884 5440 4773 4329 underlying ebitda 12 1605 1356 1170 996 859 petra kirchhoff andreas theisen underlying ebitda12 sale revenue 235 230 215 209 198 vice president director net profit noncontrolling interest 725 663 568 431 385 corporate communication ir investor relation underlying net profit 1 noncontrolling interest2 872 752 646 534 452 phone 495513081686 phone 495513081668 petrakirchhoffsartoriuscom andreastheisensartoriuscom research development cost 386 360 318 286 278 financial data per share earnings per share 472 432 370 281 239 earnings per share 34 568 490 421 349 281 dividend per share 1304 120 110 100 090 publication bilan published financial reporting system firesys balance sheet total 9068 8734 7939 7208 6563 sartorius stedim biotech sa michael konrad gmbh equity 5385 4818 4350 3956 3651 corporate communication frankfurt main germany equity ratio 594 552 548 549 556 c 91051 13781 aubagne cedex france photography financials peter ginter capital expenditure excluding financial asset goodwill 442 342 500 386 167 editorial deadline lohmar germany capital expenditure sale revenue 65 58 92 81 39 february 18 2015 depreciation amortization 356 306 259 245 230 net cash flow operating activity 1113 901 489 606 728 published net debt 874 1300 1137 1001 1028 february 27 2015 ratio net debt underlying ebitda 12 05 10 10 10 12 total number employee december 31 3697 32895 2986 2858 2581 1 adjusted extraordinary item 2 information ebitda net profit underlying presentation please refer group business development chapter glossary 3 excluding amortization defined ifrs 3 2011 2014 fair value adjustment hedging instrument 4 amount suggested board director conseil dadministration subject approval annual general shareholder meeting 5 excluding tap biosystems translation information key financial indicator please refer glossary original frenchlanguage document de référence 2014 mission sartorius stedim biotech leading provider cuttingedge equipment service devel opment quality assurance production process biopharmaceutical industry integrated solution covering fermentation filtration purifi cation fluid management lab technology supporting biopharmaceutical industry around world develop produce drug safely timely economically nextgeneration process sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement industry serf strongly rooted scientific community closely allied customer technology partner company dedicated philosophy turning science solution reference document 2014 present original french document de référence section document included translated reference document filed interest investor covered autorité de marchés financier another part reference document february 27 2015 accordance article 212 13 règlement général may used copy present reference document connection offering security obtained following supplemented prospectus note dopération autorité de marchés financier issued sartorius stedim biotech sa endorsement reference document zi le paluds avenue de jouques made issuer engages responsibility c 91051 13781 aubagne cedex signatory group website wwwsartoriusstedimcom autorité de marchés financier website reference document incorporates reference wwwamffranceorg preceding reference document 14 0094 filed 27 february 2014 13 0109 filed march 7 2013 following information included reference present reference document year 2013 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2013 management report appearing page 98 158 18 60 respectively reference document filed autorité de marchés financier 27 february 2014 number d14 0094 year 2012 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2012 management report appearing page 90 131 18 52 respectively reference document filed autorité de marchés financier march 7 2013 number d13 0109 01 shareholder 8 chairman message 10 executive committee 12 sartorius stedim biotech share 02 management report 18 structure management group 19 strategy goal 22 group business development 25 net worth financial position 30 sustainability report 43 table concordance 44 statutory auditor report sustainability report 46 opportunity risk report 54 forecast report 57 financial statement parent company sartorius stedim biotech sa december 31 2014 reference document contains statement concerning future performance sartorius stedim biotech sa statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original frenchlanguage reference document document de référence 2014 sartorius shall assume liability correctness translation original french reference document legally binding version furthermore sartorius stedim biotech sa reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use information provided including kind information incomplete incorrect therefore rejected throughout reference document difference may apparent result rounding addition content 03 corporate governance 05 annual financial statement sartorius stedim biotech sa note 70 board director committee 79 chairman report pursuant article 150 annual financial statement l 22537 french commercial code 163 statutory auditor report 91 remuneration executive financial statement nonexecutive member board 99 statutory auditor report prepared 100 accordance article l 225235 independent auditor fee 06 supplementary information 166 information legal nature 176 special report statutory auditor 04 consolidated financial related party agreement commitment statement note 177 resolution submitted annual combined shareholder meeting april 7 2015 103 statement proﬁt loss 181 information reference document comprehensive income annual financial report 104 statement financial position 184 code afep medef 105 statement cash flow 198 glossary 106 statement change equity 200 address 107 note financial statement 121 note statement proﬁt loss 124 note individual balance sheet item 146 disclosure 148 statutory auditor report consolidated financial statement shareholder chairman message dear shareholder pleased report 2014 yet another year year 2014 success also strategic excellent performance sartorius stedim standpoint key element total solution biotech group fourth year succession provider strategy continuously add new offering posted doubledigit topline growth sale portfolio product development slightly exceeded management guidance increasing alliance bolton acquisition therefore 159 constant currency business expanded across pleased report recently acquired entire portfolio driven strong business cell culture medium well tap small organic growth excellent development recent scale singleuse bioreactors developed well acquisition geographic perspective north sartorius stedim biotech umbrella even america led growth 2014 also somewhat ahead business plan believe recent acquisition especially positive effect proved ability smoothly share sale key north american integrate new company people market meanwhile surpassed 30 mark organization help extend global reach innovative product 2014 expanded also satisfied profit development portfolio adding singleuse product aseptic underlying ebitda slightly sampling acquired majority stake proportionally 18 mainly driven u startup allpure technology economy scale company underlying ebitda margin reached 235 expected fiscal 2014 also marked achievement continuous profitability expansion past year product development example took demonstrates strength consumablesdriven important step new generation bag business model strategy total solution meet industry demand full scalability provider whole see u well track increased standardization singleuse device achieve strategic 2020 growth target result international sale initiative defined three year ago deploying new strategy better penetrate account entire product portfolio also progressed strong profitable growth resulted significant multiyear investment program increase underlying earnings per share goettingen site combining two plant 16 reaching 568 based positive single site expanding production capacity result board director submit proposal well building demonstration application annual general shareholder meeting raise laboratory shanghai facility dividend yet 83 130 per share positive performance prospect also reflected development share price soared 324 2014 outperformed french stock market 2015 continue invest global success achieved 2014 show potential infrastructure capability keep behind company employee therefore growth company also continue special thanks go employee worldwide expand footprint north america asia creativity dedication constantly important pillar strategic growth initiative strive enhance business performance also addition strive outpace market appreciate continued support customer north america leverage market growth asia partner shareholder cordially invite continue u road success 2015 set ambitious target aiming increase sale revenue around 4 7 operational profit margin projected rise approximately 240 245 sincerely continued investment global infrastructure capacity result capex ratio range 6 8 based strong fundamental industry see excellent prospect business also medium long term biotech continuing outperform growing global pharma market joachim kreuzburg remaining innovation engine industry chairman board ceo biosimilars provide additional opportunity grow market health cost pressure mounting regulatory requirement increasing singleuse production technology beginning dominate major biomanufacturing step due lower production cost higher flexibility provide ssb one pioneer singleuse technology constantly strive make production process customer biopharma industry even reliable efficient executive committee joachim kreuzburg chairman board chief executive ofﬁcer head finance human resource compliance legal affair corporate communication hold doctorate economics university degree mechanical engineering joachim kreuzburg also ceo ssbs parent corporation sartorius ag chairman sartorius group executive committee oscarwerner reif executive vice president research development manages group global research development unit hold doctorate chemical engineering studied chemistry molecular biology germany usa oscarwerner reif also member sartorius group executive committee volker niebel executive vice president operation responsible production supply chain management business process management information technology hold university degree business administration economics volker niebel also belongs sartorius group executive committee reinhard vogt executive vice president marketing sale service charge marketing sale service hold vocational diploma industrial business administration reinhard vogt also member executive board sartorius ag member sartorius group executive committee 12 shareholder sartorius stedim biotech share sartorius stedim biotech share fact share 1 isin fr0000053266 liquidity provider gilbert dupont stock exchange euronext paris market segment local security compartment large cap index sbf 250 cac share cac mid small 190 cac small cac health care number share 15359238 thereof sartorius ag 743 thereof free float 257 voting right 26994873 thereof sartorius ag 846 thereof free float 154 1 december 31 2014 stock market characterized high volatility strong share price development reporting year stock market around world 2014 sartorius stedim biotech share price showed volatile performance whole performed better french stock market supported primarily expansive monetary whole close 12185 end 2013 policy ecb first half year share price rose 324 16130 end geopolitical tension worsening economic 2014 prospect fueled uncertainty course second half sbf 250 example reached share hit lowest closing price year time high 3522 point middle year 1170 january 13 2014 highest closing price june 10 2014 went 2986 point registered end reporting period october 16 2014 supported low interest december 22 2014 17165 environment ended year 3289 point represents overall gain 2014 08 shareholder sartorius stedim biotech share 13 sartorius stedim biotech share january 4 2010 december 31 2014 180 150 120 90 60 30 0 sartorius stedim biotech share 2010 2011 2012 2013 2014 sartorius stedim biotech share sartorius stedim biotech share comparison sbf 250 cac mid small nasdaq biotechnology index indexed january 4 2010 december 31 2014 700 600 500 400 300 200 100 0 sbf cac sartorius nasdaq 250 midstedim biotechnology small index biotech share 2010 2011 2012 2013 2014 sartorius stedim biotech share sbf 250 cac mid small nasdaq biotechnology index 14 shareholder sartorius stedim biotech share investor relation activity information publication relating company share may found website sartorius stedim biotech investor relation activity wwwsartoriusstedimcom focus maintaining ongoing open dialogue shareholder potential investor financial analyst analyst besides providing firsthalf annual report well recommendation financial analyst serve holding quarterly telephone conference also important foundation decision private regularly published press release presenting institutional investor investing share significant company business development currently four institution regularly prepare report material event reporting year 2014 update sartorius stedim biotech share moreover management team available capital market participant site goettingen research coverage germany aubagne france conference institute date recommendation road show conducted financial market portzamparc january 29 2015 hold center london uk paris france frankfurt gilbert dupont january 28 2015 add main germany new york usa hold oneon oddo midcap january 27 2015 buy one meeting additionally september 2014 hosted first capital market day goettingen société générale january 27 2015 hold germany providing indepth view business strategy positioning well future business potential key figure sartorius stedim biotech share 2014 2013 2012 2011 2010 reporting share price1 date 16130 12185 7340 4900 3770 high 17165 12400 7603 5489 4000 low 11700 7535 4673 3735 2800 dividends2 130 120 110 100 090 total dividend paid2 million 200 184 169 153 138 payout ratio3 229 245 261 287 305 dividend yield4 08 10 15 20 24 market capitalization million 24774 18696 11261 7510 5774 average daily trading number share 7014 9011 7464 7435 14965 trading volume share million 2438 2378 1061 852 1319 cac mid small million 9725 8629 6812 5652 7195 sbf 250 million 3289 3263 2729 2344 2801 1 daily closing price 2 2014 amount suggested board director subject approval annual general shareholder meeting 3 based underlying net result 4 dividend relation corresponding closing price year source euronext bloomberg shareholder sartorius stedim biotech share 15 dividend shareholder structure sartorius stedim biotech group applies dividend pursuant authorization annual general policy intended ensure shareholder adequately shareholder meeting board director july rewarded company success accordingly 2014 resolved cancel company 1698710 generally endeavor distribute 25 treasury share representing approx 10 30 company underlying net profit company total share capital 2014 time definition see p 199 nominal value per share increased 061 100 board director submit proposal annual general shareholder meeting april 7 2015 result number issued share without exer pay dividend fiscals 2014 130 per share cisable option totaled 15359238 december 31 net profit 872 million would 2014 compared 17042306 yearend 2013 represent gain 83 previous year issued capital sartorius stedim biotech sa figure 120 therefore total profit distributed however went 154 million 104 million would increase 184 million year ago 200 million corresponding dividend payout ratio would 229 compared 245 previous share convey double voting right year relation share closing price 16130 total 26993188 voting right december 31 2014 dividend yield would reporting date 08 previous year 10 cancellation treasury share sartorius ag hold 743 share capital 846 dividend outstanding voting right 257 share free float corresponding 154 outstanding 090 090 100 100 110 110 120 120 130 130 voting right 160 shareholding structure 120 share capital sartorius ag 743 080 free float 257 040 000 2010 2011 2012 2013 20141 1 amount suggested board director subject approval annual general shareholder meeting management report 18 management report structure management group structure management group group legal structure reporting year minor change company portfolio sartorius stedim biotech sartorius stedim biotech globally operating acquired majority stake u startup allpure company 3600 employee worldwide technology llc company initially con subsidiary 20 country parent solidated april 28 2014 company sartorius stedim biotech group sartorius stedim biotech sa holding company control group direct indirect financial controlling affiliate key performance indicator approximately 74 share capital around sartorius stedim biotech group managed using 85 voting right sartorius stedim number key performance indicator biotech sa held sartorius ag subsidiary also decisive determination variable remuneration component executive committee manager organization management group key management parameter sartorius stedim sartorius stedim biotech group consistently biotech us measure development organized function worldwide company volume currencyadjusted growth order intake accordingly managed along core operating sale revenue function key profitability measure ebitda adjusted global functional organization creates extraordinary item ie underlying ebitda effective platform central strategic control corresponding margin beyond indicator ebit fast efficient collaboration within group relevant net profit year net profit also enables company realize total solution earnings per share reported provider strategy position effectively respect global customer important indicator ratio net debt underlying ebitda group managed executive member board director sartorius stedim biotech sa addition following financial nonfinancial implementing group various strategy indicator reported regular basis project local level responsibility national affiliate management body local equity ratio company manage organization accordance capex ratio applicable statutory provision article net working capital association rule procedure keeping net cash flow operating activity principle corporate governance apply number employee throughout sartorius stedim biotech group worldwide rule annual financial forecast published management beginning fiscal year group refers development sale change group portfolio revenue underlying ebitda expected capex ratio additionally indicated group sale consolidated financial statement include revenue order intake mostly similar level parent company sartorius stedim biotech sa sartorius stedim biotech due structure major affiliate sartorius stedim biotech sa generally show considerable timing controlling interest pursuant ifrs 12 difference subject similar growth assumption reason order intake usually budgeted separately component financial forecast management report strategy goal 19 strategy goal sartorius stedim biotech leading international provides considerable cost time saving supplier product technology manu reduce risk contamination sartorius stedim facture medication vaccine biological biotech extensive portfolio singleuse basis socalled biopharmaceuticals technology industry part strategy total solution provider product company address attractive offer biopharmaceutical industry product market aboveaverage growth potential portfolio cover nearly step sale distribution activity carried production process cover cell culture medium globally field force customer seed fermentation cultivation various manufacturing process validated respective bioreactor size cell propagation well range authority product quality supply security technology equipment filter essential aseptic bag cell harvesting purification concentration way final filling see leading market position process filtration fluid management fermentation sartorius stedim biotech focus particular membrane chromatography good stepping stone singleuse product represent around three sustained dynamic profitable growth quarter sale revenue include inter alia future besides realizing organic growth potential filter bag cell culture medium customer company also intends continue expanding singleuse product innovative alternative complementary acquisition alliance conventional reusable stainless steel system integrated product service along customer process chain upstream bioprocessing downstream bioprocessing medium seed production cell removal capture polishing viral formulation preparation fermentation fermentation clariﬁcation clearance final fill service evaluation optimization engineering design implementation technical service 20 management report strategy goal sector condition continued aboveaverage growth biotechnology market sartorius stedim biotech serf customer mainly biopharmaceutical industry make global market pharmaceutical manufactured business particularly sensitive development using biotech method grew overproportionately industry reporting year around 9 outperforming global pharmaceutical market attributable mainly launch many new biopharmaceuticals strong growth pharmaceutical market past year expanded indication existing medicine proportion sale revenue international market research institute ims health accounted biologically produced medication estimate global pharmaceutical market risen last year stand around grown around 7 2014 compared gain 22 23 currently therapeutic protein 3 2013 play important role treatment condition including diabetes chronic anemia still make significant acceleration growth primarily largest category active pharmaceutical attributed comparably low number patent ingredient manufactured using biotech method expiration developed market many new monoclonal antibody also continuing gain drug approved addition introduction importance used instance government health insurance usa treatment cancer hiv autoimmune disease positive impact multiple sclerosis rheumatism according study conducted boston consulting pharmerging market continued expand dynamically group 330 monoclonal antibody whole reporting period growth undergoing clinical development phase iiii 2013 market driven expansion state significantly 2012 healthcare higher private spending strong trend towards singleuse system growth regional pharma market biopharmaceutical production 33 33 117 117 33 33 9090 compared classic procedure biotechnological 30 30 4040 35 35 100 100 production process vastly complex 12 costintensive reason manufacturer supplier intensively working develop 9 efficient production technology singleuse product playing crucial role effort require 6 significantly less capital expenditure moreover reduce cost cleaning validation minimize 3 downtime beyond advantage singleuse product provide considerable flexibility help 0 accelerate time market thanks particular cost efficiency singleuse product already well europe usa japan pharmerging 2014 markets1 established many process step 2013 1 chine brésil russie inde algérie argentine colombie égypte indonésie mexique nigeria pakistan pologne roumanie arabie saoudite afrique du sud thaïlande turquie ukraine venezuela vietnam source ims health management report strategy goal 21 continued soft demand public research sector proportion demand laboratory product come public sector research many country research budget declining result excessive public debt according frost sullivan demand public research sector reporting year slightly prioryear level competition primary mean company biotechnology market differentiate competitor innovative prowess quality performance product biotechnology sector constantly discovering new area application expects supplier equally fast moving creative developing new equipment manufacture biotech product new supplier particular seek exploit opportunity inherent environment gain foothold market carefully targeted niche product established supplier meanwhile expanding product range continuously generate round 90 sale revenue validated process replacing product production cycle expensive receive high proportion followup repeat business particular strength sartorius stedim biotech lie integrated process solution investigation development substance lab production end product offer broadest range industry strategic focus singleuse product give u another edge competition sartorius stedim biotech occupies strong position market worldwide field bioprocess filtration fermentation fluid management membrane chromatography competitor multinationals based usa emd millipore pall general electric healthcare among main rival process area thermo fisher emd millipore key player laboratory field also face competition smaller company applikon individual segment source boston consulting group medizinische biotechnologie deutschland 2014 medical biotechnology germany 2014 ims global outlook medicine 2018 evaluate pharma world preview 2018 june 2013 22 management report group business development group business development order intake sale revenue sale revenue region1 reporting year business sartorius stedim europe 46 biotech group performed positively substantial doubledigit gain order intake sale north america 30 revenue earnings order intake sale revenue million 5002 5539 4426 5002 4426 6149 7221 5539 6149 7221 4773 5440 4329 4773 4329 5884 6835 5440 5884 6835 asia pacific 21 800 market 3 650 1 acc customer location 500 350 2014 main region reported strong gain sale revenue especially europe north america 200 acquisition mentioned contributed significantly growth europe region generating highest 2010 2011 2012 2013 2014 sale accounting around 46 total group order intake revenue reported increase sale revenue 88 sale revenue constant currency 3149 million order intake reporting year climbed 171 north america represented 30 sartorius 7221 million constant currency compared stedim biotech sale revenue registered highest high prioryear revenue base sale revenue rose growth dynamic reporting period sale period 159 constant region significantly increased 355 constant currency 6835 million slightly surpassing currency 2052 million guidance issued outset year 11 14 constant currency organic growth around asia pacific accounted around 21 total sale 85 exceeded expectation driven 2014 recording gain 150 constant product line also recent acquisition cell currency 1429 million culture medium business tap biosystems developed dynamically reporting period performed better anticipated beginning year management report group business development 23 sale revenue1 region earnings million unless otherwise specified 3149 3149 2052 2052 1429 1429 205 205 sartorius stedim biotech group earnings 2871 2871 1508 1508 1258 1258 247 247 interest tax depreciation amortization 400 ebitda used key profitability measure provide complete transparent presentation 300 group profitability report earnings adjusted extraordinary item underlying ebitda information definition please refer 200 glossary page 198 underlying presentation reconciled ebitda key indicator see glossary 100 following page 0 reporting year earnings sartorius stedim europe north asia biotech advanced significantly based strong america pacific market growth sale revenue due economy scale 2014 underlying ebitda increased overproportionally 2013 184 1605 million respective margin rose 230 235 line guidance provided beginning reporting year sales1 growth growth2 million underlying ebitda margin1 group 6835 162 159 europe 3149 97 88 859 859 996 996 1356 1605 1170 1356 1170 1605 north america 2052 361 355 198 198 209 209 230 235 215 230 215 235 asia pacific 1429 136 150 200 26 market 205 169 169 1 150 24 acc customer location 2 constant currency 100 22 50 20 0 18 2010 2011 2012 2013 2014 underlying ebitda million underlying ebitda margin 1 adjusted extraordinary item extraordinary item amounted 49 million previous year 37 million essentially related integration tap biosystems corporate project including extraordinary item depreciation amortization group ebit see glossary rose 1013 million 1204 million respective margin increased 172 176 24 management report group business development underlying net profit noncontrolling interest appropriation profit group surged 752 million year ago 872 million fiscal 2014 profit figure board director submit proposal calculated adjusting extraordinary item annual general shareholder meeting april 7 2015 eliminating noncash amortization 108 million payment dividend 130 per share fiscal previous year 92 million fair value adjustment 2014 120 previous year total hedging instrument well corresponding profit distributed would accordingly increase 84 tax effect item underlying 184 million year earlier 200 million earnings per share 568 490 year relation closing price share 16130 earlier december 31 2014 would result dividend yield 08 previous year 10 underlying earnings per share 281 281 349 349 421 421 490 490 568 568 600 450 300 150 000 20101 20112 20122 20132 20142 million 2014 2013 ebit operating result 1204 1013 extraordinary effect 49 37 amortization ifrs 3 108 92 financial result 153 69 valuation hedging instrument 38 03 normalized income tax 2014 29 2013 29 361 312 underlying net result 884 764 noncontrolling interest 13 12 underlying net result excluding noncontrolling interest 872 752 underlying earnings per share 568 490 see glossary definition total listed management report net worth financial position 25 net worth financial position cash flow cash flow statement summary net cash flow operating activity million 2014 2013 sartorius stedim biotech group increased net cash flow 901 million 1113 million reporting period operating activity 1113 901 gain essentially driven higher earnings net cash flow investing activity acquisition 468 734 net cash flow net cash flow operating activity financing activity 842 80 million cash cash equivalent 185 356 gross debt owed bank 1060 1656 728 728 606 606 489 489 901 901 1113 1113 net debt owed bank 874 1300 120 90 consolidated balance sheet 60 balance sheet total sartorius stedim biotech group increased moderately 333 million 30 9068 million yearend 2013 reporting date december 31 2014 0 2010 2011 2012 2013 2014 noncurrent asset rose 6125 million 2013 6306 million 2014 primarily due investment production capacity 425 million net cash flow investing activity substantially higher last year current asset grew 2609 million figure 283 million planned increase 2762 million increase driven mainly reflects higher investment expansion aforementioned buildup working capital product capacity partly compensated decrease cash cash equivalent cash outflow 43 million related acquisition reporting period attributable takeover majority stake allpure technology llc key working capital figure day figure 451 million 2013 reflected acquisition cell culture medium business 2014 2013 tap biosystems group rate turnover inventory net cash flow investing activity inventory x 360 58 55 acquisition thus amounted 468 million compared sale revenue 734 million 2013 accordingly group financed entire investment acquisition rate turnover operating cash flow receivables trade receivables x 360 66 63 net cash flow financing activity sale revenue 842 million reflects payment dividend payback debt see note 28 rate turnover net working capital net working capital1 x 360 81 79 sale revenue 1 sum inventory trade receivables less trade payable 26 management report net worth financial position equity 4818 million 2013 financing treasury 5385 million 2014 sartorius stedim biotech group equity ratio rose markedly 594 sartorius stedim biotech group financed december 31 2013 552 welldiversified basis reporting year attractive credit market condition used noncurrent liability 1387 million refinance existing syndicated credit facility december 31 2014 compared 2337 million maturity moreover financing facility december 31 2013 current liability pooled level sartorius ag majority year year 1579 million 2296 million shareholder sartorius stedim biotech therefore mainly reflects significant reduction syndicated loan sartorius stedim biotech gross debt well change maturity due volume 250 million terminated december refinancing syndicated loan reporting 2014 since sartorius stedim biotech year using credit line volume 300 million provided sartorius ag see page 135 overall gross debt 1060 million decem information ber 31 2014 compared 1656 million year ended december 31 2013 net debt furthermore group longterm loan reporting date 874 million relative agreement kreditanstalt für wiederaufbau 1300 million year ago kfw current volume 19 million relating investment production capacity balance sheet structure another element financing structure asset equity liability factoring program maximum volume 552 552 594 594 350 million moreover sartorius stedim biotech 701 701 695 695 268 268 153 153 299 299 305 305 181 253 181 253 diverse bilateral credit line approximately 100 25 million total financing sartorius stedim biotech group comprises instrument fixed variable interest financing facility variable interest 50 rate partly hedged increase general interest rate level ratio net debt underlying ebitda 0 represents key management indicator 2013 2014 2013 2014 sartorius stedim biotech group significantly improved noncurrent asset equity 05 year ended december 31 2014 current asset noncurrent liability current liability ratio net debt underlying ebitda ratio longterm capital fixed asset stood 12 12 10 10 10 10 10 10 05 05 1093 1187 december 31 2013 20 15 10 05 00 2010 2011 2012 2013 2014 management report net worth financial position 27 sartorius stedim biotech group conduct business sartorius stedim biotech group stepped across globe thus affected currency research development activity reporting fluctuation group u dollar represents year increasing spending area 71 important foreign currency besides 386 million previous year 360 million japanese yen british pound global respective ratio rd cost sale revenue manufacturing network production facility 56 compared 61 year earlier outside germany france north america uk switzerland india enables u research development cost compensate majority currency fluctuation million natural hedging 278 278 286 286 318 318 360 360 386 386 generally hedge remaining net currency 40 exposure period 15 year ahead twothirds suitable currency 30 transaction 20 research development 10 research development activity sartorius 0 stedim biotech encompass inhouse development 2010 2011 2012 2013 2014 area core technology well integration product alliance partner university industry research development ratio sale revenue inhouse research development sartorius focus particular following technology 64 64 60 60 58 58 61 61 56 56 area membrane core component 10 type filter product several base technology broad spectrum application bioprocesses 8 like single use container sensor well control technology eg fermentation morevover 5 extensive expertise application development 3 regional perspective largest rd site located goettingen additional key rd 0 activity aubagne guxhagen bangalore 2010 2011 2012 2013 2014 royston overall research development activity become increasingly international one rd priority reporting year protect knowhow pursue targeted develop additional application new intellectual industrial property right policy polyethylene film thus continued effort systematically monitor compliance right bring new film market area storage review cost benefit viewpoint whether freezethaw application necessary continue maintain individual right connection acquisition allpure number application intellectual property technology began work reporting year right filed 2014 amounted 125 compared 87 develop new standardized product taking sample previous year result application bioreactors submitted past year issued 134 patent trademark previous year 120 also collaborating industrial balance sheet date total 1811 patent university partner development new control trademark portfolio previous year 1592 technology manufacturing process active medical ingredient socalled process analytical tool 28 management report net worth financial position 2014 2013 product range gained new sampling system number patent trademark acquisition majority stake u startup application 125 87 allpure technology allpure system registered patent trademark 134 120 based singleuse technology allows sample taken bioreactor sterile closed environment technology replaces traditional product sale reusable sampling system pose greater risk contamination sartorius stedim biotech provides product cover virtually every step biopharmaceutical production process medium cell cultivation bioreactors extensive range service various size cell propagation filter purifying cell material system storage sophisticated manufacturing process employed transport intermediate finished product customer subject strict regulation offering complemented range service quality control quality assurance compliance including consulting validation application regulation subject regular check specific package relevant authority offer extensive range service encompassing validation consulting sartorius stedim biotech launched new generation activity well equipment installation existing product line reporting year added maintenance repair help customer comply several completely new product notably applicable regulatory requirement area fluid management fermentation sale distribution activity expanded new generation singleuse bag sartorius stedim biotech market product portfolio together cooperation partner developed exclusively direct channel maintains new polyethylene film based launched team field sale representative also new singleuse bag fermentation application global key account management organization reporting year one main benefit coordinate support sale distribution activity new film interact cell key account sartorius stedim biotech began material stable cell growth ensured new film reporting year introduce new global crm combine robustness flexibility system provide support sale time meaning also used large distribution activity also stepped sale volume fermentation storage process distribution activity asia wide range application another advantage reporting year connection implementation customer single film 2020 strategy new application center validated pave way significant opened shanghai example allows reduction validation time cost presentation key product plus demonstration variety different application customer acquisition strengthen product range acquisition british company tap biosystems end 2013 added two smallvolume singleuse bioreactor system process development application product range innovative system enable customer perform large number cell culture experiment simultaneously providing quick costeffective way determine optimal development condition cell culture allows u begin working customer early stage process development management report net worth financial position 29 production supply chain management production capacity expanded sartorius stedim biotech operates welldeveloped sartorius stedim biotech expanded production global production network plant europe capacity various site reporting year north america asia largest production site response dynamic growth bioprocess located germany france puerto rico business thus new bag production system sartorius stedim biotech also manufacturing commissioned yauco aubagne operation switzerland uk tunisia india mohamdia plant company installed new casting machine production filter membrane production site generally serf goettingen site reporting year center competence particular technology scheduled commissioned 2015 production group largest plant goettingen example capacity also expanded bangalore concentrate chiefly production membrane plant fermentation filter aubagne mohamdia site primarily manufacture singleuse bag plant yauco supply membrane filter singleuse bag central distribution center principally u market guxhagen site specializes bioreactors system sartorius stedim biotech partner built new bioprocess application collaborates closely highly automated logistics center goettingen bangalore site mainly manufacture stainless site reporting year facility handle product steel unit system shipping well supplying production unit goettingen plant intend implement central distribution center asian market future based suzhou site china 30 management report sustainability report sustainability report sustainability one core value firmly methodological note embedded sartorius stedim biotech corporate culture ever since company established indicated otherwise indicator reported sustainable development company hr health safety refer entire major objective group excluding u startup allpure acquired 2014 figure thus represent primary business responsibility offer 99 total headcount environmental indicator attractive product solution customer cover production site aubagne lourdes innovation well strategic operational mhamdia goettingen guxhagen stonehouse excellence key meeting objective u tagelswangen yauco bangalore royston sustainability mean pursuing business representing 833 group total workforce objective use longterm broadly based approach encompassing social ecological interest data collected using sap social information take responsibility toward various emc environmental data case stakeholder seriously foster longterm relation local site transmit data via software system deliver benefit party involved therefore general rule required data reported monthly active management social ecological task hr ehs unit largest group site one success factor goettingen review consolidate data sartorius stedim biotech set process continuous line approach consider essential improvement groupwide recording reporting comply legal ethical standard manufacture environmental personnel data ecological responsibility keep environmental impact mind developing product innovation likewise hr policy aimed preserving right interest employee f economic actively using developing potential eo success u oyee co mpl l mp global workforce company site around l e ntia glo acti l te ian ba world employer contractor take active po ce part developing regional environment able corpo tain ra u anagement e e u c tio n l ctiv indicator social health safety p r ti n r ese rc h n y ble ctio n environmental raw material data c n r cie l ai g c defined cover impact group b ili produ u st activity since 2012 sartorius stedim biotech ibu ti na l ty n g ec f reporting key personnel environmental sus indicator metric compliance french oci r oje p n pr grenelle ii environmental law recommended table al c t f ica l io f e n r lo g ovum concordance shown page 182 183 ar ra st f h e e c nn r r u c ct indicator based generally accepted ius tu sit e r e p rodu standard permit comparison company internally figure provide basis defining reviewing controlling environmental hr target management report sustainability report 31 sustainable corporate management guideline defined anticorruption code intended help employee act ethically activity based corporate value accordance law daily work sustainability openness enjoyment value employee around globe required complete govern treat customer business partner training dealing ethically legally investor well work together within problematic situation whistleblower portal company addition value guide u telephone hotline enable employee supplier future development company customer partner report dubious conduct sartorius stedim biotech conduct business sartorius stedim biotech remuneration policy accordance legal regulation individual aim attract retain motivate employee country globally accepted ethical standard ensures internal external competitiveness action line good corporate conducting regular review local market governance control focusing sustainable value two global incentive program many added principle include compliance legal employee eligible participate linked internal group regulation protection success company achievement stakeholder interest transparent communication target defined annual performance review appropriate risk management proper accounting generally company applies industry standard auditing sartorius stedim biotech follows complies union agreement germany rule recommendation afepmedef france instance compensation paid according corporate governance code information pay rate set trade union even provided chairman report page 79 based local performancerelated component reference document business partner request supplier compliance system preemptive nature associate respect human right signing aim prevent misconduct financial loss damage code conduct upholding applicable company image key principle system human right law regulation also code conduct anticorruption code ensuring principle complied comprising basic standard legally compliant throughout entire supply chain ethical behavior help ensure operate highest level integrity binding employee following code conduct sartorius stedim biotech support respect principle defined united nation universal declaration human right convention international labor organization ilo united nation global compact furthermore reject form compulsory andor child labor respect special need protect young employee sartorius stedim biotech employee committed taskoriented open friendly fair approach interacting colleague employee third party helping create atmosphere respectful cooperation tolerate employee discriminated disadvantaged harassed excluded based gender ethnic origin life philosophy race religion age disability appearance sexual preference identity origin political position uphold freedom association right individual fairly represented labor organization choosing pursuant local law 32 management report sustainability report employment employee function employment number reported following 2287 2287 891 891 301 301 187 187 include staff member except vocational 2063 2063 807 807 259 259 161 161 trainee intern employee extended leaf 2400 absence participating early retirement plan number recorded head count ie 1800 employee counted regardless whether work full part time 1200 december 31 2014 sartorius stedim biotech 600 group employed 3666 people total 2013 3289 figure yet include 31 employee 0 u startup allpure technology sartorius stedim biotech acquired april 2014 production marketing research administration1 sale development recruited new staff response sustained strong service demand singleuse product included 173 tap biosystems employee first time 2014 2014 excluding allpure 2013 headcount increased 115 1 excluding administrative function performed sartorius europe continued region highest corporate administration gmbh part number employee accounting nearly two sartorius stedim biotech group third workforce north america recorded highest increase reporting year 144 mainly due new hire production site puerto rico sale marketing employee gender 1861 1861 2021 2021 2289 2289 employee region 1125 1125 1268 1268 1377 1377 2500 2406 2406 563 563 511 511 186 186 2127 2127 492 492 472 472 198 198 1875 2500 1250 1875 625 1250 0 625 2012 2013 20141 0 male female europe north asia america pacific market 1 excluding allpure 2014 excluding allpure 2013 management report sustainability report 33 employee age attrition rate generally subject regional 2014 1 2013 variation rate reporting year 63 83 north america asia pacific number number europe rate market 16 20 18 05 17 05 primarily includes bag manufacturing site 21 30 844 230 811 247 mhamdia tunisia 23 however 31 40 1129 308 1013 308 uncommon africa germany traditionally one 41 50 964 263 876 266 world lowest fluctuation rate site 51 60 628 171 509 155 germany employ 381 group staff 61 83 23 63 19 rate 43 2014 line german average france attrition rate 162 1 excluding allpure primarily due fixedterm contract excluding fixed term contract rate france 74 number employee function show approximately twothirds employee work absenteeism rate express proportion manufacture area directly related production planned working time lost due general area new staff member hired absence average time missed due illness followed marketing sale service optimized 69 day per employee 2014 2013 79 day marketing activity decisive factor achieving growth target applying different perspective proportion woman entire workforce slightly decreased reporting year 376 international company diversity 2013 386 average employee age remains market business region customer also 40 year reflected workforce setting team ensure different perspective background combined productively also employee benefit expense totaled 206076 million filling management vacancy aim achieve mix reporting year 168036 million culture gender age group manager accounted wage salary excluding allpure germany france usa india example detail please see page 121 represented second management level vice president continuing internationalize management lineup medium term new hire attrition rate average seniority absenteeism another priority diversity strategy ensure woman adequately represented manage 2014 1 2013 ment position number post held woman new hire 504 634 two tier management immediately redundancies2 43 36 executive board 252 december 31 2014 attrition rate3 87 100 2013 250 average seniority year 84 83 absenteeism4 rate 39 43 reporting period sartorius stedim biotech employed 96 people 2013 91 people 1 excluding allpure registered disabled number 24 work 2 redundancy companydriven dismissal layoff france 69 germany 3 express number people leaving company percentage average headcount 2014 360175 including fixedterm contract retirement reason employee leaving company 4 excluding time lost due longterm health condition maternity parental sabbatical leave sartorius biotech korea co ltd represents 16 group total workforce included 34 management report sustainability report developing potential sartorius college offer wide range training employee worldwide seminar continuing development opportunity employee extend foreign language grow successfully dynamic market environment skill professional qualification value selling need competent qualified employee course example teach field sale representative therefore make every effort enhance application specialist worldwide strategic appeal employer internally externally skill necessary provide firstclass customer advisory employer brand talent management service elearning platform within technical aim increase quantity quality talented training program provides interactive way staff available position required company employee marketing sale service focusing especially female employee unit prepare individually subsequent faceto face training session annual performance review conducted employee group subsidiary encourage individual help employee manage change process collective performance appraisal cover successfully sustainably sartorius stedim biotech identification development opportunity well operates strategic change management system review target performance site france tunisia puerto rico sartorius sartorius stedim biotech fill management vacancy stedim biotech provided 146169 hour training largely within rank accordingly 2014 corresponds average 131 hour develops promotes employee management training average cost 32890 per employee potential international level special program scope training hour currently corresponds help junior manager develop refine 313 total headcount sartorius stedim biotech management skill specific project directly intends broaden scope collected data thereby related company business sartorius stedim allowing representative statement biotech also provides separate development program group activity area line leadership guideline experienced management staff strengthen common managerial culture finding developing talented young staff structured expert career path program enables order enhance professional knowledge sartorius stedim biotech provide specific skill experience sartorius stedim biotech offer development opportunity scientist engineer young people opportunity work within rd function raise profile company many year using expert within outside company corresponding european union funding program result expert key sartorius stedim biotech marie curie scheme young scientist technology even greater incentive stay leonardo da vinci scheme international vocational company reporting year together education possible give intern also expert scientist developed possibility participate training thanks content program extended alliance kedge business school marseille internationally france intern aubagne site example attend master business administration sartorius stedim biotech generally encourages course offered employee gain new perspective area work company location international scholarship program meanwhile company also benefit employee think supporting talented student graduate act across department location department scientific technical field financially actively supported relocating staff also technically personally mentoring student within organization management report sustainability report 35 freedom flexibility work employee health safety sartorius stedim biotech complies statutory group corporate health management policy contractual working time obligation cover physical psychosocial subsidiary working time varies depending local element health enhance employee performance environment business activity motivation reduce illnessrelated cost promote awareness personal health among generally set employee demanding task employee special action day individual delegate responsibility early stage give site example 2014 introduced advisory freedom define daily work schedule assistance service especially employee traveling instance german ssb site employee opt business foreign country staying abroad various workweek schedule flextime event medical emergency safety risk parttime work teleworking number part employee obtain assistance phone find time employee 185 2013 137 equates help onsite time vice president germany 51 total head count 2013 42 may take advantage annual medical checkup selected partner clinic encouraging social dialog sartorius stedim biotech align job safety work organization condition according sartorius stedim biotech place great importance applicable law regulation strive improve communication employee interoffice memo technical organizational working condition newsletter employee magazine inform continuously reduce jobrelated medical staff example change within company condition risk health potential cause goal economic situation first global industrial accident effort responsive employee survey held 2013 yielded particularly concern employee well aubagne good result employee especially satisfied site example operate special program present job task immediate manager implement specific improvement suggested cooperation within company 2014 employee prevent potential health hazard developed followup plan action area given sartorius stedim biotech offer regular training slightly lower rating career advancement employee occupational health safety opportunity besides several activity local level environmental protection site germany planned new talent management reflects provided 2928 hour training ehs issue 2014 key finding employee survey 2013 2995 hour 50 estimated follows 15 hour per employee average multiplied france well germany sartorius stedim headcount end year biotech staff represented three employee attendance rate 70 council employee council hold regular staff meeting 2014 12 collective agreement signed french site 10 german location cover profit sharing incentive system weekend work electronic voting annual performance review france five collective agreement health insurance signed reporting year address environmental health safety issue ehs 36 management report sustainability report statistic accident work high standard quality 2014 1 2013 environmental protection 2 number work accident 54 48 sartorius stedim biotech certified according number day lost due work accidents3 1132 858 internationally recognized standard quality iso frequency rate4 88 87 9001 environment iso 14001 result comply quality requirement severity rate5 1840 1556 manufacture product prudent use 1 excluding allpure resource minimize environmental risk 2 excluding accident occurred employee manufacturing site certified iso 9001 travel home work series international standard apart 3 measured calendar day excluding sartorius biotech korea tagelswangen switzerland employ around co ltd represents 16 group total workforce 40 staff member environmental management 4 represents number accident per 1000000 theoretical working hour theoretical working hour 2014 system already certified compliance iso 616962331 14001 sartorius stedim india sartorius stedim 5 represents number day lost accident per biotech gmbh goettingen 2014 received 1000000 theoretical working hour certification energy management system introduced sartorius stedim biotech gmbh due higher headcount workrelated accident sartorius stedim biotech plastic goettingen site around world number day well sartorius stedim system guxhagen lost due work accident slightly increased compared compliance iso 50001 strive previous year number accident continuously improve existing management relation working hour however 88 nearly system working toward gradual rollout 2013 workrelated accident production site appropriate minor nature review effectiveness expedient locally respective company accident prevention measure regularly based organizational unit need ensure law accident analysis regulation related environmental protection observed technical possibility reducing environmental risk identified ecological sustainability company international environmental health occupational safety steering group responsible sustainable production ecological product harmonizing continuously improving process innovation important longterm financial three area worldwide success planning operation look beyond immediate use resource sartorius stedim biotech supply product understand entire lifecycle product directly end consumer rather including customer process develop manufacturer pharmaceutical food product efficient safe also chemical also research development provide ecological benefit building laboratory ensure product satisfy renovating factory sartorius stedim biotech assesses stringent quality requirement employ potential environmental impact defines rigorous quality check advanced manufacturing mitigation strategy necessary supplier method process cleanroom technology also required meet specification method process subject constant green approach growth coupled review part continuous improvement policy proportionate use natural resource goal moreover refined appropriately sartorius stedim biotech achieves various level requirement evolve high standard quality information health safety measure adopted achieved sartorius stedim biotech product sartorius stedim biotech employee described process documented successful page 34 35 completion host annual audit customer certification according standard reporting year environmental risk quality iso 9001 quality management identified require company make specific medical device iso 13485 respond rapidly provision annual financial statement product defect minimize adverse consequence sartorius stedim biotech established traceability system enables u recall entire product batch immediately necessary management report sustainability report 37 improved emission monitoring electricity natural gas main energy source representing 95 total energy since 2013 sartorius stedim biotech using consumption scope 2 emission occurring mainly greenhouse gas protocol ghg global consumption electricity account close standard recording greenhouse gas emission 70 company total emission apart guide reporting co2 emission thus energy saving reduction co2eq nearly 19 consider report co2 equivalent co2eq co2 compared 2013 also result improved emission gas causing climate change accuracy conversion factor specific energy present stage account emission categorized source individual process furthermore scope 1 scope 2 scope 1 record co2eq emission electricity consumption value site caused directly production site scope 2 stonehouse adjusted downwards account determines indirect emission arise power approximately 6 decrease co2eq generation external energy supplier sartorius stedim biotech yet report scope 3 amount total carbon emission released intends integrate category gradually solvent emission occur mainly filter co2eq accounting across value chain future manufacturing goettingen yauco site scope 3 considers co2eq emission associated 516 metric ton reporting year 2013 factor manufacture precursor 50 metric ton proportion figure product distribution operation relevance greenhouse gas emission taken account calculating co2eq figure greenhouse gas emission sartorius stedim biotech sa developed follows 2014 efficient use energy energy consumption greenhouse gas sartorius stedim biotech strives adapt 2014 2013 consequence climate change reduce total energy consumption mwh 71231 68952 greenhouse gas emission linked business electricity 39323 38400 improving company energy efficiency one natural gas 29119 27434 major approach reducing carbon dioxide fuels1 2009 2685 emission largest group site goettingen energy sources2 780 433 account approximately 72 energy total greenhouse gas emission consumption especially important effort co2eq3 19924 24543 reporting year introduced energy scope 14 6053 6834 management system certified iso 50001 scope 2 13871 17709 site well second goettingen plant key indicator nearby guxhagen site system enables u co2eq emission per employee 66 92 identify strategic opportunity reduce co2eq emission per sale revenue energy consumption adoption advanced tmio 292 417 technology includes energyefficient 1 data range cover diesel consumption electricity combined heat power chp plant generator data collection india site invoiced compressed air center controlling production instead based meter reading since 2014 without machinery resulted reduction around effect consumption would slightly increased 2 5600 metric ton annual carbon dioxide emission liquid gas added natural gas 2013 data collection invoiced instead based meter reading since 2014 intelligent control system enabled u realize without effect consumption would slightly additional energy saving 2014 second chp unit decreased went operation bring carbon 3 emission co2eq calculated university dioxide emission around 400 metric ton annually applied science art goettingen using emission factor result measure overall energy listed professional software called gabi 4 scope 1 excluding fuel consumption car fleet consumption goettingen site increased much slower rate sale revenue last year 38 management report sustainability report international site well sartorius stedim sustainable use water biotech continuously develops manufacturing process enhances building facility water sartorius stedim biotech us conserve resource particularly new building rinsing manufacture filter membrane increasing proportion renewable energy according precipitation bath method advanced source energy mix plant yauco casting machine help maximize water efficiency cover around 3 energy requirement site site goettingen germany bangalore solar energy furthermore factory india company operates water treatment guxhagen tagelswangen source part system thus contributing sustainable use energy need local photovoltaic plant limited resource based low water strategy use geothermal energy implemented green facility yauco sartorius stedim biotech reduces consumption drinking whole strategy supplying local water approximately 85 compared market far possible directly local conventional plant example using rain water production facility help shorten transportation route thus lower carbon dioxide emission water consumption 2014 2013 reducing climate change water consumption cbm 299596 280705 water consumption per employee cbm 100 105 sartorius stedim biotech measuring scope 3 well scope 1 scope 2 emission since 2010 waste water biological oxygen demandbod1 main production site aubagne single 201 175 use bag using bilan carbone method developed french environment energy management 1 contaminated wastewater without sanitary wastewater agency ademe record emission carbon dioxide greenhouse gas resulting entire process upstream downstream use raw material according production operation latest analysis 2013 legal regulation roughly corresponds value obtained previous year considering main source sartorius stedim biotech established material emission business workrelated travel management system test safety raw employee account around 22 material use compliance environmental environmental footprint aubagne site freight protection occupational safety regulation transport 18 packaging 10 impact europe include international rohs directive incoming raw material represents 19 restriction use certain hazardous emission following identification quantification substance electrical electronic equipment main source greenhouse gas emission european reach regulation registration local current action plan updated optimize evaluation authorisation chemical well distribution finished product include moving comparable international standard customer plan encourage carpooling public informed safety data sheet product safety transportation among measure information warning alert operating instruction hazardous substance present product management report sustainability report 39 sartorius stedim biotech defined three type raw supplier pharmaceutical industry sartorius material particularly important manufacturing stedim biotech currently prohibited regulatory product chemical solvent membrane requirement using recycled plastic filter cartridge polymer singleuse material ground product safety yet consistently send stainless steel reusable bioreactors system plastic waste recycling disposed 2013 group gradually implementing environmentally responsible way energyrich quantitative indicator raw material composite plastic waste resulting bag 2014 sartorius stedim biotech purchased 3448 metric manufacture france reused generate energy ton chemical solvent 2013 2955 metric incineration special power plant larger ton 1157 metric ton polymer recorded proportion polymer waste separated collected first time reporting year figure according type material polyamide indicates quantity purchased invoiced polyethylene recyling secondary material instead amount used sartorius stedim biotech complies european directive waste electrical electronic return recyclable material equipment weee sartorius stedim biotech strives reduce waste site germany using using waste sorting system contributes toward electronic signature hazardous material recycling reusable material lowering caustic solution oil since 2010 result proportion waste stored landfill document production hazardous waste provide digital proof proper recovery andor amount waste disposal ensuring waste fully tracked 2014 2013 end end total amount waste 2812 2949 waste recycling 1461 1499 environmentally friendly expansion waste disposal 1351 1460 group infrastructure waste per employee 093 111 recycling rate 52 51 expanding infrastructure sartorius stedim biotech complies local regulation practice land use company reduces impact organic solvent used manufacture environment selecting area premise membrane filter cartridge recovered already developed industrial zone none recycled goettingen facility account production site situated natural space solvent usage solvent reprocessing intact ecosystem possible maximize green plant site solvent recovered fed space minimize impermeable area facility back production operation without ever good example site bangalore leaving premise way maintain closed although generally estimate impact material cycle minimize transport requirement biodiversity negligible sartorius stedim biotech reduce quantity water used waste water strives meet special protection need produced conducting research biodiversity hotspot factory tunisia development also continuously reducing puerto rico located example site overall amount solvent required membrane puerto rico expanded 2012 serve manufacture use less polyethylene packaging central manufacturing logistics site sartorius stedim biotech switched delivery north american market meet highest u polypropylene sack silo manufacture standard green resourcesaving efficient injectionmolded component singleuse construction became first pharmaceutical product industry supplier worldwide achieve platinumlevel certification u green building council leed initiative 40 management report sustainability report manufacturing plant mostly situated cleaning material process based single industrial area noise pollution resident use product around half conventional relevant issue company processes1 within new building extended although singleuse product clear ecological production facility integrate advanced ecological benefit usage generates waste yet utility technology lowering energy consistent reuse recycling improve consumption preventing waste limiting noise environmental performance well ultrapure pollution employee reducing scrap plastic utilize manufacture various single result manufacturing process use product contain around 80 90 often exceed requirement imposed u local energy pure crude oil thus valuable environmental protection regulation secondary raw material high energy content polymer example mean recycled fuel heat power generation sustainable product innovation integrated solution sartorius stedim effort optimize environmental biotech flexact product range example performance product production method approach beyond ecological benefit begin research development stage generally offered singleuse technology flexact wherever safety functionality permit increase solution reduce need stationary installation proportion renewable raw material reduce equipment thus quantity material land packaging sartorius stedim biotech also work required versatile central control unit flexact partner industry scientific community instance used number different sustainable product solution efficient use biopharmaceutical process raw material instance explore possibility obtaining polymer membrane capsule technical refinement membrane filter series renewable raw material recycled substance enabled sartorius stedim biotech slash consumption determine greenhouse gas emission released ultrapure water wetting rinsing manufacture filter cartridge membrane around 95 filter significantly lower adsorption lessens amount highvalue protein solution lost result pharmaceutical highperformance product improve manufacturer substantially reduce resource customer environmental footprint recovering higher yield singleuse product becoming increasingly service unit assist customer adapting widespread manufacture innovative effective solution optimally requirement site medication practical always analyze customer process whole economic aspect also provide ecological benefit identify potential financial ecological compared conventional steel glass equipment improvement way contribute increasing singleuse product eliminate resourceintensive efficiency environmental compatibility cleaning process ultrapure water well customer process subsequent wastewater processing study 1 shown singleuse product far superior sinclair lindsay l et al environmental impact complex reusable system consumption disposable technology biopharm int november 2 2008 wwwbiopharmservicescomdocsenvironmentimpactdisposables energy water chemical product lifecycle pdf rawlings b pora h environmental impact singleuse expert compared approach based primarily reusable bioprocess system bioprocess int february reusable material based predominantly 2009 18 25 singleuse material across various scenario included typical industrial manufacturing process monoclonal antibody result clearcut manufacturer employing mostly singleuse solution use around 87 less water 30 less energy addition expert found deployment singleuse solution reduces size production unit manufacturer said require 30 less space thus also saving energy material research confirmed energy needed sterilization management report sustainability report 41 contributing society sustainable development longterm cooperation reliable partnership key tenet policy business activity many positive effect local organization maintain constructive open progress city community dialogue various local stakeholder informing sartorius stedim biotech based many year promptly comprehensively instance often one largest activity development could affect local private employer contractor example project funded reporting main manufacturing site thus supporting local year highlighted employment actively promoting regional development together cooperation partner yauco cooperate several public school company help shape economic social annually award around 20 scholarship environment providing financial support outstanding student student lowincome project education culture social affair sport family 2014 sartorius stedim biotech also shared contribute toward making region cost equipping community sport group operate attractive current future supporting needy family thanksgiving sartorius stedim biotech employee alike donating american cancer society charity walk support cancer research bohemia new york social outreach activity targeting area beyond sartorius stedim biotech participated local home region concentrate field related adoptaschool program reporting year core business fostering research education program aim create school community supporting event scientific community remain partnership positively impact student chief priority achievement group level sartorius stedim biotech donated supporting regional employment development 50000 nonprofit organization afm téléthon focus innovative genetic therapy relatively large production facility sartorius stem cell cure wiskottaldrich syndrome stedim biotech aubagne yauco goettingen chronic immunodeficiency debilitating disease among key industrial employer respective affecting blood muscle eye instance region instance headquarters aubagne city 40000 inhabitant provide attractive longterm job 450 people supporting student graduate increase around 10 compared 2013 member large french employer organization sartorius stedim biotech ensures gain young medef sartorius stedim biotech collaborates closely talent dedicated program alliance national local institute help improve international scholarship program provides financial job market situation another 180 job technical personal support student industrial sector provided production site graduate scientific technical discipline singleuse bag mhamdia tunisia program intended attract appropriately qualified expanded yauco plant provides employment young people particularly global growth around 350 people directly sartorius stedim market company enhance international biotech around 120 additional people project activity sartorius stedim biotech local service provider supplier maintenance machine building plant group headquarters aubagne collaborate security local workforce nearly 1150 people several school university included sartorius stedim biotech among large private école dingénieurs marseille enable recently employer university town goettingen qualified biotechnology engineer gain professional also major force local economy rural experience application engineer marketing region surrounding nearby guxhagen partnership french higher national school biomolecular engineering école nationale supérieure local subsidiary involved alongside de technologie de biomolécules help finance representative political industrial social scholarship awarded student choice community initiative strengthen also successfully collaborate école competitiveness respective region nationale supérieure de art métiers whose focus area directly indirectly related student given opportunity attend company business activity infrastructure logistics workshop california usa sartorius stedim environmental protection education promoting biotech participates many year actively 42 management report sustainability report program nonprofit organization biotech partner helping young people lowincome family gain access scientific technical career sponsoring event scientific community addition maintaining longterm alliance scientific institution sartorius stedim biotech regularly contributes symposium convention annual conference bioprocess industry cover subject development antibody vaccine singleuse system microbiological analysis 2014 supported example annual aseptic processing conference usbased international society pharmaceutical engineering ispe annual meeting parenteral drug association pda well various regional ispe pda convention annual meeting nonprofit society industrial microbiology covered topic fermentation cell culture environmental microbiology among others sustainable purchasing policy sartorius stedim biotech requires business partner particularly supplier conduct business activity compliance prevailing law line corporate social responsibility ethical responsibility sustainable way company code conduct defines set value principle regarding human right anticorruption protection environment supplier confirm signature code conduct acknowledge agree uphold standard sartorius stedim biotech globally standardized procurement channel contract awarded fair transparent process meet generally recognized standard according general manufacturing policy sartorius stedim biotech high inhouse manu facturing rate case nearly 100 filter membrane regarding trading good sartorius stedim biotech spent 406 million reporting year mainly supply company based europe u equates rate 6 sale revenue management report table concordance 43 table concordance grenelle ii french decree april 24 2012 page sustainable corporate management sustainability policy 30 scope reporting 30 methodological note 30 attestation regard exhaustiveness fairness information 45 social information employment total workforce breakdown region function gender age 32 33 new hire redundancy 33 compensation benefit expense 33 work organization organization working time 35 absenteeism 33 social relation organization social dialogue 31 35 outcome collective agreement 35 health safety health safety condition work 35 signed agreement regarding occupational health safety 35 work accident 36 training people development policy implemented regarding people development 34 35 training hour cost 34 equal treatment gender equality 32 33 employment people disability 33 policy discrimination 31 33 promotion compliance provision ilo convention compliance freedom association right collective bargaining 31 elimination discrimination respect employment occupation 31 elimination forced compulsory labour 31 abolition child labour 31 environmental information general environmental policy environmentrelated assessment certificate 36 training employee ehs issue 35 provision environmental risk 36 pollution waste management emission air 37 39 waste prevention recycling reduction measure 39 40 noise pollution 39 sustainable use ressources water consumption 38 raw material measure undertaken improve efficiency usage 39 total energy consumption breakdown electricity natural gas fuel 37 land use 39 climate change greenhouse gas emission 37 biodiversity protection impact biodiversity 39 societal information territorial economic social impact company activity 41 impact employment regional development 41 impact neighbouring community 41 relation maintained stakeholder condition dialogue stakeholder 31 35 41 philantrophic sponsorship action 41 42 subcontractor supplier integration social environmental stake purchasing policy 42 importance subcontracting integration csr relationship supplier subcontractor 42 fair operating practice action implemented prevent corruption 31 measure implemented promote health safety consumer 34 37 action favour human right 31 44 management report statutory auditor report sustainability report statutory auditor report sustainability report report one statutory auditor appointed responsibility statutory auditor independent thirdparty consolidated environmental social societal information based work responsibility published management report attest required csr information pre sented management report event year ended december 31st 2014 omission explained pursuant third paragraph article r 225105 french commercial code free translation english original attestation completeness csr information report issued french provided solely convenience english speaking reader report express limited assurance fact taken read conjunction construed whole csr information presented fairly accordance french law professional auditing material aspect accordance adopted standard applicable france reporting guideline formed opinion fair presentation csr information shareholder work carried team 4 people capacity statutory auditor sartorius tween december 2014 february 2015 assist u stedim biotech sa appointed independent conducting work referred corporate thirdparty certification request responsibility expert approved french national accreditation body cofrac number 310481 hereby conducted following procedure accordance present report social environ professional auditing standard applicable france mental societal information prepared year order may 13 2013 determining meth ended december 31st 2014 presented manage odology according independent third party ment report hereinafter csr information entity conduct assignment concerning pursuant article l2251021 french com formed opinion fair presentation csr infor mercial code code de commerce mation international standard isae 30002 responsibility company 1 attestation completeness csr information board director sartorius stedim biotech responsible preparing management report includ based interview management familiarized ing csr information accordance provision group sustainable development article r 2251051 french commercial strategy regard social environmental code prepared accordance reporting pro impact company business societal tocols guideline used sartorius stedim biotech commitment appropriate resulting hereafter reporting guideline action program available consultation headquarters company summary presented compared csr information presented management report management report list set forth article r 2251051 french commercial code independence quality control event omission certain consolidated independence defined regulatory text formation verified explanation provid profession code ethic well provision ed accordance third paragraph set forth article l 82211 french commercial article r 225105 french commercial code code furthermore set quality control system includes documented policy verified csr information covered con procedure designed ensure compliance rule solidated scope ie company subsidiary ethic professional auditing standard within meaning article l 2331 french applicable legal text regulation commercial code company control within meaning article l 2333 french commercial code subject limitation presented methodological memo management report management report statutory auditor report sustainability report 45 based procedure considering limita regarding consolidated csr information tions mentioned attest required csr assessed consistency relation information presented management report standing group 2 formed opinion fair presentation lastly assessed relevance explanation csr information relating necessary total partial omis sion certain information nature scope procedure believe sampling method size conducted around twenty interview peo sample used exercising professional ple responsible preparing csr information judgment enable u express limited assurance department charge data collection process higher level assurance would required appropriate responsible internal indepth verification due use sampling control risk management procedure order technique limit inherent opera tions information internal control system assess suitability reporting guideline risk material anomaly identified respect relevance completeness reliability csr information cannot totally eliminated neutrality understandability taking considera tion relevant sector best practice conclusion verify datacollection compilation processing based work subject control procedure implemented ensure mentioned qualification identify completeness consistency csr information terial anomaly likely call question fact review internal control risk management csr information taken whole presented procedure used prepare csr information fairly accordance reporting guideline determined nature scope test 1 scope available wwwcofracfr control according nature significance 2 isae 3000 assurance engagement audit review historical financial information csr information regard company 3 social indicator total number employee characteristic social environmental challeng december 31 2014 employee age employee gender e activity sustainable development strate new hire redundancy personnel expense euro gy sector best practice absenteeism rate number workrelated accident including commuting accident number calendar day lost due work accident frequency rate severity rate concerning csr information number training hour considered important3 environmental indicator total hour training ehs consolidating entity consulted docu issue total amount waste ton water consumption mentary source conducted interview cor quantity chemical solvent purchased quantity roborate qualitative information organization polymer purchased energy consumption mwh electricity natural gas fuel total greenhouse gas emission co2eq policy action performed analytical proce scope 1 scope 2 qualitative information dures quantitative information verified sustainable corporate management paragraph using sampling technique calculation remuneration encouraging social dialogue employee data consolidation verified consistency survey result employee health safety sustainable information presented man corporate management contributing toward regional employment development supporting student agement report graduate contributing toward regional employment development sustainable corporate management representative sample entity 4 sartorius stedim system gmbh sartorius stedim biotech gmbh selected4 according activity contribu et sartorius stedim filter inc tion consolidated indicator location risk analysis held interview verify marseille february 19th 2015 correct application procedure performed substantive test using sampling technique consist french original signed one statutory auditor ing verifying calculation made reconcil ing data supporting evidence selected deloitte associes sample represented 45 headcount christophe perrau julien rival 18 96 environmental quanti associé associé tative information sustainability service 46 management report opportunity risk report opportunity risk report every business activity entail opportunity risk throughout group opportunity short managed skill term nature considered annual budget done go long way determining future planning medium longerterm opportunity development company shareholder value tracked systematically part strategic planning managing risk opportunity sartorius stedim status opportunity management permanent biotech aim identify use business fixture corporate management system mean opportunity systematically well recognize also feature discussion decision evaluate risk early stage take measure making process toplevel management counter possible unrealistic expect risk management eliminate risk rather key area opportunity presented approach intentionally take certain risk presented section specific risk measure risk business activity order represent opportunity event develop successful unlocking opportunity however opposite positive direction reason discus endeavor important keep risk contained opportunity section specific risk within acceptable limit control carefully opportunity end chapter sartorius stedim biotech single unit tasked identifying managing opportunity risk area opportunity instead prefers make function integral component groupwide planning control supplier pharmaceutical laboratory system described internal control system industry sartorius stedim biotech operates compliance department responsible futureoriented highgrowth sector development group risk management system including organization respective assessment rank company one reporting process global market leader many product area believe high quality product strong brand recognition established customer managing opportunity relationship give u strong opportunity continue extending market leadership opportunity management center analysis target market sector environment well strict management process cost provides assessment trend give strong opportunity increase profitability key indication future business opportunity target area respect include continued identification potential development enhancement procurement chain ongoing context one key role relevant effort optimize production manager initially take place local rather central level marketfacing function opportunity discussed context strategic marketing product management presentation specific risk opportunity individual division play leading role beginning page 47 respect central business development unit additionally support area market monitoring data analysis implementation strategic project part strategy review member group executive committee regularly meet manager operational responsibility business development unit discus short medium longterm opportunity potential various business area subsequent step prioritizing opportunity evaluating business management perspective deriving strategic measure allocating resource proceed accordance standardized decisionmaking process applies management report opportunity risk report 47 risk management urgent reporting procedure place ensure new emerging significant risk opportunity management overall net worth financial position profitability responsibility maintenance effective risk identified audit committee receives management system ensuring comprehensive necessary detail without undue delay consistent management material risk rest audit committee coordinating developing system responsibility central internal risk classification control system compliance department audit committee monitor effectiveness risk first level risk management relates four management system furthermore carrying main risk category defined sartorius stedim statutory audit mandate annual financial biotech external risk operating risk financial risk statement consolidated financial statement corporate governance risk independent auditor examine whether early warning system place capable prompt second level consists additional subcategories identification risk could put future within main category legal risk company jeopardy production risk receivables risk organizational risk risk management system risk reporting process also includes allocation functional category example supply chain sale heart risk management system distribution human resource accordance sartorius stedim biotech risk management handbook group structural organization applies throughout entire group organization handbook includes categorize risk according scale definition framework structural implication also perform specific organization process risk reporting monitoring evaluation risk assigned value control effectiveness risk maximum impact time risk analysis management system based internationally word record maximum risk without recognized coso standard also number considering probability occurrence source contain stipulation effect risk mitigation measure handling risk including article association rule procedure group company internal guideline specific risk opportunity groupwide risk reporting system form cornerstone internal risk communication object general macroeconomic risk make possible address risk structured opportunity continuous manner document accordance relevant statutory regulatory nature various business area mean requirement sartorius stedim biotech whole insulated certain extent full force wider cyclical prescribed reporting process requires head effect macroeconomic effect little bearing central department managing director progress business group company review risk situation within area responsibility ongoing basis ability foresee mitigate direct report finding every quarter new indirect effect risk broader sense organizational unit joining consolidated group example currency crisis natural disaster company successively integrated associated damage commercially significant reporting process involves evaluating specific critical infrastructure limited risk probability occurrence scale potential impact well reporting case risk discussed section consider central risk management unit whenever defined probability occurrence low medium threshold breached case occurrence significant sartorius stedim biotech group whole individual group company 48 management report opportunity risk report supply chain risk opportunity production risk opportunity supply chain extends way manufacture large proportion procurement production sale distribution product belong core area technical problem within sequence consequential expertise involve high level vertical effect including delay delivery global supply integration product reusable fermenters chain management system instituted bioreactors manufactured collaboration throughout production process prevent supplier production risk problem largely minimizes associated risk transferred external third party analyzing controlling operation manufacture product also bear involved strongly international alignment associated risk capacity bottleneck overcapacity organization open whole series opportunity production downtime excessive reject rate high various risk opportunity encountered level tiedup working capital contain within supply chain explained detail reduce risk planning production capacity carefully using versatile machine semiautomated individual workstation flextime work schedule procurement risk opportunity continuously monitoring production process moreover global manufacturing network enables u purchase wide range raw material compensate capacity bottleneck shifting component part service supplier production regional plant consequently exposed risk unexpected delivery bottleneck price increase global regard probability occurrence concerning supply chain management system reduces risk risk described low risk happen enabling u monitor supervise procurement occur significant individual group activity moreover conduct regular supplier company review also use early warning system continued increase number framework consider opportunity various agreement concluded safeguard supply production facility able concentrate supplier strategically important raw material specific production technology result fiscal 2014 addition always maintain reserve enhance production operation greater inventory strategic raw material work efficiency international production network also alternative supplier possible make possible capitalize cost advantage offered individual site furthermore continuous present see low probability occurrence improvement production simplifying risk described risk happen occur process increasing level automation likely limited significance help drive efficiency even higher sartorius stedim biotech group opportunity arise area procurement sale distribution risk opportunity growth enables u increase order quantity thereby strengthen position use variety channel sell distribute supplier increased globalization supplier pool product around world potential risk entailed hold prospect purchasing favorable unexpected change demand structure term moreover also possibility growing price pressure noncompliance expanded purchasing activity international supply agreement concluded customer market leading u identify supplier special employ targeted market analysis identify emerging product technical expertise could eventually demand trend individual segment early enhance competitive edge time respond appropriately technical innovation focus less pricesensitive sale market product validated production process biopharmaceutical industry reduce exposure risk growing price pressure minimized risk exposure area logistics recent year setting using central warehouse optimize distribution logistics management report opportunity risk report 49 area well probability risk quality requirement growing occurring low medium according estimate stringent time least result case occurrence regulatory pressure actually regard first significant sartorius stedim biotech group foremost risk opportunity whole individual group company open new market prospect also challenging quality demand represent considerable barrier opportunity arise area sale entry potential new competitor provide distribution increasing breadth stimulus technical innovation product range bioprocess lab segment actively respond put u position sell new product existing customer business relationship established long term global rd risk opportunity presence provide opportunity moreover ongoing project strengthen direct sale especially devote considerable share resource lab segment also promise enhance research development potential risk area sale prospect may arise development result diverge market need exceeding planned development deadline unintentional transfer knowhow quality risk opportunity competitor advanced project management intensive rd controlling early involvement customer use sartorius stedim biotech product customer development process substantially wide range critical production process limit rd risk patent continuous tracking including manufacture pharmaceutical food technology competitor relevant u chemical research development secure technology position laboratory main risk encountered area noncompliance agreed quality criterion reason see low probability lead loss customer may present risk described might occur made liable compensation claim case could significant employ rigorous quality check stateoftheart sartorius stedim biotech group whole production method process cleanroom technology ensure product satisfy hand rd sphere also offer number stringent quality requirement potential opportunity intensive collaboration manufacturing method process subject partner rank among global market constant review continuous improvement leader field open opportunity process moreover refined appropriately u jointly develop innovative product requirement evolve successful completion especially high level innovation area host annual audit customer membrane technology turn expertise accreditation iso 9001 iso 13485 together specialist put u forefront global document high level quality achieved sartorius research development present u stedim biotech product process irrespective opportunity turn technical knowledge measure also maintain significant insurance potential sale even stronger position coverage product liability risk sartorius market stedim biotech established traceability system enables u recall entire production batch immediately necessary minimize adverse consequence event defect discovered product consider probability occurrence risk described low case occurrence significant sartorius stedim biotech group whole individual group company 50 management report opportunity risk report customer risk opportunity acquisition risk opportunity sartorius stedim biotech source key customer nature acquisition provide many opportunity pharmaceutical chemical food industry sale growth extension product public sector research educational portfolio development new market institution customer usually relatively contrast purchase sale company part large organization existence company entail number inherent risk time strong credit rating incorrect valuation assumption insufficient business area highly diversified customer base usage anticipated synergy effect prevent group whole dependent risk take various measure particular individual key account significant degree acquisition process performing standard due factoring program additionally diligence review addition involve external place keep risk exposure trade receivables consultant expert purchase sale customer constant low level work process early possible especially focus continuously improve receivables management drafting transaction contract adequately counter risk especially clause assuring present see low probability specific characteristic contractual warranty risk associated customer might occur guarantee provision well agreement case occurrence would likely mechanism adjustment purchase price limited significance sartorius stedim biotech liability clause immediately acquisition group whole individual group company taken place integration phase initiated potential risk likewise detected early possible prevented minimized taking competitive risk opportunity appropriate counteraction sartorius stedim biotech leading competitive consider probability occurrence position market risk described low case competitor larger u share occurrence significant sartorius stedim status globally operating company example biotech group whole individual group include emd millipore pall serve large company number customer highly regulated sector like pharmaceutical food industry technology barrier market entry substantially personnel risk opportunity high regard risk new competitor emerging low furthermore global presence significantly sartorius stedim biotech employ large number mitigates regional risk highly qualified people possible scarcity required specialist represents opportunity well risk change competitive environment example instance company prof particularly consolidation market pose good training retaining staff opportunity risk sector find counter threat demographic change ongoing process change sartorius losing employee especially key position stedim biotech remains active participant offering performancerelated remuneration model made acquisition continuously recent year targeted continuing professional development option reinforce market position open new attractive social benefit continuous potential synergy education training junior staff member within organization interesting people development consider probability occurrence opportunity success measure risk described low case apparent low attrition rate recent year occurrence likely limited significance many year seniority people accumulate sartorius stedim biotech group however cannot average employment contract certain case entirely ruled risk might significant contain clause prohibiting move direct individual group company competitor management report opportunity risk report 51 reason regard probability risk exchange rate risk opportunity occuring low risk happen occur likely limited importance sartorius generate around half consolidated sale stedim biotech group whole revenue foreign currency twothirds total revenue u dollar currency pegged u dollar positively negatively financial risk opportunity impacted currency effect especially converting currency balance sheet item global nature sartorius stedim biotech profit loss item respectively largely group operation mean business activity compensate general risk resulting inevitably exposed financial risk impact individual foreign currency taken significant aside risk associated number measure besides hedging currency group accounting exchange rate risk interest global production network thus enables u offset rate risk liquidity risk described lion share sale revenue received foreign addressed detail note currency within group cost likewise consolidated financial statement vice versa incurred foreign currency example financial risk notably exchange rate risk manufacture many product north interest rate risk balanced opportunity american market locally therefore approximately equal magnitude disadvantaged way competition u rival continuously monitor exchange rate consider probability occurrence net currency exposure ie proportion risk described following low risk foreign currency sale revenue remains happen occur significant settled cost use derivative sartorius stedim biotech group whole financial instrument notably spot forward individual group company swap transaction basis current anticipated net currency exposure foreign currency level make policy hedge risk associated group accounting 70 exposure advance following 18 month hedging transaction set one group except general typical risk inherent staff monitored another separate group accounting process specific risk concerning group accounting discernible typical accounting error connection example incorrect interest rate risk opportunity discretionary decision measurement asset liability use various common concluded fixed interest agreement standardized control mechanism integrated portion outstanding loan eliminate risk accounting process ensures error posed variable interest payment however recognized corrected early stage financial instrument outstanding reporting date subject interest based market rate almost twothirds currently covered interest rate swap interest rate risk opportunity apply remainder monitor interest rate trend interest rate exposure constantly facility arrange additional hedging transaction consider necessary economically advisable individual loan 52 management report opportunity risk report liquidity risk opportunity observed technical possibility limiting environmental risk identified sartorius stedim biotech group actively manages ongoing basis liquidity centrally order check minimize liquidity risk optimize liquidity management assess probability occurrence within organization environmental risk low case occurrence significant group company use various long shortterm financial affected instrument purpose syndicated credit facility place far risk opportunity group refinanced ahead schedule december 2014 based highly attractive market condition besides risk already described sartorius prevailing time financing structure stedim biotech group exposed potential risk converted holding company area result pronounced dependence groupwide financing subsidiary financed system since errorfree operation primarily financing contract within group essential smooth functioning company business process reduce security risk shortterm liquidity procurement also employ continuously enhancing implementing security various measure addition credit line guideline policy rule measure accessed repaid short notice based requirement iso 27001 number bilateral credit line place smaller standard german federal office scale individual group company furthermore information security bsi standard furthermore use cash pooling agreement selected group company existing application system company primary tool manage liquidity checked potential risk regular external within group internal audit appropriate measure taken minimize risk identified continuous alignment strategy business strategy tracking regulatory risk new technical development use advanced hardware software minimize risk inherent role supplier biopharmaceutical operation system environment new erp industry health care provider mean system commissioned sartorius stedim biotech sartorius stedim biotech also affected goettingen group headquarters 2012 underlying development area possibility successively rolled group site around regulatory authority fda emea adopting world starting 2014 conducting project restrictive approach approval new continued focus controlling risk medication remains principal source risk involved maintaining precautionary context move would reduce number backup system implementation new system new pharmaceutical product marketed brings whole series opportunity especially would consequently downgrade future prospect relation efficiency gain standardization sartorius stedim biotech medium term harmonization business process worldwide believe low probability occurrence risk mentioned case environmental risk occurrence significant sartorius stedim biotech group whole sartorius stedim biotech established environmental management system encompasses integrated division cover whole series environmentally relevant regulation minimize environmental risk management system certified compliance iso 14001 company relatively large manufacturing site respective company organizational unit ensure particular site law regulation relating environmental protection management report opportunity risk report 53 process risk legal dispute proceeding could substantial negative impact group result allowance made balance sheet cover cost potential proceeding insurance taken insurance policy cover wide range risk possible economically advisable insurance policy include coverage liability business interruption transport material pecuniary damage risk provide comprehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature extent insurance protection make adjustment necessary assessment overall risk situation risk outlook expedient feasible adopted countermeasure arranged balance sheet measure reporting year cover discernible risk within sartorius stedim biotech group potential damage net worth financial situation profitability judge probability occurrence risk presented low case occurrence significant sartorius stedim biotech group whole individual group company thorough analysis entire risk situation according current review discernible risk present could jeopardize continued existence group similarly based current review discernible risk could jeopardize future existence group 54 management report forecast report forecast report strong growth prospect moderate growth europe japan pharmaceutical industry growth european japanese pharmaceutical future global pharmaceutical industry market likely remain moderate 1 driven large part constantly expanding 4 next year continuing aging global population increasing access austerity measure impact respective healthcare healthcare emerging developing country system general increase prevalence lifestyle chronic disease new medication especially targeting condition currently difficult treat emerging country still driving growth also fuel significant growth expiry patent austerity measure cut healthcare spending expansion pharmerging market contrast particular industrialized country remain average around 8 11 per hand tend slow future growth industry annum 2014 2018 period rapid growth driven demographic trend market researcher ims health forecasting also notably rising level state investment overall growth 4 7 global healthcare system increased private spending pharmaceutical industry period 2014 2018 especially among fastexpanding middle class thus share global pharmaceutical market accounted pharmerging market u pharmaceutical market expected likely increase next five year post solid growth approximately 30 u pharmaceutical market world largest expected register growth 5 8 average period 2014 2018 expansion driven principally continuous rollout state health insurance demographic change price increase management report forecast report 55 pronounced longterm trend drive average growth biopharmaceutical industry global trend pharma market sector trend q aging population q average growth1 4 7 q patent expiry western country q increasing cost pressure eg q increasing population due healthcare reform improved access health care biopharma market developing economy q growing number chronic q average growth1 6 8 trend toward biotech civilization disease q continued market penetration approved indication technology trend singleuse technology q label expansion q higher yield efﬁciencies q doubledigit growth q personalized medicine cell cultivation q highest growth innovative q biosimilars q availability innovative segment eg bioreactors singleuse technology ﬂuid management q strong pipeline eg mabs q higher ﬂexibility change manufacturing system multipurpose 1 source ims global use medicine outlook 2017 2018 evaluate pharma world preview 20132014 june 20132014 bioplan 10 th annual report april 2013 biotech sector still growing faster market whole expert forecast suggest biopharma segment expiry patent significant factor pharmaceutical market enjoying traditional market likely increasing particularly strong growth year continue effect growth biotechnology market noting outperform market whole going forward expiry whole series patent ims health proportion sale revenue accounted report sale come known medication vaccine manufactured using biotech biosimilars biobetters likely swell method expected rise today figure u 10 billion 2020 around 22 23 approximately 26 period 2018 expert expect biotechnology market whole grow around 6 8 average 2014 continued exceptional growth driven 2018 part biopharmaceuticals already gained approval increasing market penetration expanding range indication part segment persistently strong research development pipeline proportion new development based biological manufacturing process particularly high around 40 56 management report forecast report biopharma growing market percentage worldwide rx otc pharmaceutical sale biotech v conventional technology biotech share within top 100 product 21 45 52 2006 2013 20201 568bn 754bn 1065bn biotechnology conventional unclassified 1 2020 split biotech n45 avg 36bn conv n55 avg 27bn source evaluate pharma world preview 2014 outlook 2020 june 2014 publicsector research demand stabilizes future business development ongoing widespread reduction national budget outlook fiscal 2015 incorporates risk likely affect overall level demand opportunity outlined report supply public sector 2015 however according biopharmaceutical industry business development frost sullivan important u market likely generally driven stable longterm trend stabilize current year thus global demand therefore economic fluctuation play less role public sector may broadly flat 2015 example decision regulatory agency regarding drug approval use medication source ims global use medicine outlook 2017 2018 ims searching terra firma biosimilars assuming trend toward biomanufacturing nonoriginal biologics market evaluate pharma preview pharmaceutical increasing utilization single 20132014 june 20132014 bioplan 10th annual report use technology continue expect sale april 2013 2014 midyear report forecast analysis revenue grow considerably 2015 thus global market laboratory product forecast sale revenue rise 4 7 constant currency compared strong prior year base management expects underlying ebitda margin rise 240 245 without currency effect considered please refer definition underlying ebitda margin page 199 glossary moreover 2015 plan invest 6 8 sale revenue mainly expansion production capacity regard financial position forecast end 2015 ratio net debt underlying ebitda edge without taking potential portfolio change account management report financial statement parent company sartorius stedim biotech sa december 31 2014 57 financial statement parent company sartorius stedim biotech sa december 31 2014 financial statement parent company annual shareholder meeting acknowledges informed new tax regulation sartorius stedim biotech sa parent company dividend according 2013 finance law group reminder since 1 january 2013 abolished right choose withholding tax company transformed mixt holding 21 submitting dividend company company managing distribution progressive scale tax income investment group real estate application 40 allowance french company retained without modification accordance article 158 3 2 4 french general code 2014 sale revenue generated sartorius stedim biotech sa 1465 k relative 1501 k 2013 dividend paid april 14 2015 operating profit 2817 k versus 2133 k 2013 net financing income totalled 27194k versus amount distributed january 1 2011 22717k 2013 eligible tax rebate follows net profit 2014 20875 k compared income eligible tax rebate 26198 k 2012 income fiscal year ended dividend distributed dec 31 2013 18412315 0 appropriation net profit dec 31 2012 16876856 0 dec 31 2011 15327238 0 annual shareholder meeting asm suggest appropriate net profit 2484526366 reporting year 2014 director receive sartorius stedim biotech sa share capital director meeting attendance fee whose amount allocation established board director consideration limit set asm follows share capital december 31 2014 legal reserve 49634313 total capital amount fifteen million three hundred fiftynine thousand two hundred thirtyeight balance resulting deduction legal reserve euro 15359238 divided 15359238 2434892053 share worth one euro 1 fully subscribed paid heading article 6 bylaw following amount added balance yearearlier profit carried forward 903234834 evolution share capital would yield distributable profit sartorius stedim biotech sa 3338126887 beginning 2014 fiscal year share total amount dividend disbursed capital company ten million three shareholder 1996700940 hundred ninety five thousand eight hundred six euro sixty six cent 1039580666 balance resulting disbursement 1341425947 year share capital company rose ten million three hundred ninety five remaining amount 1341425947 thousand eight hundred six euro sixty six carried next year cent 1039580666 ten million four hundred five thousand three hundred forty eight euro therefore considering company hold twenty eight cent 1040534828 treasury share net dividend 130 paid stock option exercised reduced ii nine million every share par value 1 three hundred sixtynine thousand one hundred thirtyfive euro eighteen cent 936913518 58 management report financial statement parent company sartorius stedim biotech sa december 31 2014 rose iii fifteen million three hundred share purchased share buyback fiftynine thousand two hundred thirtyeight euro program allocated following 15359238 following condition objective reduction share capital 849969 share representing approximately five per cent 5 company share capital ex must kept mind extraordinary change payment within scope potential ex shareholder meeting held 19 april 2010 ternal project term seventh resolution authorized 848741 share representing approximately five per board director trade share cent 5 company share capital de share buyback program specified livered case exercise right attached maximum number share purchased security giving access mean immediate company authorisation could exceed ly future date share capital ten per cent 10 total number share company comprising share capital maximum purchase price fortyfive euro 45 per share board director report submitted ii share thus purchased allocated extraordinary shareholder meeting 8 april 2014 following objective proposed said meeting reallocate share purchased share buyback program handle secondary market liquidity objective cancellation part share share company share capital reduction accordance deliver share case exercise right authorisation granted extraordinary attached security giving access company shareholder meeting 19 april 2010 share capital allocate repurchased share bought extraordinary shareholder meeting held 8 april company officer employee company 2014 authorized board director proceed andor company group within scope cancellation one several installment stock option plan free granting decision alone portion share acquired share company saving plan etc company context share repurchase retain company share programme limit ten per cent 10 purchased order return exchange pay company share capital period twentyfour 24 ment within scope potential external project month provided ten percent 10 limit cancel repurchased share applied company share capital share capital reduction company necessary adjusted take account transaction pursue objective subsequently affecting share capital company occur permitted applicable law regulation subsequent shareholder meeting meeting held 19 april 2010 board extraordinary shareholder meeting held director unanimously decided implement 8 april 2014 authorized board director share buyback program pursuant condition set reduce company share capital accordingly forth extraordinary shareholder meeting held 19 april 2010 extraordinary shareholder meeting held 8 april 2014 granted board director course 2010 fiscal year company authorization period twentysix 26 month acquired one million six thousand ninetyeight date extraordinary shareholder seven hundred ten 1698710 share meeting held 8 april 2014 representing approximately exceeding ten per cent 10 share capital pursuant share buyback program authorized extraordinary shareholder meeting held 19 april 2010 share acquired aggregate amount sixtyone million three hundred twentyseven thousand one hundred ninety euro seven cent 6132719007 corresponding average price thirtysix euro ten cent 3610 per share management report financial statement parent company sartorius stedim biotech sa december 31 2014 59 meeting 17 july 2014 board operation done increase director light authorisation granted nominal unit value seventeen million fortytwo extraordinary shareholder meeting hold thousand three hundred six 17042306 existing 8 april 2014 reduced share capital nominal share sixtyone cent 061 one euro 1 amount one million thirtysix thousand two hundred thirteen euro ten cent said extraordinary shareholder meeting 103621310 cancelling entirety authorized board director implement share acquired share buyback program decision increase share capital authorised extraordinary shareholder meeting consequently determine definitive nominal held 19 april 2010 ie one million six hundred amount share capital increase based ninetyeight seven hundred ten 1698710 share number share existing date specified amount share decision board director complete represents less ten per cent 10 share share capital increase capital company date operation difference purchase price authorisation granted period five cancelled share 6132719007 nominal 5 year date extraordinary value 103621310 difference equal sixty shareholder meeting held 8 april 2014 million two hundred ninety thousand nine hundred seventysix euro ninetyseven cent 17 july 2014 board director using 6029097697 charged delegation power granted available premium thirtyseven million eight extraordinary shareholder meeting 8 april 2014 hundred eightyeight thousand nine hundred twenty decides carry share capital increase nine euro eighteen cent 3788892918 capitalization five million nine hundred ninety balance twentytwo million four hundred two thousand one hundred two euro eightytwo thousand fortyseven euro seventynine cent cent 599010282 drawn issue 2240204779 item retained earnings premium set forth annual account company financial period closed operation reduction share capital 31 december 2013 approved extraordinary le share capital amounted nine million three shareholder meeting held 8 april 2014 hundred sixtynine thousand one hundred thirtyfive euro eighteen cent 936913518 divided share capital increase carried fifteen million three hundred fiftynine thousand increase thirtynine cent 039 nominal two hundred thirtyeight 15359238 share amount fifteen million three hundred fiftynine nominal unit value sixtyone cent 061 thousand two hundred thirtyeight 15359238 share comprising share capital company increase share capital nominal unit value went sixtyone cent 061 one euro 1 extraordinary shareholder meeting held 8 april 2014 decided increase share capital sum cost relating share capital maximum nominal amount six million six hundred increase charged one several fortysix thousand four hundred ninetynine available reserve deduct amount euro thirtyfour cent 664649934 calculated sum necessary increase legal reserve basis number share existing date aforementioned shareholder meeting end definite completion reduction carried proportional increase company share capital done capitalisation available sum drawn issue 17 july 2014 company share capital premium amount fifteen million three hundred fifty nine thousand two hundred thirtyeight euro 15359238 divided fifteen million three hundred fiftynine thousand two hundred thirty eight 15359238 share nominal unit value one euro 1 60 management report financial statement parent company sartorius stedim biotech sa december 31 2014 number share share capital share par share capital share number new date nature transaction value increase premium share transaction transaction exercise share 1st half 2010 subscription option 061 162669 4869394 26667 16999388 103696270 exercise share 2nd half 2010 subscription option 061 85766 2285999 14060 17013448 103782036 exercise share 1nd half 2011 subscription option 061 61000 1344000 10000 17023448 103843036 exercise share 2ndhalf 2011 subscription option 061 15250 722500 25000 17025948 103858286 exercise share 1st half 2012 subscription option 061 50980 1734460 83580 17034306 103909266 exercise share 2st half 2012 subscription option 061 42700 2023000 70000 17041306 103951966 exercise share year 2013 subscription option 061 6100 86200 10000 17042306 103958066 exercise share year 2014 subscription option 061 95416 1348340 156420 17057948 104053482 reduction capital cancellation treasury year 2014 share 061 10362131 16987100 15359238 93691351 increase capital year 2014 nominal value change 100 59901028 15359238 153592380 sartorius stedim biotech sa shareholding december 31 2014 situation sartorius stedim biotech sa shareholding shareholder share voting right 50 sartorius ag sartorius ag 10 less 50 none none 5 less 10 none none management report financial statement parent company sartorius stedim biotech sa december 31 2014 61 past three year ownership sartorius stedim biotech share capital distributed follows december 312012 december 31 2013 december 31 2014 number share voting number share voting number share voting shareholder share capital right share capital right share capital right sartorius ag 9770178 573 725 9770178 573 725 9770178 636 726 single voting right double voting right 9770178 573 725 9770178 573 725 9770178 636 726 vl finance 1642095 96 122 1642095 96 122 1642095 107 122 single voting right double voting right 1642095 96 122 1642095 96 122 1642095 107 122 total sartorius group 11412273 670 846 11412273 670 846 11412273 743 848 treasury share 1698710 100 00 1698710 100 00 personnel shareholder general public 3930323 231 154 3931323 231 154 3946965 257 152 single voting right 3719587 218 138 3720587 218 138 3736229 243 139 double voting right 210736 12 16 210736 12 16 183150 12 14 total share 17041306 1000 1000 17042306 1000 1000 15359238 1000 1000 belonging sartorius ag reverse merger sartorius stedim legal disclosure threshold crossed company vl finance said individually passed 9 december 2010 following sale letter received 7 august 7 2014 amf autorité sartorius stedim biotech share share de marché financier intended person buyback program share threshold 20 following threshold occurred regularization voting right 10 issued capital sartorius stedim biotech held individually simplified joint stock company vl finance1 date 1642095 share sartorius stedim zone industrielle le paluds avenue de jouques biotech representing 3284190 voting right 13400 aubagne said individually passed 965 issued capital 1760 voting 31 december 2007 following sale market right company3 share sartorius stedim biotech threshold 13 25 voting right 20 15 company sartorius ag said individually issued capital sartorius stedim biotech passed 7 december 2011 following held individually date 2012095 share allocation double voting right threshold sartorius stedim biotech representing 4024190 23 voting right company sartorius voting right 1191 capital 2128 stedim biotech held individually date voting right company2 9770178 share sartorius stedim biotech representing 19540356 voting right 5738 german company sartorius ag weender issued capital 6771 voting right landstrasse 94 108 37075 goettingen germany company4 said individually passed 31 december 2007 following decrease total number company vl finance said individually company sartorius stedim biotech voting right passed 7 december 2011 following threshold 50 voting right increase total number voting right sartorius stedim biotech individually held company sartorius stedim biotech threshold date 9770178 share sartorius stedim 15 voting right company biotech representing many voting right ie sartorius stedim biotech held individually 5782 issued capital 5166 date 1642095 share sartorius stedim voting right company2 biotech representing 3284190 voting right 62 management report financial statement parent company sartorius stedim biotech sa december 31 2014 964 issued capital 1138 voting 3284190 voting right ie 1069 issued capital right company4 1217 voting right company7 letter received 18 july 2014 completed occasion company sartorius ag particular letter received 7 august 2014 passed directly indirectly company vl company vl finance5 individually passed finance control threshold said 17 july 2014 reduction issued held 1 august 2014 11412273 share capital company sartorius stedim biotech6 sartorius stedim biotech representing 22824546 threshold 10 issued capital sartorius voting right ie 7430 issued capital stedim biotech held individually 1642095 8456 voting right company7 sartorius stedim biotech share representing follows share issued capital voting right voting right vl finance 1642095 1069 3284190 1217 sartorius ag 9770178 6361 19540356 7239 total sartorius ag 11412273 7430 22824546 8456 letter following declaration intent hold agreement financial instrument made referred 4 4 bi article l 233 9 commercial code company vl finance say six 6 month come provided article l 233 7 entered temporary reverse commercial code vii agreement share voting right company sartorius stedim biotech threshold crossing passive nature without acquisition share result intend request appointment new cancellation treasury share held company member board director sartorius sartorius stedim biotech stedim biotech provided concert sartorius ag vl finance sa already represented consider additional acquisition board five 5 total eight sartorius stedim biotech share 8 director 1 act agreement another shareholder controlled company sartorius ag controlled company sartorius ag towards sartorius stedim liability proceeding constituted mr c franken mr u baro mr k sartoriusherbst dealing property biotech company bequeathed mr horst sartorius administered independently executor mr arnold picot already control sartorius stedim 2 based issued capital date 16897988 share biotech company member concert representing 18912368 voting right pursuant second sartorius ag vl finance sa holding date paragraph article 22311 general regulation 3 based issued capital date 17013448 share declaration 7430 issued capital representing 18664042 voting right pursuant second 8456 voting right sartorius stedim paragraph article 22311 general regulation biotech 4 based issued capital date 17025948 share representing 28857961 voting right pursuant second wish pursue strategy implemented paragraph article 22311 general regulation 5 controlled company sartorius ag controlled company sartorius stedim biotech described liability proceeding constituted mr c franken mr u baro company reference document mr k sartoriusherbst dealing property company sartorius stedim biotech filed bequeathed mr horst sartorius administered amf 27 february 2014 independently executor mr arnold picot 6 see press publication company dated 17 july 17 2014 7 basis issued capital composed 15359238 consider transaction listed share representing 26993188 voting right pursuant article 223 17 6 general regulation second paragraph article 223 11 general amf regulationcontrol company december 31 2014 management report financial statement parent company sartorius stedim biotech sa december 31 2014 63 control company december 31 2014 authority delegated annual shareholder meeting board director still valid sartorius ag hold directly indirectly 74 share capital 85 outstanding voting right multiple delegation granted board treasury share without voting right director combined shareholder meeting 8 april 2014 staff shareholding 1 able increase share capital company capitalizing everything portion exception stock subscription plan stock issue premium increasing nominal value option plan company run employee existing share currently amounting 061 1 profitsharing scheme limit equal 664649934 corresponding maximum nominal amount increase share capital delegation power granted treasury share held period 5 year date shareholder sartorius stedim biotech sa meeting 8 april 2014 17 july 2014 board director decided share capital following decision taken extraordinary increased capitalizing amount 599010282 shareholder meeting 8 april 2014 treasury deducted share premium account share held company cancelled contained year ended 31 december 2013 see information page 57 sartorius stedim biotech sa operation realized increasing nominal value share capital existing share amounting 061 1 2 able reduce share capital unpaid capital cancellation share purchased share buyback program limit amount 10 none adjusted capital account necessary transaction affecting share capital performed combined shareholder meeting 8 april 2014 actual completion date capital reduction authorized unissued capital made board director authorization granted period 26 month date none shareholder meeting 8 april 2014 17 july 2014 board director decided share capital reduced nominal amount security representative share capital 103621310 cancellation overall treasury share pursued share buyback none program amounting 1698710 share representing less 10 share capital time transaction difference value cancelled share 6132719007 nominal amount 103621310 equal 6029097697 charged share premium account amounting 3788892918 retained earnings account amounting 2240204779 3 ability issue share andor security giving access share capital company andor security giving right allotment debt instrument preferential subscription right shareholder limit 2000000 corresponding maximum nominal amount increase share capital maximal nominal amount debt instrument delegation authority granted period 26 month date shareholder meeting 8 april 2014 64 management report financial statement parent company sartorius stedim biotech sa december 31 2014 4 ability issue share andor security giving 8 ability issue share andor security giving access share capital company andor access share capital company security giving right allotment debt consideration contribution kind consisting instrument without preferential subscription right company share andor security giving access shareholder public offering share capital maximum ten per cent 10 limit deducted overall limit 2000000 share capital outside public exchange offer increase share capital overall limit initiated company limit amount 10 2000000 debt instrument delegation share capital deducted overall limit authority granted period 26 month 2000000 increase share capital date shareholder meeting overall limit 2000000 debt instrument 8 april 2014 delegation authority granted period 26 month date shareholder meeting 5 ability issue share andor security giving 8 april 2014 access share capital company andor security giving right allotment debt 9 ability issue share andor security giving access instrument without preferential subscription right share capital company consideration shareholder private placement security tendered public exchange offer set forth article l411 2 ii french monetary initiated company without preferential financial code limit deducted subscription right shareholder limit overall limit 2000000 increase share deducted overall limit 2000000 increase capital overall limit 2000000 debt share capital overall limit 2000000 instrument delegation authority granted debt instrument delegation authority period 26 month date granted period 26 month date shareholder meeting 8 april 2014 shareholder meeting 8 april 2014 6 ability event issuance share 10 ability increase share capital andor security giving access share capital capitalization reserve earnings premium company public offering private sum upon capitalization would placement set forth article l411 2 ii permitted limit 2000000 corresponding french monetary financial code without maximum nominal amount increase preferential subscription right shareholder share capital independent limit delegation set issuance price condition defined authority granted period 26 month shareholder meeting maximum ten date shareholder meeting 8 april 2014 per cent 10 share capital per year limit amount 10 share capital period 12 month deducted overall limit 1 security giving access 2000000 increase share capital share capital overall limit 2000000 debt instrument delegation authority granted period 26 month date shareholder meeting stock option 8 april 2014 7 ability increase number share andor share subscription plan security giving access share capital company issued event share capital stock option plan detailed table increase without preferential subscription authority delegated board director right shareholder limit amount 15 setting new plan recently expired board initial issue share deducted overall director longer delegated limit 2000000 increase share capital authority set new plan overall limit 2000000 debt instrument delegation authority granted period 26 month date shareholder meeting 8 april 2014 management report financial statement parent company sartorius stedim biotech sa december 31 2014 65 number total number share number number date total option senior number sub subscribed option target number agm number granted executive initial scrip granted performance beneficiary authorized option senior bene bene tion jan 1 based valid plan board meeting granted executive ficiaries ficiaries price dec 31 14 exercisable option option june 23 2000 aug 2 2000 139105 0 0 5 859 0 0 0 0 sept 28 june 23 2000 2001 142855 0 0 7 1194 0 0 0 0 june 23 2000 oct 14 2002 12100 0 0 1 678 0 0 0 0 sept 10 june 23 2000 2003 22000 0 0 1 79 0 0 0 0 june 23 2000 feb 11 2004 66000 0 0 1 642 0 0 0 0 june 23 2000 july 23 2004 140000 0 0 19 923 15642 0 0 0 sept 15 june 10 2005 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2005 35000 0 0 2 2951 0 3000 0 1 total 684560 0 0 51 15642 8000 0 2 8000 agm annual general shareholder meeting change number stock option january 1 2012 december 31 2014 2014 2013 2012 outstanding share january 1 23642 24642 40000 allocated period 0 0 cancelled period 0 0 exercised period 15642 1000 15358 lapsed period 0 0 outstanding december 31 8000 23642 24642 share capital dilution option exercised fiscal year december 31 2014 total number share reported year 15642 option exercised capable issued basis performance ten significant accounted total based share subscription option potential 8000 option exercised 2014 share 0052 fully diluted share capital share subscription warrant share subscription option granted senior executive company option sartorius stedim biotech sa issued share exercised fiscal 2014 subscription warrant none pledging share share subscription option granted ten top sartorius stedim biotech sa share pledged nonsenior executive beneficiary option exercised 2014 fiscal year pledging asset none none 66 management report financial statement parent company sartorius stedim biotech sa december 31 2014 dividend distribution policy company dividend distribution policy based net profit generated group level relevant fiscal year well group foreseeable growth profitability april 8 2014 annual shareholder meeting voted payment net dividend 120 per share dividend available payment april 15 2014 dividend interim dividend unclaimed five year following payment date must paid state ie france article 2277 french civil code 2013 2012 2011 2010 2009 dividend per share fiscal year 120 110 100 090 060 number share 15343596 15342596 15327238 15314738 16972721 dividend corrected per share 1 120 110 100 090 066 1 compared number share december 31 2013 senior executive membership committee director receives lumpsum amount 4000 per information sartorius stedim biotech sa senior full year membership addition executive list position hold attendance fee 1200 insofar hold held past five year included chair instead receive lumpsum corporate governance report amount 8000 per full year hold chairperson addition attendance fee remuneration activity committee director meeting attendance fee due together remuneration term previous subsection hereof director meeting attendance fee calculated annual basis method calculating fee valueadded tax reimbursed changed 2014 fiscal year corporation insofar member board entitled invoice corporation separately director receive director meeting attendance valueadded tax exercise right fee whose amount allocation established board director consideration limit resolution applied set asm director got executive top management activity group level context director receives fixed remuneration executive corporate officer receive 25000 per year paid annual remuneration membership financial statement adopted annual shareholder meeting fall due total 207200 paid director meeting payment annual shareholder meeting attendance fee 2014 chairman board receives twice amount furthermore member board receive attendance fee 1200 per meeting reimbursement expense addition annual remuneration management report financial statement parent company sartorius stedim biotech sa december 31 2014 67 compensation executive management team director meeting base fixed annual long term stock departure attendance salary incentive incentive option indemnity fee k k k k k k k total 2013 33560 15830 8460 8740 530 00 00 00 total 2014 41730 16850 10850 13500 530 00 00 00 joachim kreuzburg1 2013 14430 6350 2680 5210 190 00 00 00 joachim kreuzburg1 2014 17330 6750 3730 6670 180 00 00 00 volker niebel1 2013 5510 2800 2070 540 100 00 00 00 volker niebel1 2014 6250 3000 2430 710 110 00 00 00 1 oscarwerner reif 2013 5490 2800 2070 540 80 00 00 00 oscarwerner reif1 2014 6220 3000 2430 710 80 00 00 00 reinhard vogt1 2013 8130 3880 1640 2450 160 00 00 00 reinhard vogt1 2014 11930 4100 2260 5410 160 00 00 00 1 detail please refer chapter corporate governance page 86 93 independent auditor payment term trade payable independent auditor sartorius stedim december 31 2014 balance trade payable biotech sa totaled 975229 trade payable comprised following ernst young represented xavier senent alternate auditor auditex 76 invoice paid 30 day regarding invoice issue date deloitte associés represented christophe perrau alternate auditor beas 23 invoice paid 60 day regarding invoice issue date group decided settle recommendation green book european community date cumulative overdue trade approval financial statement payable amounted 1 31 december 2014 annual shareholder meeting 7 april 2015 propose nomination kpmg december 31 2013 balance trade payable replace ernst young audit totaled 1701683 trade payable comprised following current regulated agreement 8183 invoice paid 30 day regarding invoice issue date shareholder sartorius stedim biotech group requested approve agreement 18 invoice paid 60 day regarding covered article l225 38 french invoice issue date commercial code duly authorized board director form submitted date cumulative overdue trade payable amounted 017 68 management report financial statement parent company sartorius stedim biotech sa december 31 2014 fiveyear financial result parent company sartorius stedim biotech sa k 2010 2011 2012 2013 2014 share capital end period share capital capital stock 10378 10386 10395 10396 15359 number share outstanding 17013448 17025948 17041306 17042306 15359238 transaction financial performance sale revenue excl vat 65026 71855 81942 1501 1465 profit tax employee profit sharing plan amortization depreciation provision expense reversal 25884 23617 26218 21180 25967 income tax 1185 1069 678 292 468 contribution employee profitsharing plan 0 0 0 0 0 net profit 21066 23860 26198 20875 24845 dividend paid proposal dividend 13783 15327 16877 16878 18412 earnings per share eps tax employee profitsharing amortization depreciation provision expense 159 145 158 126 166 eps tax employee profitsharing amortization depreciation provision expense 124 140 154 122 162 dividend per share 090 100 110 110 120 personnel workforce size 293 336 388 0 0 personnel cost 11177 11843 14171 0 0 social security cost 6007 6574 7969 0 0 corporate governance 70 corporate governance board director committee board director committee board director joachim kreuzburg board director composed eight member chairman chief executive officer two independent director appointed threeyear period date birth april 22 1965 nationality german organization work board composition must suited shareholding first appointment 29 june 2007 structure size nature activity mandate renewed 16 april 2013 sartorius stedim biotech sa particular appointed date annual general circumstance facing shareholder meeting 2016 approve financial statement fiscal year ending composition board director 31 december 2015 december 31 2014 number sartorius stedim biotech share held 1 historical reason due shareholding structure company composition current directorship position board director comittees reflected within group search reference shareholder long lasting chairman executive board vorstand balance director representing sartorius ag shareholder independant director vice chairman supervisory board executive sartorius stedim biotech gmbh managing director sartorius lab holding gmbh reference shareholder take responsibility member board director towards shareholder direct distinct sartorius stedim north america inc board director one take particular member board director care avoid possible conflict interest sartorius stedim filter inc transparency information provided member board director market fairly take interest account sartorius stedim japan kk member board director board director consider would sartorius stedim lab ltd desirable balance membership président vl finance sa committee stablished particular member board director representation woman men nationality sartorius japan kk diversity skill taking measure appropriate member board director guarantee shareholder market denver instrument beijing co ltd mission carried necessary member board director independence objectivity make public sartorius scientific instrument beijing co ltd reference document objective method member board director resuts politics subject sartorius hong kong ltd member board director sartorius north america inc président member executive committee sartorius stedim fmt sa past directorship held past five year within group vice chairman supervisory board sartorius weighing technology gmbh member board director sartorius stedim sus inc member board director sartorius biohit liquid handling oy corporate governance board director committee 71 current directorship position volker niebel outside group member advisory board regionalbeirat executive member commerzbank ag germany executive vice president operation member advisory board beirat date birth august 14 1956 otto bock holding gmbh co kg germany nationality german member economic advisory board wirtschafts beirat norddeutsche landesbank germany first appointment 29 june 2007 member supervisory board aufsichtsrat mandate renewed 16 april 2013 carl zeiss ag germany appointed date annual general shareholder meeting 2016 approve past directorship held past five year financial statement fiscal year ending outside group 31 december 2015 member advisory board beirat hameln group gmbh germany number sartorius stedim biotech share held 1 educational professional background current directorship position diplommaschinenbauingenieur dr rer pol within group university degree mechanical engineering managing director geschäftsführer doctorate economics sartorius stedim biotech gmbh member board director 19921995 research associate institute sartorius stedim north america inc solar energy research hamelin member board director germany sartorius north america inc 19951999 research associate faculty member board economics management sartorius stedim filter inc university hanover germany member board director since sartorius ag goettingen germany sartorius stedim india pvt ltd may 1 1999 recent position member board director promotion executive board sartorius weighing india pvt ltd vice president finance member board director investor relation sartorius stedim lab ltd since member executive board member board director nov 11 2002 sartorius ag goettingen germany sartorius stedim aseptics sa may 1 2003 spokesman sprecher managing director nov 10 2005 executive board sartorius ag sartorius stedim bioprocess sarl goettingen germany managing director sartorius stedim biotech sarl since ceo executive board chairman managing director nov 11 2005 sartorius ag goettingen sartorius stedim integrated service sarl germany currently responsible managing director member operation corporate strategy executive committee sartorius stedim fmt sa legal affair compliance member board director corporate communication biohit biotech suzhou co ltd past directorship held past five year within group member board director sartorius stedim sus inc managing director sartorius stedim sus sarl managing director sartorius stedim dd sarl managing director sartorius stedim industry sarl member board director sartorius stedim system inc 72 corporate governance board director committee educational professional background 19952009 sartorius ag goettingen germany diplombetriebswirt university degree business recent position vice president administration economics rd technology 2007 2009 sartorius stedim biotech gmbh recent position vice president 19831985 schmidt clemens lindlar rd technology germany sale manager petro since 2009 managing director sartorius chemical industry usa stedim biotech gmbh goettingen 19851998 gambro ab lund sweden germany 19982001 skanska ab malmö sweden member executive management team poggenpohl reinhard vogt gmbh herford germany 20012007 sartorius ag goettingen germany executive member recent position executive vice president marketing sale service senior vice president operation date birth august 4 1955 biotechnology division nationality german since 2007 managing director sartorius stedim biotech gmbh goettingen first appointment 29 june 2007 germany mandate renewed 16 april 2013 appointed date annual general shareholder meeting 2016 approve oscarwerner reif financial statement fiscal year ending 31 december 2015 executive member executive vice president research development number sartorius stedim biotech share held 1 date birth november 11 1964 nationality german current directorship position within group first appointment 29 april 2009 member executive board sartorius ag appointed 17 april 2012 managing director appointed date annual general sartorius stedim biotech gmbh shareholder meeting 2015 approve member board director financial statement fiscal year ending sartorius stedim north america inc december 31 2014 member board director sartorius north america inc number sartorius stedim biotech share held 1 member board director sartorius stedim malaysia sdn bhd current directorship position within member board director group sartorius stedim australia pty ltd managing director sartorius stedim biotech gmbh member board director member board director sartorius stedim sartorius australia pty ltd switzerland ag member board director denver instrument beijing co ltd past directorship held past five year member board director none sartorius scientific instrument beijing co ltd member board director educational professional background sartorius shanghai trading co ltd diplomchemiker dr rer nat university degree m member board director degree chemistry molecular biology doctorate sartorius stedim shanghai trading co ltd chemical engineering member board director sartorius hong kong ltd 19911995 research associate institute member board director chemical engineering tap biosystems group ltd university hanover germany member board director sartorius stedim switzerland ag corporate governance board director committee 73 member board director managing director l2 l conseil sarl sartorius japan kk management consulting service human resource member board director management sartorius stedim japan kk member board director educational professional background sartorius korea ltd phd organic chemistry 1972 mba 1966 past directorship held past five year master degree sanskrit 1969 within group member board director 19691977 scientific employee charge sartorius stedim sus inc research french cnrs member board director national center scientific sartorius stedim india pvt ltd research later university member board director california berkeley california usa sartorius stedim biotech beijing co ltd 19771981 psa automobile citroën managing director geschäftsführer head department charge sartorius weighing technology gmbh overall manufacturing planning managing director geschäftsführer programming sartorius lab holding gmbh 19811985 renault automation robotics vice president strategic planning educational professional background 19851989 ceo chairman board industriekaufmann vocational diploma industrial hightech startup company business administration specializing artificial intelligence cognitech 19791983 sarstedt ag nuembrecht germany 19892005 consultant human resource general manager sarstedt ab management company executive sweden especially multicultural 19832007 sartorius ag goettingen germany environment recent position senior vice 20052007 ceo stedim biosystems president sale marketing 20072008 executive vice president biotechnology division sartorius stedim biotech since 2007 managing director sartorius since managing director l2 l conseil stedim biotech gmbh goettingen may 2008 sarl management consulting germany service management human since 2009 member executive board resource sartorius ag goettingen germany currently responsible marketing sale service bernard lemaître nonexecutive member liliane de lassus date birth december 16 1938 nationality french nonexecutive member date birth december 29 1943 first appointment 29 june 2007 nationality french mandate renewed 16 april 2013 appointed date annual general first appointment 29 june 2007 shareholder meeting 2016 approve mandate renewed 16 april 2013 financial statement fiscal year ending appointed date annual general 31 december 2015 shareholder meeting 2016 approve financial statement fiscal year ending number sartorius stedim biotech share held 31 december 2015 200 691 number sartorius stedim biotech share held 1 current directorship position outside group current directorship position outside president financière de la seigneurie sa group member board director senova system inc 74 corporate governance board director committee member board director educational professional background sycovest asset management paris bankkaufmann diplomkaufmann banker university member supervisory board degree business administration dr rer pol post azulis capital sa paris doctoral lecture qualification venia legendi betriebs member supervisory board wirtschaftslehre authorization teach business solon venture ltd london managerial economics university member supervisory board qualium investment sa paris 19701975 research assistant assistant professor university munich past directorship held past five year 19761984 university professor faculty outside group business administration university member supervisory board intrasense sa hanover germany director institute management educational professional background organization 19792007 founder ceo chairman 19801981 visiting scholar stanford university stedim sa california usa 19841987 university professor faculty business administration technical arnold picot university munich director institute general industrial nonexecutive member business administration date birth december 28 1944 since 1988 university professor executive nationality german director institute information organization first appointment 29 june 2007 management faculty economics mandate renewed 16 april 2013 ludwig maximilian university appointed date annual general munich shareholder meeting 2016 approve 20042005 konrad adenauer visiting professor financial statement fiscal year ending georgetown university washington 31 december 2015 dc usa number sartorius stedim biotech share held 1 henri riey current directorship position within group nonexecutive member chairman supervisory board independent member sartorius ag date birth november 5 1961 chairman supervisory board nationality monegasque sartorius stedim biotech gmbh first appointment 29 june 2007 past directorship held past five year mandate renewed16 april 2013 within group appointed date annual general chairman supervisory board shareholder meeting 2016 approve sartorius weighing technology gmbh financial statement fiscal year ending 31 december 2015 current directorship position outside group number sartorius stedim biotech share held 50 member supervisory board takkt ag member supervisory board current directorship position outside wissenschaftliches institut für infrastruktur und group kommunikationsdienste gmbh und president aidea wikconsult gmbh president groupe hr sa director princess grace foundation monaco past directorship held past five year outside group past directorship held past five year none outside group none corporate governance board director committee 75 educational professional background educationnal professional background diplôme institut supérieur de gestion france degree earned french higher institute graduated essec ecole supérieure de science business management institut supérieur de gestion economiques et commerciales 19851988 fund manager paribas bank 1984 1987 international distiller vinters 19881996 fund manager responsible france product manager european equity fund management 1988 1990 urgo laboratory adhesive team barclays bank france marketing manager 19961999 head research barclays asset 1991 1995 roc sa johnson johnson head management europe international marketing group 19992004 executive vice president barclays 1998 2000 sanofi pasteur msd france product asset management charge manager adult vaccine fund management business 2001 2005 sanofi pasteur head range 2004 2013 cfo hendyplan sa europe adult vaccine marketing director 2006 2008 sanofi pasteur msd executive manager business management board director 18 february 2015 2009 2010 sanofi pasteur msd vice president proposed annual shareholder meeting business management nominate independent member mr annemarie since 2011 managing director smag sàrl advice griffin mr susan dexter biotech medtech strategy professional background management annemarie graffin susan dexter nonexecutive member nonexecutive member independent director independant director date birth 3 may 1961 date birth october 11 1955 nationality french nationality american number share sartorius stedim biotech held 0 number sartorius stedim biotech share held 0 mandate current function current directorship position member supervisory board valneva se biosense technology woburn massachusetts usa since march 2013 clinical diagnostic technology based cellular member supervisory board nanobiotix sa impedence since january 2014 managing director smag consulting sarl since september 2011 past directorship held past five year biosense technology woburn massachusetts usa active number mandate exercised achieved within kalon biotherapeutics college station last past five year texas usa retired cmo member board director themis bioscience gmbh july 2012 december 2014 member board director portugal sanofi degree certification pasteur msd march 2008 december 2010 member board director spain sanofi b immunology marketing double major pasteur msd march 2009 december 2010 honor american university washington dc usa member board director uk sanofi harvard university negotiation course lawyer pasteur msd march 2009 december 2010 harvard university cambridge massachusetts usa member board director ireland sanofi finance nonfinancial manager harvard pasteur msd march 2009 december 2010 university dow chemical company internal training program 76 corporate governance board director committee work history shareholder meeting 7 april 2015 nominate two new independent administrator order reach 1975 1980 university massachusetts medical threshold school research mammalian cell culture animal toxicology study pursuant principle good corporate basic research governance independent member may 1980 1986 collaborative research biotechnology principal shareholder employee former group sale emerging market employee supplier banker group major bioprocessing supplement raw customer may link likely material biomanufacuting impair judgment 1986 1998 celltech biologics lonza biologics business developmentbioprocessing sartorius stedim biotech sa board director manufacturing biotechnology includes two independent director mr liliane de based biotherapeutics lassus mr henri riey 1998 2004 collaborative bioalliance dow chemical company dow biotechnology contract criterion needed qualify independent manufacturing service vice president director following business develoment microbial fermentation service technology may employee senior executive implementation single use employee director parent company bioprocessing technology one consolidated company may 2004 2008 xcellerex inc ge healthcare five previous year chief business officer cmo service may senior executive company using fully integrated singleuse company directly indirectly hold bioprocessing technology sale director position employee single use bioprocessing technology senior executive company either 2008present latham biopharm group principal currently less five year consultant vp business development hold director position multiple cmos offering contract may significant client supplier business manufacturing service banker investment banker company biotechnology life science industry group company group strategic consulting singleuse represents significant part business disposable technology implementation may close family tie one project management highlevel senior executive business development marketing may auditor company advisor speak bioprocess five past year international may director company twelve year registered address balanced representation woman men regard social mandate member board director general manage term men woman representation ment domiciled company headquarters objective board reach maintains percentage least 20 woman threeyear notice least 40 woman sixyear notice independent director starting 2010 shareholder meeting board composed least ten member company controlled majority difference sixyear period shareholder portion independent administrator gender cant higher administrator board member least two 31 december 2014 board director third board 31 december 2014 composed 125 woman respect board director sartorius stedim sa 20 percentage mentioned order get composed 25 independent member line proposed 7 april 2015 shareholder independence criterion defined apefmedef meeting nominate two new woman administrator code order comply proposed order reach threshold corporate governance board director committee 77 staggering mandate term company knowledge within last five year member board director according apef medef governance code listed company staggering term convicted fraud last five organized order avoid renewing group year subject official public mandate promote harmonious renewing investigation sanction statutory regulatory administrator mandate 31 december 2014 authority afferent rule relating staggering term associated capacity manager respected given operation firm bankruptcy receivership liquidation closely related presence reference past five year shareholder purchasing company sartorius stedim disqualified court acting 2007 thereby nominated member capacity member administrative board time order get line management supervisory body issuer rule board director partially acting capacity management renewed seven member 2016 three executive conducting business issuer member 2018 past five year plurality mandate company knowledge family relationship accordance apef medef governance code exist among member company board listed company executive director cant director exercise two mandate director listed company outside group including foreign furthermore company knowledge company addition collect notice conflict interest duty member board accepting new director board director private interest mandate listed company duty director must inform board soon aware conflict interest moreover administrator cant exercise even possibility potential conflict must four mandate listed company outside refrain participation discussion group including foreign company relevant subject matter voting recommendation applied nomination associated resolution renewal administrator mandate company knowledge settlement information agreement reached shareholder client supplier others appoint member board board director met eight time director fiscal 2014 company knowledge service accordance bylaw sartorius stedim contract linking board member sartorius biotech sa company diretor owns personally stedim biotech group granting least one share company benefit director fulfill mentioned threshold knowledge company administrator regard number mandate listed linked sartorius stedim biotech service company contract conferring advantage executive director maximum two measure taken ensure control done mandate company belonging group abusive way following 2 independent member board 8 non executive director maximum four member board director mandated company belonging group 2 independent member board 4 member audit committee 2 independent member board 4 member remuneration committee 78 corporate governance board director committee audit committee audit committee currently composed four member mr henri riey chairman committee since december 5 2007 mr arnold picot mr liliane de lassus mr bernard lemaître chairman audit committee mr de lassus independent chairman board director also ceo group permanent guest audit committee voting right audit committee met five time fiscal 2014 remuneration committee remuneration committee currently composed four member mr arnold picot chairman committee since june 29 2007 mr liliane de lassus mr henri riey mr bernard lemaître two four member remuneration committee independent remuneration committee met twice fiscal 2014 information organization function activity committee fiscal 2013 please refer chairman report pursuant article l 225 37 french commercial code included publication following page corporate governance chairman report pursuant article l 225 37 79 chairman report pursuant article l 225 37 pursuant article l 225 37 french corporate governance code commercial code chairman board director us report cover fiscal year since fiscal 2008 sartorius stedim biotech sa ended december 31 2014 present composition board director therefore decided adopt board director application afepmedef recommendation reference code principle balanced representation men corporate governance see wwwmedeffr woman condition preparation organization work board director afepmedef corporate governance code internal controlling control procedure code defines set regulation good implemented company within group responsible corporate governance follows comply explain principle implemented pursuant last paragraph article l 225 235 country european union listed french commercial code company company comply recommendation independent auditor prepare report code must explain corporate concerning report chairman board governance report director internal control risk management procedure relative preparation processing accordance article 251 corporate accounting financial information governance code listed company effect presented date code listed company referring code required precisely identify reference document application recommendation case nonapplication one provision company required provide comprehensible relevant circumstantial explanation according rule apply explain recommended amf recommendation n2014 08 22 september 2014 company indicate specific table recommendation applied related explanation 80 corporate governance chairman report pursuant article l 225 37 specific table recommendation afep medef code governance listed company article provision code removed explanation 32 disclosure option selected board director opted chairman function respect essential shareholder third meeting board committee chief executive party fully informed choice made officer order simplify company operational separation office chairman chief executive management increase effectiveness officer maintenance position single office organization take account presence controlling shareholder company share capital 104 nonexecutive director meeting nonexecutives director meet without recommended nonexecutive director meet executive member tough open transparent periodically without executive inhouse director debate possible even presence executive internal rule operation board director must member provide meeting year time evaluation chairman chief executive officer deputy chief executive respective performance shall carried participant shall reflect future company executive management 161 independent director within audit committee historical reason related company share option proportion independent director audit composition specialized committee reflecting committee excluding director representing employee research shareholder order reflect balance shareholder director representing employee director representing shareholder taken account least equal twothirds independent director committee include executive director composed 50 independent director 1621 examination deadline account practical reason fact nonresident member audit committee board part committee audit committee verifies appointment extension term office account board director meeting member audit committee chairman proposed committee however access document appointmentsnominations committee specially information necessary function within reasonable reviewed board deadline allowing take notice verify satisfactory manner 18 committee charge compensation 181 independent director within compensation committee historical reason related company share option composition specialized committee reflecting research shareholder order reflect balance director representing shareholder independent director composed mainly independent director composed 50 independent director chairman compensation committee sartorius stedim biotech group nonindependent also chairman compensation committee sartorius group ag management coherency reason 20 director ethic 20 attendance fee retained action director shareholder personally hold board director left freedom fairly significant number share received attendance director invest insignificantly company fee default hold share upon assuming executive member perceiving attendance fee function must use acquired attendance fee therefore stock option purchase obligation acquired responsibility board complete formulated otherwise list director basic obligation 22 termination employment contract case appointment executive director 22 termination employment contract case recommendation applied 2 4 appointment executive director director employee appointed executive director volker niebel still employment contract sartorius recommended terminate employment contract stedim biotech gmbh put place started company company affiliated group work sartorius group according german law whether contractual termination resignation23 necessary change employment contract someone becomes managing director company work also considered sartorius stedim biotech group controlled german majority shareholder biggest group company german company therefore respect german rule regulation common whole group observed respective group level corporate governance chairman report pursuant article l 225 37 81 article provision code removed explanation 23 compensation executive director 2324 award applicable oscar werner reif volker niebel award option share executive director must joachim kreuzburg reinhard vogt representing conditional attainment performance target group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech performance action element detailed document reference within part company governance report internal control executive director may awarded stock option share joachim kreuzburg receive 11 november performance share time departure 2015 subject performance criterion nevertheless accordance legal provision stock option give back share leaf performance share awarded employee sartorius ag 11 november 2017 half share necessary provide another scheme involving leaf sartorius ag 11 november 2019 share corporate performance incentive scheme profitsharing transferred incentive grow sartorius scheme mandatory scheme granting bonus group would participate increase share share etc price total amount stock option plan performance share must represent small fraction capital right balance must struck according benefit derived shareholder management level dilution must taken account furthermore necessary ensure awarded stock option performance share valued accordance ifrs standard represent disproportionate percentage aggregate compensation option share awarded executive director end board must systematically review award new stock option performance share view compensation item awarded executive director concerned board shall responsible determining percentage compensation accordance market standard exceeded said award award overly concentrated executive director according situation company size industry broad narrow scope award number officer etc board must define maximum percentage option performance share may awarded executive director compared aggregate award approved shareholder resolution authorizing award plan submitted vote meeting shareholder must mention maximum percentage form award subceiling executive director award made calendar period eg disclosure financial statement previous financial year probably year order limit windfall effect windfall effect associated bear market prohibited value awarded option performance share may markedly different company earlier practice unless material change scope business justifies revision scheme accordance term determined board announced upon award performance share awarded executive director conditional upon acquisition defined quantity share awarded share available price discount applied upon award stock option particular stock option awarded executive director executive director beneficiary stock option andor performance share must make formal commitment engage hedging transaction respect risk either option share resulting exercise option performance share end period determined board director holding share 82 corporate governance chairman report pursuant article l 225 37 article provision code removed explanation exercise exercise executive director option acquisition share must related serious demanding performance condition met period several consecutive year condition may internal andor external performance requirement ie related performance company benchmark sector etc possible relevant internal external performance requirement combined necessary determine period preceding disclosure annual interim financial statement exercise stock option possible board director supervisory board must determine period applicable determine procedure implemented executive director prior exercise stock option order ensure hold information likely prevent exercise 2325 termination payment severance payment joachim kreuzburg reinhard vogt acceptable executive director whose company oscarwerner reif capped maximum two failed personally failed may receive year remuneration reference made respect termination payment upon departure remuneration agreed service contract lined remuneration report approximately half remuneration fix remuneration half remuneration variable remuneration performance target variable remuneration taken account calculating severance payment case early termination service contract law give major role shareholder making predefined benefit paid termination office executive director subject procedure related party agreement imposes total transparency make termination payment conditional upon performance requirement performance requirement must assessed least two financial year performance requirement set board must demanding may allow indemnification executive director unless departure imposed regardless form departure linked change control strategy payment termination benefit executive director must excluded said executive director elect leave company order hold another position assigned another position within group able benefit near future pension right termination payment exceed applicable two year compensation fixed variable nocompetition clause additionally applied aggregate two benefit must exceed ceiling see hereafter artificial increase compensation period preceding departure prohibited group also communicates appendix applied recommendation order give overall idea practice concerning corporate governance corporate governance chairman report pursuant article l 225 37 83 condition preparation organization board director shall examine corporate work board director consolidated account approve manage ment report section annual report dealing corporate governance setting internal rule regulation company policy respect remuneration stock option procedure governing organization functioning board director defined although modification social internal rule regulation board purpose board director must seize published website sartorius stedim shareholder meeting transaction concern biotech sa publication particular preponderant share asset activity report group internal rule modified board board director shall convene annual share director 18 february 2015 order bring holder meeting propose change article line new provision afrp medef association governance code listed company mission mentioned summarize internal board director deal matter concerning bylaw board director proper operation company take decision subject concern activity report board director fiscal 2014 mission board director met eight time main mission board director fiscal year average attendance 98 follows board reviewed approved corporate board director shall define company consolidated account 2013 strategic goal assess overall perspective least year proposed board director considered debated ceo ensure goal implemented following meeting shall also appoint corporate officer responsible managing company pursuit strategy 1 strategic direction major group project review delegation authority 2 annual halfyear quarterly financial statement board director shall review management 3 budget presented executive management group monitor quality information 4 information financial structure provided shareholder market cash flow item financial statement material event 5 significant offbalance sheet commitment occur especially company shareholding 6 risk indicator group 7 internal organization project board director responsible approving 8 stock market performance strategic investment project transaction 9 selfassessment board member particular acquisition disposal likely 10 element remuneration due attributed materially affect company result structure 11 modification bylaw balance sheet risk profile 12 operation capital 13 project acquisition follow board director beforehand decide recent acquisition significant transaction outside scope 14 situation statutory auditor announced strategy regard green book board director shall deliberate prior 2014 board member carried formal making change management structure assessment work board director company shall informed principal questionnaire sent board member organizational change summary result show positive overall assessment board performance selfassessment 84 corporate governance chairman report pursuant article l 225 37 show director consider well informed board committee executive management company belief ceo moderating properly audit committee remuneration discussion board director committee responsible studying making preparation board main deliberation evaluation three objective order improve board efficiency take stock modality performance circumstance committee relieve board board legal power decision verify important question properly allowed cause division within college prepared debated stay responsible accomplishment measure effective contribution adminis mission committee dont replace trator board work due competency emanation board director facilitating involvement debate work committee chairman submitted work report committee board may consult board discussion performance function main company executive member informed independent auditor invited two board chairman board director subject meeting reporting back board committee board may request external information provided director technical study relating matter within competence expense company board meeting director receive report informed chairman board agenda item require prior consideration director board director subject due time following notification reporting back board preliminary figure annual interim case making use external consultancy service statement generally sent director least example remuneration advice order obtain one week meeting audit committee information concerning system level always held day day remuneration force main market board meeting committee ensure objectivity concerned service addition board meeting chairman regularly informs director event development board meeting preceded meeting may material impact group operation least one two committee depending information previously communicated item agenda committee report board board work observation submit opinion proposal recommendation member board director receive copy press release published company procedure committee also defined director may time request internal rule regulation information chairman board shall assess relevance request member committee board chosen board director appointment renewal president audit committee mandate proposed remuneration committee subject specific review board director corporate governance chairman report pursuant article l 225 37 85 duty audit committee audit committee duty area external controlling consist audit committee assist board director company accounting policy reporting submitting recommendation board treasury hedging instrument internal director concerning statutory auditor external controlling financial communication risk appointment reappointment annual management shareholder meeting end committee steer statutory auditor selection procedure member audit committee therefore submits recommendation board either financial accountant expertise director proposed shareholder meeting committee proposes board director proportion independent administrator selection procedure particularly tender audit committee lower two third might necessary supervises tender validates tender specification also approves committee include executive director choice consulted firm ensuring highest lowest bidder respect audit committee shall consult selected statutory auditor well financial accounting financial investment director shall analyzing issuing opinion definition possible interview take place scope timetable assignment fee committee requires without presence management company analyzing independence legal auditor committee ask external expert needed end committee informed year ensuring expertise independence statutory auditor audit committee duty field declaration independence accounting policy internal controlling consist mainly amount fee paid network statutory auditor company controlled review annual corporate consolidated firm entity hold accrued benefit account reviewing halfyearly annual directly linked mission corporation consolidated account including auditor note financial statement management report presented board information concerning benefit accomplished director annual general shareholder audit directly linked auditor mission meeting convened approve statement fiscal 2014 presenting observation committee examines statutory auditor recommendation board director risk threating independence protective review account committee consider measure made reduce risk also important operation conflict ensure amount fee paid interest could occurred company group portion represents revenue office ensuring suitability consistent application network likely impair statutory accounting method procedure chosen auditor independence context company guaranteeing correct accordance green book policy application role audit established european commission proposed next sartorius stedim review accounting treatment significant biotech sa shareholder meeting 7 april 2015 transaction carried company nominate review scope consolidated company necessary reason certain company included 86 corporate governance chairman report pursuant article l 225 37 kpmg auditory auditor replacing ernst main subject audit committee review young audit following salustro reydel alternate auditor replacing 1 examining corporate consolidated annual auditex account reviewing financial statement quar terly halfyearly annual corporate con audit committee duty field risk solidated account including implementation analysis prevention consist specific action related ifrs standard 2 working hedging instrument defining internal audit plan group 3 review internal audit work company obtaining report audit carried 4 review quarterly risk management report defining necessary action plan 5 approval auditor fee implementing new procedure respective 6 30 june 31 december 2014 audit company account auditor presented essential result audit option decided examining company exposure significant 7 situation statutory auditor regard risk risk mapping committee review risk green book balance sheet commitment appreciates importance weakness received informs board appropriate duty remuneration committee verifying appropriate application internal control purpose remuneration committee help accounting financial reporting procedure company board director establish remuneration policy corporate officer audit committee duty area financial particular incentive mechanism granting communication consists reviewing company share subscription option share purchase option proposed financial communication respect free allotment share company may publication halfyearly annual corporate introduce account quarterly result remuneration committee must put board committee may also perform activity director best condition determine deemed necessary appropriate committee overall remuneration benefit executive board director director board director responsible decision otherwise committee must activity report audit committee fiscal 2014 informed remuneration policy non executive director occasion committee audit committee met five time fiscal associate executive director year average attendance 100 remuneration committee also re activity report audit committee ponsibility give recommendation regard board director help board fully informed new potential director committee member facilitating deliberation circumstantially considered element need taken account deliberation desirable balance membership board regard composition evolution shareholding company balance men woman within board identification evaluation potential candidate desirability extension term need particular organize procedure order select future independent administrator achieve study potential candidate taking measure regarding others corporate governance chairman report pursuant article l 225 37 87 activity report remuneration committee within scope remuneration committee 2014 consulted board director proposal concerning remuneration committee met twice fiscal year average attendance 100 total budget allotted director fee term allocation thereof taking account activity report board director help actual presence director board meeting board fully informed facilitating possibly committee meeting deliberation presentation report fixed remuneration corporate officer made remuneration committee necessary term variable remuneration board deliberate remuneration general policy granting share sub executive director without presence scription option share purchase option free allotment company share remuneration committee deliberated main policy director nomination renewal following topic 1 target achievement limitation power chairman 2 reviewing remuneration chief executive officer corporate officer 3 reviewing payment director fee june 29 2007 board director voted 4 structure board director evaluation combine function chairman chief implementation executive board executive officer without limitation power supervisory board included internal regulation 5 number woman board director board director mainly strategic renewal term duty director investment project transaction especially acquisition disposal may lead material remuneration mr joachim kreuzburg profit loss impact procedure concern mr reinhard vogt discussed within operation one million euro corporate remuneration committee sartorius stedim biotech governance structure adopted overwhelming determined remuneration committee majory french company board sartorius ag director allows simplifying operational management company order increase efficiency taking account presence controlling shareholder company capital well continued application company best principle corporate governance remuneration senior executive senior nonexecutive board member mandataires sociaux total remuneration including benefit paid year senior executive chairman board director chief executive officer director including sharebased payment disclosed corporate governance report sartorius stedim biotech group remuneration committee set review remuneration board director executive member furthermore remuneration committee also responsible checking annual director fee paid director 88 corporate governance chairman report pursuant article l 225 37 dr joachim kreuzburgs reinhard vogts internal control procedure remuneration determined annually sartorius ag supervisory board remuneration consists fixed variable component introduction line respective area responsibility variable portion contains short mid longterm objective defined chairman component shortterm component paid internal control system sartorius stedim biotech every year mid term component paid every follows three year based average achieved target threeyear term long term prevent risk would endanger quality component comprised phantom stock plan asset sartorius stedim biotech even existence subject risk remuneration component ensure executive management activity depends development sartorius ag share transaction completed conduct price period least four formerly three employee comply guideline defined year year payable price exceeds executive management applicable law regula least 75 formerly 10 per year relative time tions fundamental value standard internal phantom stock assigned share price rule business ethical code outperformed tecdax comparative index convention healthcare industry amount paid capped maximum 25 ensure accounting financial information time share price time phantom stock management data provided executive assigned based case actual annual management company accurately reflect tranche concerned use component operation sartorius stedim biotech designed longterm incentive effect prevent risk arising operation error fraud entail risk recommendation adopted especially accounting financial area german french corporate governance code date payment made dr kreuzburg reinhard vogt according phantom stock plan scope internal control part remuneration cross charged annually internal control system described cover parent sartorius stedim biotech group company affiliate remuneration oscarwerner reif volker niebel discussed within remuneration component internal control committee subsequently voted annual shareholder meeting sartorius stedim environment internal control biotech gmbh oscarwerner reif volker niebel employment contract core business people individual remuneration consists fixed variable attribute including integrity ethical value component line respective degree expertise environment operate responsibility engine drive organization foundation support company risk assessment process risk mapping company must aware deal risk face must set objective integrate sale production marketing financial activity organization operates concert must also establish mechanism identify analyze manage related risk corporate governance chairman report pursuant article l 225 37 89 control activity risk management control activity undertaken every level sartorius stedim biotech group inevitably group ensure internal control exposed wide variety risk nature efficient checking accuracy completeness operation around world accordingly internal authorization validation recording transaction risk management system set help ensuring different people discharge different identify assess manage risk efficiently duty reduce risk error fraud within risk management system ad hoc committee comprised representative different information communication department regularly study current issue risk management enables committee provide availability accurate reliable complete executive management overview risk information essential achieve business company exposed enabling take objective enable proper reporting party appropriate action required concerned compliance applicable law regulation internal auditing department monitoring control management internal auditing department charge monitoring effectiveness suitability risk responsibility authority must defined management internal control system understood level company internal sartorius stedim biotech group company well control function effectively duty must compliance activity process internal assigned way person work always external rule standard provides checked approved different person independent auditing consulting service size local unit concerned permit focus primarily compliance relevant legal responsibility initiating authorizing recording provision improvement business process processing transaction must always assigned company ensure independence different individual internal auditor audit committee receives least year report internal auditing unit management responsible maintaining department work done according internal check internal control time audit plan established committee finding regard group affiliate internal controlling role finance controlling department executive management finance controlling department track monitor operation project optimize chairman chief executive officer group profitability cash flow providing responsible internal control system internal external stakeholder reliable management level also responsible information development operation monitoring management internal control controlling system two department define group accounting providing necessary assurance step rule method principle financial process implemented fiveyear business plan budget etc well reporting tool order monitor daytoday audit committee business audit committee responsible carrying necessary review evaluation internal controlling procedure including relating financial information also assist preparation group consolidated financial statement information audit committee see page 78 90 corporate governance chairman report pursuant article l 225 37 procedure preparing group executive management review effectiveness financial statement accounting internal controlling financial reporting regularly financial information particular verifies transaction recorded consistently accordance ifrs account affiliate prepared accordance international accounting standard applied group accounting policy data group set accounting reporting adjusted necessary produce company manual order ensure pertinence account comply applicable local legal transaction asset recognized within time set tax provision integrated consolidation software used management reporting purpose produce group financial statement internal control 2014 since 2013 group decided implement internal control perspective group hard close process 30 november order focused following year anticipate improve annual audit accounting standard training code conduct anticorruption code consolidated financial statement prepared accordance ifrs accounting standard collaborator consult sartorius code currently adopted european union conduct sartorius anticorruption code consolidated financial statement comply initial training process closed transferred accounting rule method detailed note controlled operation consolidated financial statement role group finance controlling midterm prospect department group continue work internal control finance controlling department check issue strengthening approach risk mapping quality reporting package submitted risk management process based affiliate focusing primarily following element element amf internal control reference checking corporate data consolidated adjustment framework entered locally intercompany elimination accounting treatment nonrecurring transaction addition process defining mandatory reporting period verifying principal minimum standard internal control applying movement opening closing balance group company followed sheet prepare cash flow statement pursued 2015 finance department also verifies result procedure including currency translation intercompany elimination etc aubagne february 18 2015 key point review include preparation chairman validation statement change shareholder equity cash flow statement joachim kreuzburg financial information reporting group rule procedure relation financial reporting accounting set accounting reporting manual application compliance principle rule procedure direct responsibility finance director affiliate must ensure information provided via management information system complies fully applicable disclosure requirement corporate governance remuneration executive nonexecutive member board 91 remuneration executive nonexecutive member board information remuneration sartorius ag executive board member also executive board member executive member board sartorius stedim biotech however component remuneration element parameter remuneration member described refer parameter executive board member differ financial key figure sartorius group total member time member executive board major shareholder sartorius ag variable remuneration member mem bers sartorius ag executive board receive variable portion remuneration contains fixed variable remuneration sartorius ag component paid annually component portion fixed remuneration charged determined multiyear performance assessment sartorius stedim biotech sa reflecting role category component general making director company portion defined one half target achievement possible scheme director meeting attendance fee part bylaw company annually paid variable remuneration portion total remuneration charged ssb group management service portion variable remuneration paid detail please refer section related party annually linked weighted target achievement financial statement note page 146 following financial key figure sale reve nue order intake underlying ebitda ratio net debt underlying ebitda component 1 remuneration executive member minimum target achievement required maxi board member executive mum payout ratio defined amount paid board major shareholder sartorius ag depends degree respective financial joachim kreuzburg reinhard vogt target achieved financial target mentioned line budget approved annually general fixed remuneration supervisory board sartorius ag total amount remuneration executive b longterm incentive board member sartorius ag reflects scope responsibility executive member con component determined multiyear assessment cerned executive member personal performance depend degree respective target company economic situation sustainable achieved progress addition amount benchmarked peer company vertical remu consolidated net profit neration structure within company well peer company remuneration comprised subordinate target basis assessment fixed variable component reviewed consolidated net profit minority interest ex annually supervisory board sartorius ag cluding amortization impairment value intan ensure remains appropriate case gible asset due business combination pursuant 100 target achievement variable remuneration ifrs 3 target achievement component component represent approximately half total based threeyear average consolidated net remuneration excluding pension commitment profit achieved compared average annual fringe benefit target set variable remu budget three year smooth neration refer financial key figure sartorius amount paid partial payment amounting group sartorius stedim biotech group 50 target achievement first fiscal fully consolidated specifically sartorius stedim year effected overpayment result biotech represents approx 70 business partial payment offset final asset sartorius group therefore develop calculation target achievement third ment sartorius stedim biotech significant year remuneration component fixed influence financial result sartorius variable minimum target achievement cap group thus variable remuneration applied component well 92 corporate governance remuneration executive nonexecutive member board phantom stock plan pension commitment joachim kreuzburg reinhard vogt according company remuneration policy eligible participate phantom stock plan executive board member sartorius ag receive responsibility sartorius ag level performancerelated benefit commitment defined benefit plan reappointed first issue shadow share called phantom time addition including basic pension stock executive board member member commitment provide executive board member treated owner certain number make contribution variable earn share sartorius ag without however entitled ings company match contribution receive dividend development value bonus amount executive board member may phantom stock linked development choose receive defined benefit form sartorius share increase decrease monthly retirement pension old age one share price taken account later phantom time payment cover member retirement pen stock valuated based share price time sion old age invalidity well form equivalent paid provided associ survivor benefit surviving spouse chil ated condition met phantom stock cannot trad dren decedent ed entail share subscription right beyond commitment joachim kreuzburg according sartorius phantom stock plan additionally entitled former company pension executive board member credited beginning scheme receive performancebased retirement bene every year phantom stock unit valued fit based salary german federal civil servant agreed monetary sum value phantom stock classified grade 10 salary class b ministry offi paid entire annual tranche cials according federal civil service remunera payment requested earliest tion act bundesbesoldungsgesetz benefit period four year later eight year paid form retirement pension old age invalidity well form survivor benefit executive board member entitled receive surviving spouse child decedent payment phantom stock unit share price time payment request appreciat member turned 65 shall considered ed least 75 per year relative time phan regular age limit member shall auto tom stock assigned share price matically entitled receive benefit outperformed tecdax comparative index phantom stock plan rule subsequent change remuneration component parameter used comparative stock valuation amount paid capped maximum 25 remuneration system provides supervisory time share price time phantom stock board sartorius ag discretion may grant assigned based case actual annual executive board member special compensation based tranche concerned member exceptional performance assignment phantom stock payment severance cap monetary equivalent depend mean value calculat ed average price class sartorius ag service contract include severance pay cap share closing auction xetra trading frank maximum two annual salary cover case furt stock exchange last 20 day trading sartorius ag executive board membership previous year last 20 day trading terminated prematurely prior submission payment request serf compensate shortterm fluctuation noncompetition clause share price executive board member sartorius ag payment phantom stock blocked four week postcontractual noncompetition obligation preceding scheduled publication date quarterly accordance german law obligation last preliminary yearend result 20 day trad two year executive board member left ing stock exchange following actual publica group time noncompetition tion quarterly preliminary yearend result clause waived terminated executive board blackout period intended prevent executive board member may claim half recent annual member profiting insider knowledge remuneration received company corporate governance remuneration executive nonexecutive member board 93 fringe benefit grant date amount 4950 k considering agreed condition amount resulting decem member executive board sartorius ag ber 16 2014 spread employee benefit entitled use company car reclaim ex expense account sartorius ag recog penses incurred business travel covered nized full vesting period account accident insurance insurance fringe sartorius stedim biotech affected benefit addition receiving remuneration fiscal 2014 component mentioned insurance provides application deductible excess amount required law 2 remuneration executive member board part sartorius sharebased payment stedim biotech group oscarwerner reif volker niebel remuneration policy executive board member sartorius ag provide transfer general fixed remuneration sartorius ag share compensation member exception made december 2014 total amount remuneration executive joachim kreuzburg granted entitlement member reflects role director company receive sharebased remuneration due third scope responsibility executive reappointment member executive board member concerned executive member personal chairman ceo sartorius ag performance company economic situation sustainable progress addition amount third term joachim kreuzburg member benchmarked peer company executive board chairman ceo sartorius ag vertical remuneration structure within compa expire november 10 2015 resolution ny well peer company remuneration supervisory board sartorius ag december 16 comprised fixed variable component 2014 joachim kreuzburg reappointed member reviewed annually ensure remains appro executive board chairman ceo priate case 100 target achievement term november 11 2015 november 10 variable remuneration component represent approxi 2020 due joachim kreuzburgs excellent perfor mately half total remuneration excluding fringe mance developing company since start benefit portion fixed component allocated tenure executive board company role director company portion wished continue successful cooperation defined scheme director meeting attendance despite alternative offer made fee part bylaw company reason new remuneration contract pro vides supplementary remuneration component variable remuneration transfer 25000 ordinary share 25000 preference share sartorius ag joachim kreuzburg fol variable portion remuneration contains lowing basic structure agreed upon component paid annually component transfer share granted shall effected determined multiyear assessment time determined joachim kreuzburg earlier november 11 2015 however share annually paid variable remuneration granted shall subject holding period end november 10 2019 joachim kreuzburg portion variable remuneration paid leave company prior november 11 2017 annually linked weighted target achievement request entitlement granted said share following financial key figure sale transfer shall lapse entirety joa revenue order intake underlying ebitda ratio chim kreuzburg leaf company november net debt underlying ebitda 11 2017 november 11 2019 component minimum target achievement request half entitlement granted said quired maximum payout ratio defined share shall lapse share already transferred amount paid depends degree entitlement lapsed shall returned respective financial target achieved company remuneration component financial target mentioned line included total remuneration fair value budget approved annually time granted share respective fair value derived number share granted price class share 94 corporate governance remuneration executive nonexecutive member board b longterm incentive table summarizing remuneration option share granted longterm component multiyear assessment executive board member determines degree target achieved joachim kreuzburg consolidated net profit chairman board chief executive officer subordinate target basis assessment k year 2014 year 2013 consolidated net profit minority interest ex remuneration due 1652 1369 cluding amortization impairment value intan valuation option granted gible asset due business combination pursuant reporting period 0 0 ifrs 3 target achievement component valuation performance based threeyear average achieved compared share granted previous year 81 74 threeyear average annual budget total 1733 1443 smooth amount paid partial payment amounting 50 target achievement first fiscal year effected overpayment amount crosscharged company result partial payment offset sartorius ag sartorius stedim biotech group final calculation target achievement concerning joachim kreuzburg submitted third year remuneration component vote annual shareholder meeting fixed variable minimum target achievement accordance afepmedef code amounted cap applied component well 743 k severance cap volker niebel executive vice president operation oscarwerner reif limited service agreement sartorius stedim biotech gmbh place case k year 2014 year 2013 severance would receive payment amount remuneration due 625 551 reflecting remaining duration contract valuation option granted capped two year given contract expire reporting period 0 0 april 30 2016 severance payment would reflect valuation performance remaining duration volker niebel employed share granted previous year 0 0 sartorius stedim biotech according german labor total 625 551 contract case termination german labor law would apply potential severance due amounting half monthly salary based oscarwerner reif total package per year employment minimum executive vice president research development noncompetition clause k year 2014 year 2013 remuneration due 622 549 executive director postcontractual non valuation option granted competition obligation accordance reporting period 0 0 german law sartorius stedim biotech sa valuation performance controlled german company obligation share granted previous year 0 0 last two year director left group total 622 549 time noncompetition clause waived terminated director may claim half recent annual remuneration received company fringe benefit executive member entitled use company car reclaim expense incurred business travel covered accident insurance insurance fringe benefit addition receiving remuneration component mentioned corporate governance remuneration executive nonexecutive member board 95 reinhard vogt summary remuneration executive vice president marketing sale service executive board member k year 2014 year 2013 joachim kreuzburg1 chairman board chief executive officer remuneration due 1144 769 valuation option granted reporting period 0 0 year 2014 year 2013 valuation performance amount amount amount amount share granted previous year 49 44 k due paid due paid total 1193 813 fixed remuneration 675 675 635 635 variable remuneration amount crosscharged company annually paid 373 268 268 272 sartorius ag sartorius stedim biotech group longterm concerning reinhard vogt submitted vote incentive 667 479 521 395 annual shareholder meeting accordance exceptional afepmedef code amounted 749 k remuneration director attendance fee benefit kind2 18 18 19 19 total 1733 1440 1443 1321 1 joachim kreuzburg receives salary sartorius ag duty performed entire sartorius group remuneration determined annually supervisory board sartorius ag 2 company car volker niebel 1 executive vice president operation year 2014 year 2013 amount amount amount amount k due paid due paid fixed remuneration 300 300 280 280 variable remuneration annually paid 243 189 207 201 longterm incentive 71 68 54 54 exceptional remuneration director attendance fee benefit kind2 11 11 10 10 total 625 568 551 545 1 volker niebel receives salary sartorius stedim biotech gmbh duty performed sartorius stedim biotech group 2 company car 96 corporate governance remuneration executive nonexecutive member board oscarwerner reif1 information remuneration executive vice president research development nonexecutive board member year 2014 year 2013 remuneration nonexecutive board member amount amount amount amount defined bylaw sartorius stedim biotech sa k due paid due paid comprises fixed remuneration meeting attendance fixed fee reimbursement outofpocket expense remuneration 300 300 280 280 member also serving member committee variable board receive higher fixed remuneration remuneration annually paid 243 189 207 201 longterm incentive 71 68 54 54 table director meeting attendance fee exceptional remuneration received remuneration nonexecutive board member director attendance fee k year 2014 year 2013 benefit kind2 8 8 8 8 liliane de lassus total 622 565 549 543 director attendance fee 498 474 remuneration 1 oscarwerner reif receives salary sartorius bernard lemaître stedim biotech gmbh duty performed director attendance fee 498 450 sartorius stedim biotech group 2 remuneration company car arnold picot director attendance fee 538 526 remuneration reinhard vogt1 henri riey executive vice president marketing sale service director attendance fee 538 526 remuneration year 2014 year 2013 total 2072 1976 amount amount amount amount k due paid due paid fixed remuneration 410 410 388 388 performance share available variable board member remuneration annually paid 226 164 164 166 number share longterm performance share available incentive 541 270 245 86 available date reporting acquisition exceptional corporate officer1 plan period condition remuneration joachim kreuzburg applicable director volker niebel applicable attendance fee oscarwerner reif applicable benefit kind2 16 16 16 16 reinhard vogt applicable total 1193 860 813 656 liliane de lassus applicable bernard lemaître applicable 1 reinhard vogt receives salary sartorius ag arnold picot applicable duty performed entire sartorius henri riey applicable group remuneration determined annually total supervisory board sartorius ag 2 company car 1 performance share bonus share allocated board member within framework l2251971 article following commercial law subjected additional requirement laid recommendation afepmedef october 2008 corporate governance remuneration executive nonexecutive member board 97 performance share granted board member performance share program place board member sartorius stedim biotech sa information provided table refers phantom stock plan sartorius ag described page 92 plan relates joachim kreuzburg reinhard vogt executive board member sartorius ag valuation share performance share granted according agm reporting period corporate officer number consolidated issuer date share granted account date date performance company group plan year methodology acquisition availability conditions1 joachim kreuzburg 2008 193 jan 1 2014 jan 1 2018 volker niebel oscarwerner reif reinhard vogt 1220 117 jan 1 2014 jan 1 2018 liliane de lassus bernard lemaître arnold picot henri riey total 3228 310 stock option granted reporting stock option granted historical information period board member issuer company group applicable applicable stock option granted top ten noncorporate officer exercised stock option exercised reporting period board member applicable applicable 98 corporate governance remuneration executive nonexecutive member board additional information executive board member indemnity compensation due employment additional regard termination noncompetition corporate officer contract pension plan contract position clause indemnity yes yes yes yes joachim kreuzburg ceo chairman 1 3 2700 675 volker niebel 2 none 350 300 oscarwerner reif 2 none 800 300 reinhard vogt 1 3 1640 410 1 joachim kreuzburg reinhard vogt service contract without social security component sartorius ag duty performed member executive board major shareholder sartorius ag standard practice germany 2 oscarwerner reif volker niebel service contract employment contract respectively sartorius stedim biotech gmbh duty performed managing director company standard practice germany 3 general pension plan place sartorius ag level joachim kreuzburg reinhard vogt level entitlement benefit paid company pension plan depends respective tenure corporate governance statutory auditor report prepared accordance article l 225 235 99 statutory auditor report prepared accordance article l 225 235 statutory auditor report prepared accordance information internal control risk article l 225 235 french commercial code code management procedure relating de commerce report prepared chairman preparation processing accounting board director sartorius stedim biotech financial information free translation english report issued professional standard require perform french provided solely convenience necessary procedure assess fairness englishspeaking user report read information provided chairman report conjunction construed accordance respect internal control risk management french law professional standard applicable france procedure relating preparation processing accounting financial information year ended december 31 2014 procedure consist mainly shaeholders obtaining understanding internal control risk management procedure relating capacity statutory auditor sartorius preparation processing accounting stedim biotech accordance article l 225 financial information information 235 french commercial code code de presented chairman report based commerce hereby report report prepared existing documentation chairman company accordance article l 22537 french commercial code code obtaining understanding work involved de commerce year ended december 31 2014 preparation information existing documentation chairman responsibility prepare submit board director approval report determining material weakness internal control risk management procedure internal control procedure relating implemented company provide preparation processing accounting information required article l 22537 financial information would noted french commercial code code de commerce relating course work properly disclosed matter corporate governance chairman report role basis work matter report information relating company internal control report matter information risk management procedure relating pre contained chairman report respect paration processing accounting financial internal control risk management procedure information contained report prepared relating preparation processing chairman board director article l 22537 accounting financial information french commercial code code de commerce confirm report also includes information information required article l 22537 french commercial code code de commerce confirm report prepared chairman noted role verify board director also contains fairness information information required article l 22537 french commercial code code de commerce conducted work accordance professional standard applicable france marseille february 19 2015 french original signed statutory auditor ernst young audit deloitte associés xavier senent christophe perrau 100 corporate governance independent auditor fee independent auditor fee principal independent auditor ernst young audit deloitte et associés 08 avenue du prado bp 116 13267 marseille 10 place de la joliette le dock atrium 104 cedex 08 france bp 64529 13567 marseille cedex 02 france represented xavier senent represented christophe perrau first commissioned combined general first commissioned annual general share shareholder meeting june 28 1985 date holder meeting may 19 2006 date commission commission expires 2015 annual general shareholder expires 2018 annual general shareholder meeting meeting approve 2014 financial statement approve 2017 financial statement member compagnie régionale de versailles member compagnie régionale de versailles independent auditor fee ernst young deloitte k 2014 2013 2014 2013 audit independent audit certification parent company consolidated financial statement parent company 55 458 80 349 87 171 110 232 subsidiary 61 508 50 218 398 783 340 716 service directly related audit service parent company subsidiary subtotal 116 967 130 568 485 955 450 947 service legal tax corporate 4 33 23 45 17 36 information technology 0 00 99 432 0 00 8 17 subtotal 4 33 99 432 23 45 25 53 total 120 1000 229 100 508 1000 475 100 corporate governance independent auditor fee 101 substitute independent auditor auditex beas tour ernst young faubourg de larche 79 villa houssay 92200 neuilly sur seine france 92037 parisla défense cedex france first commissioned annual general share represented alain pons holder meeting april 21 2009 date commission commissioned annual general shareholder expires 2015 annual general shareholder meeting meeting may 19 2006 date commission expires approve 2014 financial statement 2018 annual general shareholder meeting approve 2017 financial statement member compagnie régionale de versailles member compagnie régionale de versailles total 2014 2013 2014 2013 142 151 190 188 255 817 277 899 714 760 667 659 255 817 277 899 856 911 857 847 57 183 25 81 84 89 42 42 0 00 6 19 0 00 113 112 57 183 31 101 84 89 155 153 312 1000 308 100 940 1000 1012 100 consolidated financial statement note consolidated financial statement note statement profit loss comprehensive income 103 statement profit loss comprehensive income note 2014 2013 12 month 12 month k k sale revenue 9 683524 588378 cost sale 341873 295253 gross profit sale 341652 293125 selling distribution cost 144295 128674 research development cost 38563 35998 general administrative expense 38653 30022 operating income expense 11 233 2915 earnings interest tax ebit 120373 101346 financial income 12 2411 949 financial expense 12 17672 7850 financial result 15261 6901 profit tax 105112 94445 income tax 13 31378 26970 net profit period 73734 67474 attributable equity holder sartorius stedim biotech 72472 66276 noncontrolling interest 23 1262 1198 earnings per share 15 472 432 diluted earnings per share 15 472 431 statement comprehensive income 2014 2013 12 month 12 month k k net profit period 73734 67474 cash flow hedge 3612 2141 income tax cash flow hedge 1084 642 net investment foreign operation 6898 1832 income tax net investment foreign operation 2069 549 currency translation difference 20560 6986 item probably reclassified profit loss net tax 13203 4204 actuarial gain loss defined benefit obligation 6957 1048 income tax actuarial gain loss 1885 314 item reclassified profit loss net tax 5072 734 total comprehensive income 81865 64005 attributable equity holder sartorius stedim biotech 80111 62893 noncontrolling interest 1753 1112 note consolidated financial statement integral part statement 104 consolidated financial statement note statement financial position statement financial position dec 31 2014 dec 31 2013 note k k1 noncurrent asset goodwill 16 314437 308955 intangible asset 16 111924 116459 property plant equipment 17 192195 175858 financial asset 1214 1304 asset 653 567 deferred tax asset 18 10169 9359 630593 612503 current asset inventory 19 109975 94939 trade receivables 20 124787 107199 financial asset 21 6847 9585 current tax asset 8890 8073 asset 7123 5512 cash cash equivalent 18544 35605 276166 260912 total asset 906758 873415 equity equity attributable ssb sa shareholder 532478 478340 issued capital 22 15359 10396 capital reserve 235047 278791 retained earnings including net profit 282072 189152 noncontrolling interest 23 6034 3499 538512 481838 noncurrent liability pension provision 24 30583 22601 provision 25 2891 3003 loan borrowing 26 15880 119911 finance lease liability 16770 17296 financial liability 26 44724 37338 deferred tax liability 18 27814 33536 138662 233685 current liability provision 27 6224 4998 trade payable 28 81139 66351 loan borrowing 26 71764 27078 finance lease liability 1567 1274 financial liability 28 48078 41129 current tax liability 10107 4476 liability 10705 12585 229584 157891 total equity liability 906758 873415 1 figure adjusted final purchase price allocation tap biosystems detailed note 8 consolidated financial statement note statement cash flow 105 statement cash flow 2014 2013 12 month 12 month k k profit tax 105112 94445 financial result 15261 6901 earnings interest tax ebit 120373 101346 depreciation amortization fixed asset 35559 30558 increase decrease provision 1314 440 income tax paid 27793 28247 gross cash flow operating activity 129453 104097 increase decrease receivables 15285 7260 increase decrease inventory 11053 5016 increase decrease liability 8197 1714 net cash flow operating activity 111312 90107 capital expenditure 47067 29276 proceeds disposal fixed asset 592 1058 payment 3953 99 net cash flow investing activity 42522 28318 payment acquisition consolidated subsidiary business operation net cash acquired 4291 45090 proceeds disposal consolidated subsidiary business operation 0 0 net cash flow investing activity acquisition 46813 73408 change capital 144 10 interest received 688 267 interest paid financial charge 4982 5604 dividend paid shareholder sartorius stedim biotech sa 18410 16875 noncontrolling interest 401 342 gross cash flow financing activity 22961 22544 loan borrowing raised 0 103590 loan borrowing repaid 61247 89055 net cash flow financing activity 84208 8010 net increase decrease cash cash equivalent 19709 8689 cash cash equivalent beginning period 35605 27807 net effect currency translation cash cash equivalent 2648 891 cash cash equivalent end period 18544 35605 106 consolidated financial statement note statement change equity statement change equity foreign cash flow currency non issued capital hedging pension retained translation group controlling total k capital reserve reserve reserve earnings reserve equity interest equity balance jan 1 2013 10395 278782 1277 5203 148324 1278 432299 2727 435026 net profit period 0 0 0 0 66276 0 66276 1198 67474 comprehensive income period 0 0 1499 775 1283 6940 3383 86 3470 total comprehensive income 0 0 1499 775 67559 6940 62893 1112 64005 stock option 1 9 0 0 0 0 10 0 10 dividend 0 0 0 0 16875 0 16875 341 17216 change 0 0 0 0 12 0 12 2 14 balance dec 31 2013 jan 1 2014 10396 278791 222 4428 199021 5662 478339 3499 481838 net profit period 0 0 0 0 72472 0 72472 1262 73734 comprehensive income period 0 0 2528 5033 4829 20029 7639 491 8131 total comprehensive income 0 0 2528 5033 67643 20029 80111 1753 81865 stock option 9 135 0 0 0 0 144 0 144 dividend 0 0 0 0 18410 0 18410 401 18811 purchase price liability forward non controlling interest 0 0 0 0 7255 0 7255 0 7255 change non controlling interest 0 0 0 0 0 0 0 1271 1271 change capital 4954 43879 38925 0 0 0 0 change 0 0 0 0 452 0 452 88 540 balance december 31 2014 15359 235047 2306 9461 279473 14367 532478 6035 538513 amount 7225k shown retained earnings refers acquisition allpure technology llc please refer note 8 change capital include cancellation treasury share capital increase change nominal value share detail please refer note 22 consolidated financial statement note note financial statement 107 note financial statement 1 general information 2 effect new financial reporting standard sartorius stedim biotech leading provider cuttingedge equipment service compared yearearlier consolidated financial development quality assurance production statement following new amended standard process biopharmaceutical industry obligatorily applied first time integrated solution covering fermentation filtration purification fluid management cell culture medium ifrs 10 consolidated financial statement supporting biopharmaceutical industry around world develop produce drug safely timely ifrs 11 joint arrangement economically nextgeneration process sartorius stedim biotech focus singleuse ifrs 12 disclosure interest entity technology addedvalue service meet rapidly changing technology requirement amendment ia 27 separate financial industry serf strongly rooted scientific statement community closely allied customer technology partner company dedicated amendment ia 28 investment associate philosophy turning science solution joint venture headquartered aubagne france sartorius stedim ifrs 10 revise definition control biotech sa listed euronext paris isin code basis determination scope fr 0000053266 consolidated entity ifrs 11 stipulates accounting joint arrangement ifrs 12 compliance european regulation combine disclosure requirement interest 16062002 july 19 2002 requiring listed company subsidiary joint arrangement associate non use international accounting standard consolidated structure entity consolidated financial statement sartorius stedim biotech group year ended december 31 initial application ifrs 10 11 lead 2014 compliant standard significant sartorius stedim biotech group interpretation ifrs ifric iasb adopted special purpose entity associate jointly european union available controlled entity existing ifrs 12 lead following site additional disclosure consolidated financial statement see note 6 httpeceuropaeuinternal_marketaccountingiasind ex_enhtm furthermore following standard interpretation applied initially consolidated financial statement prepared euro unless otherwise specified amount amendment ia 32 financial instrument disclosed thousand euro abbreviated k presentation offsetting financial asset case sum figure given financial liability report may precisely equal stated total percentage may exact due rounding amendment ifrs 10 11 12 transition guidance consolidated financial statement approved board director february 18 2015 amendment ifrs 10 12 ia 27 investment submitted approval shareholder entity meeting april 7 2015 amendment ia 36 recoverable amount disclosure nonfinancial asset amendment ia 39 novation derivative continuation hedge accounting 108 consolidated financial statement note note financial statement amendment mentioned necessarily applicable group firsttime application result material impact group financial statement sartorius stedim biotech following standard interpretation revision amendment yet applied consolidated financial statement reporting year yet adopted eu application obligatory 2014 applicable endorsement financial standard interpretation title year from1 eu commission standard amendment ia 19 employee contribution july 1 2014 yes annual improvement ifrss 20102012 cycle issued dec various 2013 july 1 2014 yes annual improvement ifrss 20112013 cycle issued dec various 2013 january 1 2015 yes amendment ifrs 10 ifrs 12 ia 28 investment entity applying consolidation exception january 1 2016 amendment ifrs 10 sale contribution asset investor associate ia 28 joint venture january 1 2016 amendment ifrs 11 accounting acquisition interest joint operation january 1 2016 ifrs 14 regulatory deferral account january 1 2016 amendment ia 1 disclosure initiative january 1 2016 amendment ia 16 ia 41 agriculture bearer plant january 1 2016 amendment ia 16 clarification acceptable method depreciation ia 38 amortization january 1 2016 amendment ia 27 equity method separate financial statement january 1 2016 annual improvement ifrss 20122014 cycle issued sep various 2014 january 1 2016 ifrs 15 revenue contract customer january 1 2017 ifrs 9 financial instrument january 1 2018 interpretation ifric 21 levy june 17 2014 yes 1 required applied endorsed eu commission standard may provide earlier mandatory application process measuring potential impact standard interpretation consolidated financial statement sartorius stedim biotech group progress group anticipate stage analysis significant impact consolidated account presently firsttime application planned reporting period standard interpretation amendment enter force consolidated financial statement note note financial statement 109 3 significant accounting policy foreign currency translation consolidated financial statement sartorius basis preparation stedim biotech group prepared thousand euro annual financial statement consolidated financial statement group individual company foreign currency transaction based principle historical cost translated exchange rate applicable acquisition construction production time transaction monetary asset debt exception item reflected fair value whose value given foreign currency financial asset held trading available sale translated exchange rate balance sheet derivative date rate gain loss recognized profit loss period consolidation subsidiary annual financial statement prepared foreign currency translated pursuant consolidated financial statement sartorius ia 21 effect change foreign exchange stedim biotech group include annual financial rate accordance concept functional statement company controlled currency foreign subsidiary regarded directly indirectly sartorius stedim biotech sa independent subdivision sartorius stedim term ifrs 10 consolidated financial statement biotech group balance sheet item accounting investment subsidiary translated exchange rate balance sheet controlling interest exists sartorius stedim date income expense item converted biotech sa subsidiary power govern average rate translation difference financial operating policy enterprise resulting use different exchange rate obtain economic benefit activity balance sheet item statement profit loss enterprise included consolidated financial recognized comprehensive statement time sartorius stedim income shareholder equity biotech sa subsidiary acquired control longer included time control certain defined loan granted longterm basis transferred entity outside group group applies principle net investment foreign operation foreign currency translation subsidiary included basis difference resulting loan recognized annual financial statement reporting comprehensive income according ia 2132 period parent company using uniform group recognition measurement method intragroup asset liability equity income expense cash flow relating transaction tween member group eliminated full consolidation business combination business combination measured according acquisition method identifiable acquired asset assumed liability potential liability recorded fair value date combination significant acquisition purchase price allocation carried assistance independent thirdparty valuation specialist valuation based information available acquisition date expense directly related business combination reported profit loss period 110 consolidated financial statement note note financial statement exchange rate major currency item general administrative expense includes euro considered follows mainly employee benefit expense cost material general administrative area yearend exchange rate average exchange rate 1 2014 2013 2014 2013 profit loss item cannot allocated one mentioned functional area recognized usd 121410 137910 132881 132806 income expense includes essentially gbp 077890 083370 080619 084938 effect currency translation sale fixed asset jpy 14523000 14472000 14030709 12958904 allowance trade receivables reorganization inr 7671900 8536600 8106162 7793433 extraordinary expense income grant cny 753580 834910 818674 816496 related income recognized income reasonable assurance condition attached grant complied sale revenue grant received recognized period necessary match systematic basis revenue derived selling product cost intended compensated rendering service recognized sale revenue operational revenue recognized operating income sale recognized borrowing cost statement profit loss significant risk reward ownership good borrowing cost expensed incurred unless transferred customer company retains directly attributable acquisition neither continuing managerial effective control construction production qualifying asset good sold amount revenue cost therefore part cost asset incurred incurred measured reliably qualifying asset defined asset take sufficiently probable economic period least twelve month get ready benefit associated transaction flow intended use company income tax functional cost current income tax determined based general operating expense type assigned respective local taxable income period local function following functional area tax rule addition current income tax include corresponding profit cost center expense adjustment uncertain tax payment tax refund relating crossfunctional initiative project period yet assessed change deferred tax assigned respective functional cost based asset liability included income tax ex appropriate allocation principle cept change recognized comprehensive income directly equity item cost sale report cost product sold acquisition cost merchandise sold deferred tax asset liability determined based besides directly imputable expense raw temporary difference carrying material supply employee benefit expense amount tax basis asset liability energy expense cost sale also includes including difference consolidation loss carry overhead allocated manufacturing forward tax credit measurement based area corresponding depreciation tax rate expected effective period amortization asset realized liability settled selling distribution cost pertain particular purpose tax rate tax rule used cost sale marketing organization enacted substantively enacted distribution advertising market research reporting date deferred tax asset recognized extent probable taxable profit research development cost comprise cost level relevant tax authority available research product process development unless utilization deductible temporary recognized asset amortization capitalized difference loss carried forward development cost also indicated item consolidated financial statement note note financial statement 111 goodwill capitalized development cost essentially cover cost allocated staff involved rd goodwill represents future economic benefit raw material supply outside service arising asset acquired business directly attributable overhead intangible asset combination individually identified generated internally amortized straight line separately recognized basis useful life generally exceed four year according ia 36 goodwill acquired business combination may amortized rather must internally generated intangible asset may tested annually impairment soon recognized development cost included indication asset impairment period incurred cost research activity reported expense period purpose impairment testing goodwill must incurred allocated acquirer cashgenerating unit cgus expected benefit amortization intangible asset based synergy combination cashgenerating unit following period useful life cgu represents lowest level within entity goodwill monitored internal management software 2 5 year purpose may larger segment capitalized development cost 4 6 year customer relation technology 5 15 year brand name na intangible asset intangible asset acquired stated cost less accumulated regular amortization calculated according straightline method useful life intangible asset period asset expected contribute directly indirectly cash flow entity cost incurred within scope development new product method capitalized internally generated intangible asset following criterion met technical feasibility completing intangible asset available use sale intention complete intangible asset use sell ability use sell intangible asset demonstration intangible asset generate probable future economic benefit availability adequate technical financial resource complete development use sell intangible asset ability measure reliably expenditure attributable intangible asset development 112 consolidated financial statement note note financial statement property plant equipment group lessee finance lease amount equal fair value leased property property plant equipment item reported lower present value minimum lease cost subject depreciation depreciated payment recognized asset balance scheduled straightline method applied sheet simultaneously recognized financial depreciation reported consolidated financial liability minimum lease payment essentially statement consist finance charge reduction outstanding liability measured according depreciation fixed asset based following effective interest method leased asset period useful life depreciated straightline basis period expected useful life shorter lease term building 15 50 year machinery 5 15 year group lessor finance lease sale revenue factory office equipment 3 13 year equal net investment lease recognized well lease receivable leasing rate receives also apportioned finance charge reduction liability according impairment intangible tangible asset effective interest method book value carrying amount property plant operating lease lease rate paid equipment intangible asset examined lessee recognized expense lease whether indication asset might rate received lessor recognized income impaired pursuant ia 36 impairment asset respectively leased asset continues asset impaired recoverable amount recognized lessor balance sheet property asset estimated recoverable amount asset plant equipment cashgenerating unit higher fair value less cost sell asset cgu value use event individual asset recoverable inventory amount cannot estimated recoverable amount asset cashgenerating unit cgu estimated raw material supply including merchandise reported inventory average cost estimated recoverable amount asset principle finished good work progress cgu go book value carrying amount reported cost conversion cost includes carrying amount reduced recoverable amount direct cost allocated material appropriate portion production cause asset impairment removed material handling overhead general administrative book value asset cgu credited expense fixed asset normal depreciation newly estimated recoverable amount however amortization rate provided book value increase limited value asset expense caused production cgu would asset impairment loss would assessed previous financial year inventory must evaluated lower amount cost net realizable value net realizable value represents estimated selling price lease ordinary course business less estimated cost completion estimated cost necessary lease considered agreement whereby lessor marketing sale distribution inventory conveys lessee return payment series risk exist risk reduced shelf life payment right use asset agreed result storage period limited usability period time according ia 17 lease classified inventory marked accordingly either operating finance lease finance lease lease transfer substantially risk reward incidental ownership asset lease designated operating lease consolidated financial statement note note financial statement 113 trade receivables provision trade receivables reported provision recognized liability third discernible risk covered book value trade party incurred outflow resource receivables receivables representative probable amount obligation fair value considering maturity date reasonably estimated amount recognized credit risk determining recoverability trade provision represents best estimate receivables group considers change obligation balance sheet date provision credit quality date credit originally original maturity one year granted discounted present value expenditure expected settle obligation end reporting period construction contract provision regularly reviewed adjusted construction contract contract specifically information becomes available circum negotiated construction asset stance change provision warranty cost combination asset closely interrelated based historical experience interdependent term design technology function ultimate purpose use restructuring provision set connection outcome construction contract program materially change scope business estimated reliably revenue constructiontype performed segment business unit manner project generally recognized business conducted case percentageofcompletion method based restructuring expense include termination benefit percentage cost date compared total compensation payment due termination estimated contract cost expected loss agreement supplier dealer including leasing construction contract recognized expense contract restructuring provision recognized immediately group detailed formal plan either commenced implementation announced contract disclosed receivables liability percentage completion cumulative work contract cost contract result exceeds financial instrument advance payment received construction contract recognized receivables amount due financial instrument contract give rise customer balance deduction advance financial asset one entity financial payment received negative obligation liability equity instrument another entity construction contract recognized liability financial asset mainly include cash cash amount due customer equivalent availableforsale financial asset trade loan receivables derivative financial instrument positive fair value pension obligation financial liability group mainly comprise pension provision similar obligation loan bank trade payable finance lease recognized consolidated financial statement payable derivative financial instrument sartorius stedim biotech group accordance negative fair value actuarial principle ia 19 employee benefit stipulates projected unit credit method initially financial instrument recognized method measurement addition known fair value transaction cost directly attributable pension life expectancy expected cash acquisition issue financial instrument value method take account future salary recognized determining carrying amount pension increase financial instrument measured fair value profit loss subsequently financial actuarial gain loss recognized asset liability measured according comprehensive income directly equity pension category cash cash equivalent availablefor reserve according standard ia 19r sale financial asset loan receivables financial liability measured amortized cost financial asset liability classified held trading assigned 114 consolidated financial statement note note financial statement cash cash equivalent cash flow hedge group considers highly liquid investment effective portion change fair value less three month maturity date derivative instrument designated cash flow hedge acquisition cash equivalent mainly includes recognized comprehensive income check cash hand deposit bank cash ineffective portion recognized immediately net cash equivalent measured cost income financial result amount accumulated equity reclassified net income period hedged item affect net income investment investment nonconsolidated subsidiary statement cash flow associate security measured cost active market exists share security statement cash flow cash flow present fair value asset cannot reliably ed according allocation operating activity measured investing activity financing activity instance cash flow operating activity loan receivables determined using indirect method ie expense without effect payment added financial asset classified loan receivables profit tax income without effect measured amortized cost using effective payment subtracted cash flow interest method less impairment loss financing activity composed primarily change impairment loss trade receivables equity addition repayment loan recognized using separate allowance account 4 critical accounting judgment key financial liability source estimation uncertainty financial liability measured except derivative preparation consolidated financial financial instrument amortized cost using statement management us estimate effective interest method assumption based best knowledge current future situation period however actual result may differ estimate derivative financial instrument estimate assumption revised regular basis impact change immediately derivative financial instrument foreign recognized income expense period currency exchange contract interest rate swap contract measured fair value derivative addition group management exercise judgment financial instrument classified held trading defining accounting treatment specific trans unless designated hedging instrument action existing standard inter hedge accounting applied change pretations specifically treat accounting fair value derivative financial instrument problem concerned recognized either net income case hedge comprehensive income assumption estimate primarily concern following topic consolidated financial statement note note financial statement 115 business combination trade receivables accounting business combination requires allowance doubtful account involves asset acquired liability assumed significant management judgment review recorded respective fair value date individual receivables based individual customer group obtains control application creditworthiness current economic trend well acquisition method requires certain estimate analysis historical bad debt portfolio assumption made especially concerning fair basis value acquired intangible asset property plant equipment liability assumed acquisition date useful life acquired employee benefit pension provision intangible asset property plant equipment obligation pension postemployment measurement based large extent benefit determined accordance actuarial anticipated cash flow actual cash flow vary valuation valuation rely key assumption used calculating fair value may including discount rate expected salary increase materially affect group future result mortality rate discount rate assumption operation determined reference yield highquality corporate bond appropriate duration currency end reporting period impairment asset due changing market economic condition impairment test conducted certain event lead underlying key assumption may differ actual assumption asset might impaired development may lead significant change case carrying amount asset pension postemployment benefit obligation compared recoverable amount higher net realizable value value use difference recognized full directly calculation value use generally based equity period occur without discounted cash flow method using cash affecting profit loss sensitivity analysis see flow projection five year projection note 23 pension employee benefit provision take account past experience represent management best estimate future sale revenue cost development cash flow provision contingent liability planning period extrapolated using individual contingent asset growth rate key assumption management based determination value use include provision recognized legal constructive estimated growth rate weighted average cost obligation exist balance sheet date capital tax rate estimate determine amount obligation certain material impact respective value estimate assumption applied ultimately amount impairment including evaluation probability carrying amount exceeds recoverable amount amount cost incurred typically significant impairment loss recorded estimate involved determination provision related onerous contract warranty cost asset retirement obligation legal proceeding intangible asset capitalization selfconstructed intangible asset also includes certain level estimation assumption eg evaluation feasibility development project expected market prospect determination useful life 116 consolidated financial statement note note financial statement income tax segment business activity may result revenue expense operating result group operates various tax jurisdiction regularly reviewed entity chief operating therefore determine tax position decision maker executive member board respective local tax law tax authority view director discrete financial information complex subject different available internal reporting internal control interpretation taxpayer local tax authority reporting within sartorius stedim biotech based deferred tax asset recognized approach operating total solution deductible temporary difference unused tax provider customer accordingly loss extent probable future identification sartorius stedim biotech reportable taxable profit available operating segment biopharm deductible temporary difference unused tax loss utilized future development key performance indicator operating uncertain partly beyond management control segment sartorius stedim biotech group assumption necessary estimate future taxable socalled underlying ebitda ebitda corresponds profit well period deferred tax earnings interest tax depreciation asset recover amortization underlying ebitda mean ebitda adjusted extraordinary item connection estimate revised period extraordinary item expense income sufficient evidence revise assumption exceptional onetime nature management considers probable portion accordingly distort sustainable profitability deferred tax asset cannot realized segment material impact net worth corresponding valuation allowance taken financial position earnings group example account item restructuring expense large group project well proceeds loss disposal sale transfer financial asset property 5 operating segment plant equipment provided recurrent nature according ifrs 8 operating segment identification reportable operating segment segment asset segment liability based management approach ie reported regular basis chief operating segment defined analogously internal decision maker therefore part control reporting structure entity therefore segment report area activity considered operating biopharm group k 2014 2013 change 2014 2013 change sale revenue 683524 588378 16 683524 588378 16 underlying ebitda 160474 135586 18 160474 135586 18 sale revenue 235 230 235 230 ebit 120373 101346 19 120373 101346 19 sale revenue 176 172 176 172 capital expenditure 44242 34217 29 44242 34217 29 consolidated financial statement note note financial statement 117 reconciliation segment profit loss key figure geographical area refer company location except sale revenue k 2014 2013 reported according customer location underlying ebitda segment 160474 135586 noncurrent asset correspond property plant depreciation equipment well intangible asset amortization 35227 30558 group affiliate allocated extraordinary effect 4873 3682 various region goodwill resulting reverse ebit 120373 101346 acquisition stedim 2007 associated financial result 15261 6901 intangible asset presented noncurrent asset profit tax 105112 94445 europe european region following country account material noncurrent asset germany 2083 million 1974 million 2013 supplementary information region france 3067 million 3102 million 2013 provide additional information required ifrs 8 amount sale revenue single customer table present supplementary exceed 10 consolidated sale revenue information geographical region european 2014 2013 region includes market western eastern europe north american region comprised u marketplace canadian market japan china australia south korea india well country allocated asia pacific region market segment primarily consists latin america africa sale revenue noncurrent asset k 2014 2013 2014 2013 europe 314888 287145 573100 565043 north america 205234 150807 26879 19599 asia pacific 142920 125769 16830 15537 market 20481 24657 1747 1094 group 683524 588378 618556 601273 6 scope consolidation 2014 financial statement following subsidiary sartorius stedim hungary sartorius icr russia tap biosystems phc ltd uk tap biosystems ltd uk sartorius stedim financiére sa france sartorius stedim integrated service sarl tunisia sartorius stedim biotech sarl tunisia included scope consolidation figure minor importance assessing financial position group sale revenue total asset non consolidated company 1 group figure 118 consolidated financial statement note note financial statement financial statement following company included group financial statement ownership europe parent sartorius stedim biotech sa aubagne france company sartorius stedim belgium nv vilvoorde belgium 100 sartorius stedim nordic taastrup denmark 100 sartorius stedim biotech gmbh goettingen germany 100 sartorius stedim plastic gmbh goettingen germany 100 sartorius stedim system gmbh guxhagen germany 100 sartorius stedim uk ltd epsom uk 100 sartorius stedim lab ltd louth uk 100 tap biosystems group ltd royston uk 100 tap esop management ltd royston uk 100 automation partnership cambridge ltd royston uk 100 sartorius stedim fmt sa aubagne france 100 sartorius stedim france sa aubagne france 100 sartorius stedim aseptics sa lourdes france 100 sartorius stedim ireland ltd dublin ireland 100 sartorius stedim italy spa florence italy 100 sartorius stedim netherlands bv rotterdam netherlands 100 sartorius stedim austria gmbh vienna austria 100 sartorius stedim poland sp zoo kostrzyn poland 100 sartorius stedim switzerland ag tagelswangen switzerland 100 sartorius stedim spain sa madrid spain 100 north america sartorius stedim filter inc yauco puerto rico 100 sartorius stedim north america inc bohemia new york usa 100 automation partnership inc greenville usa 100 allpure technology llc new oxford usa 50 asia pacific sartorius stedim australia pty ltd dandenong south victoria australia 100 sartorius stedim biotech beijing co ltd beijing china 100 sartorius stedim shanghai trading co ltd shanghai china 100 sartorius stedim india pvt ltd bangalore india 100 sartorius stedim japan kk tokyo japan 100 sartorius korea biotech co ltd seoul south korea 49 sartorius stedim malaysia sdn bhd kuala lumpur malaysia 100 sartorius stedim singapore pte ltd singapore 100 market sartorius stedim bioprocess sarl mhamdia tunisia 100 associate joint venture included scope consolidation company consolidated full ownership rate equal share voting right company sartorius stedim poland sp zoo included scope consolidation first time far company included due minor importance company initial consolidation lead material effect group figure company sartorius korea biotech co ltdis included scope consolidation based contractual agreement group hold exercisable call option remaining interest company see note 23 consolidated financial statement note note financial statement 119 7 statement cash flow preliminary fair fair value value date acquisition date acquisition statement cash flow show impact cash k k inflow outflow cash cash equivalent intangible asset 22075 15945 group cash flow classified property plant operating investing financing activity according equipment 6960 6960 ia 7 statement cash flow inventory 3681 6442 trade receivables 7610 7254 context cash equivalent asset asset 810 816 converted cash within short maturity generally cash cash equivalent 2846 2846 less three month amount considered deferred tax net 3475 2155 statement cash flow includes mainly cash hand provision 208 208 bank balance similar item equal loan borrowing 7413 7413 amount statement financial position liability 14966 18474 net asset acquired 17920 12013 2014 group received grant related asset connection purchase construction purchase price 33050 33050 production facility puerto rico amount goodwill 15130 21037 41 million cash inflow reported cash flow investing activity payment 2013 comparative column statement financial position retreated impact following noncash transaction concluded reflected statement cash flow purchase price paid cash acquisition capital expenditure finance lease amounted related cost amounting 376 k 00 million 2014 22 million 2013 recognized expense statement profit loss 2013 8 business combination acquisition pure technology llc acquisition tap biosystems group plc april 25 2014 sartorius stedim biotech acquired 5001 u startup pure technology llc december 2013 sartorius stedim biotech amount 6 million u dollar cash payment acquired 100 share british tap biosystems latter company based new oxford pennsylvania usa group plc company primarily specializes operating market four year design development small scale multi 2013 earned sale revenue around 3 million parallel fermentation system particularly u dollar 25 employee pure specializes biopharmaceutical application addition singleuse component solution biopharmaceutical company array product cover automated cell application provides product culture system bioprocessing bench top complementary group portfolio equipment biotech application bioprocess solution segment acquisition sartorius stedim biotech extends share pure remaining former current portfolio fermentation business owner also transferred sartorius stedim multiparallel small scale bioreactors range biotech 2022 latest exact time 15 milliliter 250 milliliter tap portfolio acquisition well purchase price depend stand gain substantial market penetration based future business performance entity sartorius stedim biotech greater sale strength purchased respective liability recognized global reach well benefit present value expected future payment synergy related product fluid disclosed financial liability amount management cell culture medium business 71 million counterpart financial liability recognized equity according present preliminary purchase price allocation determined access method change fair value 2013 finalized 2014 follows liability posted within financial result within profit loss year 120 consolidated financial statement note note financial statement preliminary purchase price allocation follows preliminary fair value acquisition date k intangible tangible asset 2067 inventory 467 trade receivables asset 307 cash cash equivalent 41 provision liability 484 net asset acquired 2398 5001 1199 purchase price 4332 goodwill 3133 noncontrolling interest 1199 goodwill recognized represents asset separately identified recognized also generate economic benefit group especially expansion group portfolio strengthened position relevant biopharmaceutical market well synergy resulting combination named sartorius stedim biotech group chosen recognize amount noncontrolling interest level prorated share net identifiable asset without goodwill partial goodwill method deferred tax recognized upon initial consolidation due structure transaction future period deferred tax liability recognized arising taxable temporary difference full amount goodwill deductible local tax purpose inclusion company scope consolidation january 1 would significant impact group figure due low business volume activity since acquisition date acquired company contributed materially group result either transaction cost 02 million recognized expense consolidated financial statement note note statement profit loss 121 note statement profit loss 9 sale revenue employee benefit expense sale revenue broken geographical item broken follows area consists following 2014 2013 2014 2013 12 month 12 month 12 month 12 month k k k k wage salary 168470 140487 france 45515 43247 social security 33192 28895 germany 87963 79186 expense retirement country 550045 465945 benefit pension 4901 2768 total 683524 588378 total 206564 172149 amount 13441 k earned 11 operating income expense subsidiary sartorius group 2014 11198 k 2013 2014 2013 12 month 12 month k k turnover broken product sale amounting 6511 million service amounting currency translation gain 10327 9654 324 million corresponds providing service income decrease allowance bad debt 793 1633 respectively 565 million 234 million 2013 income release use provision liability 1627 937 income grant 2185 2186 10 functional cost income 3655 4412 operating income 18588 18823 statement profit loss built according cost sale format ie expense currency translation loss 7650 10062 allocated relevant function extraordinary expense 4873 3682 production sale marketing research allowance bad debt 933 790 development general administration expense 4899 1374 operating expense 18355 15908 operating expense nature reconciled total operating profit loss statement nature note 14 income expense 233 2915 material expense employee benefit expense follows item reported income grant discloses grant expense essentially related research development project recognized raw material supply income soon sufficiently reliable indication necessary prerequisite met item consists following income includes income acquired 2014 2013 cell culture medium business 12 month 12 month k k extraordinary item amounted 49 million purchase consumed 165023 143964 previous year 37 million essentially cover cost purchased service 26651 13847 onetime expense strategic group project total 191674 157811 integration acquisition related item 122 consolidated financial statement note note statement profit loss 12 financial result considering french german average tax rate impact tax legislation expected 2014 2013 tax rate sartorius stedim biotech group 12 month 12 month roughly 29 following table describes k k difference tax expense expected interest similar income 423 168 income tax expense reported affiliated particular financial year company 0 137 income derivative financial instrument 105 0 2014 2013 12 month 12 month financial income 1883 781 k k financial income 2411 949 expected tax expense 29 30482 27389 interest similar expense 5283 4050 difference group average income tax rate 2375 1050 affiliated company 122 96 permanent difference 1251 895 expense derivative financial taxfree income instrument 4655 293 tax exemption 1444 884 interest expense pension 837 778 3463 620 financial expense 6896 2729 total 31377 26970 financial expense 17672 7850 total 15261 6901 effective tax rate 299 286 financial income includes mainly fair item contains mainly withholding tax value change liability connection tax previous year impact purchase noncontrolling interest pure french valueadded tax cotisation sur la valeur see note 8 ajoutée de entreprises cvae expense derivative contain effect cancellation hedging relationship 14 profit loss statement nature interest rate swap upon refinancing group financial expense include currency effect 2014 2013 12 month 12 month financial liability k k sale revenue 683524 588378 purchase consumed 165023 143964 13 income tax cost purchased service 26651 13847 personnel cost 206564 172149 2014 2013 amortization 12 month 12 month depreciation 35559 30558 k k operating cost 129355 126514 current income tax 34675 27374 subtotal 563151 487031 deferred tax 3297 404 operating profit ebit 120373 101346 total 31378 26970 financial income expense 15261 6901 income tax 31378 26970 noncontrolling interest 1262 1198 matter principle income tax france group net profit 72472 66276 calculated 3443 estimated taxable profit year germany rate 30 applied taxable income income generated outside france germany taxed particular rate valid corresponding country consolidated financial statement note note statement profit loss 123 15 earnings per share according ia 33 earnings per share earnings per share class share must determined separately basic earnings per share basic eps calculated basis weighted average number ordinary share period diluted earnings per share measured taking account share subscription option outstanding end period certain group employee acquired entitlement subscribe total 15642 share 1000 december 31 2013 therefore diluted net earnings per share calculated basis 2014 financial year item including number existing potential future share including optional share treasury share included calculation earnings per share 2014 2013 net profit tax k 73734 67474 group net profit tax k 72472 66276 earnings per share 472 432 diluted earnings per share 472 431 number share statutory level 15359238 17042306 treasury share share buyback program 0 1698710 dilution stock option exercised 7871 63 number share used earnings per share calculation 15351367 15343533 future option 8000 23642 potential option 0 0 number share used diluted earnings per share calculation 15359367 15367175 124 consolidated financial statement note note individual balance sheet item note individual balance sheet item 16 goodwill intangible asset goodwill monitored internal management purpose may larger segment combination former sartorius biotechnology goodwill division former stedim group newly founded sartorius stedim biotech group follows goodwill strategy total solution provider customer k various interdependency within gross book value jan 1 2013 288055 business lowest level goodwill currency translation 597 monitored biopharm segment therefore change scope consolidation acquired goodwill allocated cgu acquisition 21497 gross book value dec 31 2013 308955 2013 impairment test conducted 2014 amortization impairment loss measure recoverable amount basis jan 1 2013 0 value use particular cashgenerating unit currency translation 0 biopharm segment cash flow forecast consider amortization impairment loss 0 previous experience generally based amortization impairment loss group management forecast period three dec 31 2013 0 five year calculation based terminal net book value dec 31 2013 308955 year growth rate 25 year 2017 rate derived market expectation goodwill forecast significant growth rate targeted k biopharmaceutical market major growth driver gross book value jan 1 2014 308955 sartorius stedim biotech group aging currency translation 2337 people increase population improved change scope consolidation access drug emerging market well acquisition 3146 ongoing paradigm shift reusable product gross book value dec 31 2014 314437 singleuse product utilized bio manufacturing amortization impairment loss jan 1 2014 0 biopharmaceutical industry currency translation 0 amortization impairment loss 0 discount rate applied correspond weighted amortization impairment loss capital cost rate recognized follows dec 31 2014 0 net book value dec 31 2014 314437 2014 2013 tax tax tax tax item reported goodwill amount biopharm 314437 k capitalized difference asset segment 83 65 84 68 resulting business combination according ia 36 goodwill acquired business combination may amortized rather must tested 2014 impairment test result annually impairment soon recognition impairment loss context indication asset impairment various sensitivity analysis based realistic variation assumption disclosed result increase recorded 2013 concern acquisition impairment either following variation would tap biosystems 2014 acquisition refers theoretically represent breakeven point pure see note 8 2014 2013 purpose impairment testing goodwill must discount rate 157 144 allocated acquirer cashgenerating terminal growth rate 179 132 unit cgus expected benefit cash flow 717 660 synergy combination cashgenerating unit cgu represents lowest level within entity consolidated financial statement note note individual balance sheet item 125 intangible asset patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2013 26754 10779 100978 33655 54 172220 currency translation 297 0 78 40 0 415 change scope consolidation acquisition 6904 0 7414 1656 0 15974 capital expenditure 890 0 0 5139 0 6029 disposal 595 0 0 0 0 595 transfer 82 0 0 0 0 82 gross book value dec 31 2013 33738 10779 108314 40410 54 193295 amortization impairment loss jan 1 2013 10543 0 36090 16853 0 63486 currency translation 155 0 20 18 0 193 amortization impairment loss 2000 0 7362 4775 0 14137 disposal 593 0 0 0 0 593 transfer 0 0 0 0 0 0 amortization impairment loss dec 31 2013 11794 0 43432 21610 0 76836 net book value dec 31 2013 21945 10779 64882 18800 54 116459 patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2014 33738 10779 108314 40410 54 193295 currency translation 1098 0 790 233 0 2122 change scope consolidation acquisition 1478 0 437 134 0 2049 capital expenditure 491 0 0 8447 251 9189 disposal 126 0 0 68 0 194 transfer 88 0 0 0 54 34 gross book value dec 31 2014 36768 10779 109541 49156 251 206495 amortization impairment loss jan 1 2014 11794 0 43432 21610 0 76836 currency translation 349 0 144 48 0 541 amortization impairment loss 3212 0 7726 6384 0 17321 disposal 126 0 0 0 0 126 transfer 0 0 0 0 0 0 amortization impairment loss dec 31 2014 15228 0 51302 28042 0 94572 net book value dec 31 2014 21540 10779 58239 21114 251 111924 126 consolidated financial statement note note individual balance sheet item stedim brand name acquired 2007 considered 2014 development cost 8447 k indefinite useful life therefore recognized asset 5139 k 2013 amortized foreseeable limit period capitalized development cost essentially covered brand name expected generate cost allocated staff involved rd net cash inflow group brand name raw material supply outside service tested annually impairment soon directly attributable overhead internally generated indication asset impairment intangible asset amortized according straightline method useful life integration stedim brand usually exceed five year sartorius stedim biotech brand separate measurement relevant cash flow longer amortization intangible asset allocated possible therefore separate impairment test corresponding function statement profit carried 2014 recoverability brand loss capitalized development cost amortization name considered level biopharm disclosed research development cost segment cashgenerating unit cgu customer relationship obtained part reverse acquisition stedim constitute material intangible asset book value customer relationship amounted 405 million 2013 459 million year ended december 31 2014 remaining period useful life eight year 17 property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2013 130914 82300 58409 9488 281112 currency translation 1539 962 741 28 3269 change scope consolidation acquisition 5555 1212 225 0 6992 capital expenditure 3398 7823 7625 9342 28188 disposal 212 896 3156 78 4342 transfer 646 2673 1266 4319 266 gross book value dec 31 2013 138763 92150 63628 14406 308948 depreciation jan 1 2013 33572 49038 38212 0 120822 currency translation 261 540 440 0 1240 depreciation 4458 5470 6487 6 16421 disposal 58 468 2734 0 3260 transfer 0 27 375 0 348 depreciation dec 31 2013 37711 53472 41901 6 133090 net book value dec 31 2013 101053 38678 21727 14400 175858 consolidated financial statement note note individual balance sheet item 127 factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2014 138763 92150 63628 14406 308948 currency translation 2741 1739 1499 81 6061 change scope consolidation acquisition 5 1 107 6 119 grant related asset 4060 0 0 0 4060 capital expenditure 3642 6181 6470 18760 35053 disposal 626 1997 5925 404 8952 transfer 3189 3066 842 6922 175 gross book value dec 31 2014 143654 101141 66622 25926 337343 depreciation jan 1 2014 37711 53472 41901 6 133090 currency translation 393 1025 834 0 2252 depreciation 4898 6538 6802 0 18238 disposal 607 2360 5465 0 8432 transfer 0 6 0 6 0 depreciation dec 31 2014 42394 58682 44072 0 145148 net book value dec 31 2014 101260 42458 22550 25926 192195 depreciation included statement profit capitalized property plant equipment include loss according use asset cost asset held finance lease amounting sale selling distribution cost research 17384 k 2013 17760 k cost acquisition development cost general administrative expense asset total 18702 2013 18352 k operating expense 2014 rental payment amounting 57 million 2014 fiscal 2013 significant 2013 44 million made asset leased impairment loss recognize intangible asset operating lease property plant equipment 18 deferred tax deferred tax asset deferred tax liability dec 31 2014 dec 31 2013 dec 31 2014 dec 31 2013 k k k k intangible asset 179 272 22066 27345 tangible asset 13 0 5748 3811 inventory 3124 2857 1011 2281 receivables current asset 1097 664 347 959 provision 6604 4989 0 0 liability 1578 628 1326 726 gross amount 12594 9410 30498 35122 carry forward taxable loss 259 1535 0 0 offset 2684 1586 2684 1586 net amount 10169 9359 27814 33536 change 810 5722 thereof recognized profit loss 1099 4396 128 consolidated financial statement note note individual balance sheet item deferred tax asset k 2014 2013 cash flow hedge 1084 642 balance sheet date group unused tax actuarial gain loss loss amount carried forward 35 million defined benefit obligation 1885 314 deducted future taxable profit 81 million net investment foreign 2013 deferred tax amount reported approx operation 2069 549 13 million loss 69 million 2013 total 5038 1505 concerning remaining loss carried forward deferred tax amount recognized lack visibility future taxable profit 19 inventory like 2013 deferred tax asset dec 31 2014 dec 31 2013 relation company reported loss year k k review earlier reporting year raw material supply 29017 27472 work progress 33434 22624 finished good deferred tax liability merchandise 45941 43157 payment account 1583 1686 deferred tax liability connection total 109975 94939 intangible asset refer asset acquired business combination consequently mainly linked customer relationship dec 31 2014 dec 31 2013 k k addition group recorded deferred tax liability gross amount inventory 119626 103666 tax amount 13 million approx writedowns 9651 8727 200 million cumulative undistributed earnings net amount inventory 109975 94939 subsidiary 13 million 2013 effect group considers cumulative undistributed earnings intended systematically reinvested 20 current trade receivables subsidiary rather might used pay dividend france germany dec 31 2014 dec 31 2013 k k group recognize deferred tax liability trade receivables third remaining retained earnings subsidiary party 116703 94565 earnings intended reinvested amount due operation dividend paid customer contract work 2070 7705 amount 5 dividend taxed receivables subsidiary french german taxation rule sartorius ag group 6014 4929 applicable withholding tax furthermore trade receivables 124787 107199 additional income tax consequence could arise case intermediate holding company therefore possible estimate amount taxable receivables subsidiary sartorius ag temporary difference undistributed earnings group item refers company sartorius group fiscal 2014 previous year tax effect hedging instrument deferred tax asset 2014 group transferred 249 million recognition actuarial gain loss trade receivables item unrelated entity pension reserve recognized directly 216 million 2013 factoring program consolidated equity likewise amount current group provided transferee credit income tax incurred net investment foreign guarantee part expected loss operation recognized comprehensive receivables transfer qualify income deferred current income tax derecognition ia 39 accordingly group recognized comprehensive income continues recognize full carrying amount disclosed follows table receivables recognized cash received transfer secured borrowing consolidated financial statement note note individual balance sheet item 129 group business area group aging trade receivables past due impaired carry longterm construction contract customerspecific contract recognized dec 31 2014 dec 31 2013 application ia 11 construction contract based k k percentage completion method 130 day 19790 14059 3190 day 8775 8757 item amount due customer contract 91180 day 1496 3502 work represents net amount cost incurred plus 181360 day 485 298 recognized profit less recognized loss progress 360 day 118 302 billing connection construction contract total 30665 26917 aggregate amount cost incurred recognized profit loss project progress reporting date 17426 k 2013 29921 k project trade receivables 30665 k 2013 26917 k advance payment 15356 k 2013 22215 k past due reporting date valuation recorded year contract revenue allowance made material project progress 12423 k 2013 21901 k change creditworthiness debtor could expected would pay amount trade receivables reported outstanding trade receivables yet due discernible risk covered book value trade financial asset written receivables receivables representative indication impairment fair value considering maturity date credit risk determining recoverability trade receivables group considers change 21 financial asset credit quality date credit originally granted significant concentration dec 31 2014 dec 31 2013 credit risk due large base unrelated customer k k accordingly necessary make derivative financial provision cover risk beyond allowance already instrument 57 2890 considered financial asset 6790 6695 current financial asset 6847 9585 development trade allowance dec 31 2014 dec 31 2013 k k 22 issued capital valuation allowance beginning year 2897 4278 beginning 2014 fiscal year share increase year 933 789 capital company ten million three derecognition hundred ninety five thousand eight hundred consumption 504 449 six euro sixty six cent 1039580666 recovery amount previously impaired 793 1636 year share capital company rose foreign currency translation ten million three hundred ninety five difference 82 86 thousand eight hundred six euro sixty six valuation allowance end year 2615 2897 cent 1039580666 fifteen million three hundred fiftynine thousand two hundred thirty eight euro 15359238 following condition meeting 17 july 2014 board director light authorization granted extraordinary shareholder meeting hold 8 april 2014 reduced share capital nominal amount one million thirtysix thousand two hundred thirteen euro ten cent 103621310 cancelling entirety share acquired share buyback program authorized extraordinary shareholder 130 consolidated financial statement note note individual balance sheet item meeting held 19 april 2010 ie one million six 17 july 2014 board director using hundred ninetyeight seven hundred ten delegation power granted 1698710 share extraordinary shareholder meeting 8 april 2014 decides carry share capital increase difference purchase price capitalization five million nine cancelled share 6132719007 nominal hundred ninety thousand one hundred two value 103621310 difference equal sixty euro eightytwo cent 599010282 million two hundred ninety thousand nine drawn issue premium set forth hundred seventysix euro ninetyseven annual account company financial cent 6029097697 charged period closed 31 december 2013 approved available premium thirtyseven million extraordinary shareholder meeting held eight hundred eightyeight thousand nine hundred 8 april 2014 twentynine euro eighteen cent 3788892918 balance twentytwo share capital increase carried million four hundred two thousand fortyseven increase thirtynine cent 039 nominal euro seventynine cent 2240204779 amount fifteen million three hundred fifty item retained earnings nine thousand two hundred thirtyeight 15359238 share comprising share capital company operation reduction share capital nominal unit value went sixtyone cent share capital amounted nine million three 061 one euro 100 hundred sixtynine thousand one hundred thirtyfive euro eighteen cent 936913518 divided december 31 2013 december 31 2014 fifteen million three hundred fiftynine dilutive instrument share thousand two hundred thirtyeight 15359238 subscription option plan share registered share nominal unit value sixtyone cent name owner least four year benefit 061 double voting right consolidated financial statement note note individual balance sheet item 131 dividend key figure board director submit proposal dec 31 2014 dec 31 2013 annual general shareholder meeting payment k k dividend year ended december 31 2014 sartorius korea biotech co ltd follows payment net dividend 130 per sale revenue 28576 21595 share 2013 120 ie total disbursement net result 2426 2349 1996700940 2013 1841231520 total asset 19338 13495 attributed profit loss 1238 1198 dec 31 2014 dec 31 2013 allpure technology llc number share sale revenue 1885 0 beginning period 17042306 17041306 net result 49 0 stock option exercised 15642 1000 total asset 3328 0 cancellation treasury attributed profit loss 24 0 share 1698710 0 number share end period 15359238 17042306 significant restriction group nominal value per share 100 061 ability access use asset settle issued capital amount k 15359 10396 liability mentioned entity 23 noncontrolling interest 24 pension employee benefit provision noncontrolling interest recognized statement financial position amounting 6034 k defined contribution plan refer subsidiary sartorius korea biotech pure technology llc interest sartorius sartorius stedim biotech group company korea biotech 49 remaining 51 subject make payment defined contribution plan exercisable call option therefore assumed primarily relating governmentrun pension plan sartorius stedim biotech control entity country percentage company pay interest pure technology 5001 social security contribution national insurance remaining share purchased sartorius contribution oldage retirement benefit cannot stedim biotech latest end 2022 reliably determined 2014 total expense recognized remaining company amounted purchase price noncontrolling interest 13786 k 2013 11108 k entity variable depending future performance activity noncontrolling interest allocated follows respective entity dec 31 dec 31 2014 2013 k k sartorius korea biotech co ltd 4639 3499 allpure technology llc 1395 0 total 6034 3499 132 consolidated financial statement note note individual balance sheet item defined benefit plan measurement postemployment benefit obligation based following actuarial pension provision similar obligation assumption recognized consolidated financial statement sartorius stedim biotech group accordance actuarial principle actuarial gain loss germany shown directly comprehensive income according standard ia 19r actuarial loss dec 31 2014 dec 31 2013 transferred pension reserve discount rate 190 350 essentially resulted change discount rate future salary increase 300 300 totaled 6957 k actuarial gain 1048 k future pension increase 200 200 2013 amount 24054 k relates particular pension provision retirement pension plan france germany provision totaled 17837 k 2013 primarily relate direct commitment dec 31 2014 dec 31 2013 defined benefit pension plan discount rate 180 350 commitment employee earn benefit future salary increase 300 300 year service rendered company benefit future pension increase 200 200 earned depend salary level age respective employee pension benefit generally funded asset amount reported statement profit assumed discount factor reflect interest rate loss comprehensive income consist paid reporting date prime following corporate industrial bond matching maturity denominated relevant currency 2014 2013 corporate bond available matching k k longterm maturity insufficiently available current service cost 1175 1089 matching interest rate determined past service cost 336 0 extrapolation net interest expense 732 690 component defined benefit cost recognized profit loss 1571 1779 return plan asset excl interest 3 35 actuarial gain loss 6907 1025 component defined benefit cost recognized comprehensive income 6910 1060 total 8481 719 consolidated financial statement note note individual balance sheet item 133 statement profit loss current service plan asset cost disclosed according assignment employee respective function 2014 2013 k k amount included consolidated statement plan asset jan 1 4416 3948 financial position arising group obligation interest income 105 88 respect defined benefit plan follows return plan asset excl interest 3 35 dec 31 2014 dec 31 2013 actuarial gain loss 12 5 k k group contribution payment 798 572 present value obligation 35557 27017 currency translation difference 174 74 fair value plan asset 4974 4416 employee contribution 160 153 net liability 30583 22601 employer contribution 475 451 contribution plan participant 459 391 change scope present value defined benefit obligation consolidation 0 0 developed follows change 0 0 plan asset dec 31 4974 4416 2014 2013 k k present value obligation jan 1 27017 26831 composition plan asset current service cost 1175 1089 past service cost 336 0 plan asset primarily refer insurance interest cost 837 778 contract germany switzerland major equity debt investment included actuarial gain loss 6895 1030 subsidiary south korea deposited amount currency translation difference 253 159 09 million 08 million 2013 local bank retirement benefit paid cash cash equivalent reporting year 877 1115 employee contribution 160 153 contribution plan participant 411 391 change 23 79 present value obligation dec 31 35557 27017 actuarial gain loss defined benefit obligation allocated follows 2014 2013 k k experience adjustment 736 492 change demographic assumption 0 55 change financial assumption 6176 588 total 6913 1025 134 consolidated financial statement note note individual balance sheet item sensitivity analysis sensitivity analysis presented may representative actual change defined increase decrease actuarial assumption benefit obligation unlikely change would following impact defined assumption would occur isolation one another benefit obligation furthermore present value defined benefit obligation calculated using method 2013 applied calculating defined benefit obligation liability recognized statement k financial position projected unit credit method demographic assumption life expectancy 1 year 1 year maturity analysis effect 421 402 financial assumption undiscounted cash flow defined benefit discount rate 100 bps 100 bps obligation allocated maturity follows effect 3226 4098 future salary increase 50 bps 50 bps dec 31 2014 dec 31 2013 effect 475 449 k k future pension increase 25 bps 25 bps 1 year 1204 865 effect 599 571 15 year 4924 4046 610 year 8794 6922 10 year 49263 46260 2014 total 64185 58093 k demographic assumption weighted average duration defined benefit life expectancy 1 year 1 year obligation 159 year 2013 151 year effect 761 749 financial assumption discount rate 100 bps 100 bps effect 5244 6729 future salary increase 50 bps 50 bps effect 711 667 future pension increase 25 bps 25 bps effect 898 854 25 noncurrent provision payment employee early retirement plan total k k k balance jan 1 2013 3056 592 3648 currency translation 0 17 17 consumption 1170 35 1205 reversal 33 0 33 addition 527 84 611 reclassification 0 0 0 balance dec 31 2013 2380 623 3003 consolidated financial statement note note individual balance sheet item 135 payment employee early retirement plan total k k k balance jan 1 2014 2380 623 3003 currency translation 0 0 0 consumption 1062 0 1062 reversal 0 0 0 addition 891 53 944 reclassification 0 6 6 balance dec 31 2014 2209 682 2891 noncurrent provision comprise mainly provision noncurrent provision reported present partial retirement employee anniversary value reporting date discount rate bonus included item employee early retirement plan 03 2013 obligation arise mainly german group company 08 partial retirement plan allow employee work parttime 3 5 year actual retirement provision employee beneficiary early retirement plan partial retirement maximum according ia 19r treatment severance period five year actuarial gain loss payment earned future period must well past service cost obligation recognized profit loss respective period recognized income expense service 26 noncurrent liability loan borrowing balance current balance current dec 31 2014 dec 31 2014 dec 31 2013 dec 31 2013 k k k k liability bank 48132 32253 146989 27078 loan sartorius ag 39511 39511 0 0 total loan borrowing 87643 71764 146989 27078 december 2014 sartorius group refinanced syndicated loan facility led bnp paribas commerzbank ag lbbw single 400 million loan facility according loan agreement future financing group channeled parent company sartorius ag time sartorius ag signed loan agreement sartorius stedim biotech gmbh secures financing sartorius stedim biotech group long term credit volume agreement 300 million euro interest rate variable credit margin based armslength principle see also note 322 parallel sartorius stedim biotech group reimbursed longterm syndicated loan 250 million euro negotiated september 2013 136 consolidated financial statement note note individual balance sheet item noncurrent liability noncurrent liability include liability remaining purchase price cell culture dec 31 2014 dec 31 2013 medium business company lonza amount k k 36660 k currently expected liability derivative financial paid two tranche 2017 2022 instrument 1881 2573 liability 42843 34765 furthermore item includes forward liability total 44724 37338 acquisition noncontrolling interest company pure see chapter 8 amount 6183 k owner remaining share derivative financial instrument represent fair sell share company sartorius stedim value interest rate swap agreement context biotech group latest 2022 purchase price refinancing described designation depending performance activity interest rate swap agreement cancelled amount recognized compre hensive income posted profit loss period 27 current provision financial 2013 2014 current provision developed follows warranty total k k k balance jan 1 2013 1331 3103 4433 currency translation 23 105 128 consumption 425 890 1315 release 246 3980 4226 addition 1165 4861 6026 change scope consolidation 208 0 208 change 0 0 0 balance dec 31 2013 2009 2989 4998 warranty total k k k balance jan 1 2014 2009 2989 4998 currency translation 55 110 165 change scope consolidation 0 0 0 consumption 817 438 1255 release 799 487 1286 addition 2787 815 3602 change 0 0 0 balance dec 31 2014 3235 2989 6224 consolidated financial statement note note individual balance sheet item 137 measuring provision recognizable 29 financial obligation contingent obligation based past business asset liability transaction past event probably resulting cash payment resource representative like previous year significant economic benefit whose amount contingent liability contingent asset reliably estimated reported provision reported group major financial obligation refer operate lease follows provision considered result legal constructive obligation respect third dec 31 2014 dec 31 2013 party k k operate lease due within one year 4675 4333 28 current liability due within 2 5 year 7212 7645 due thereafter 2070 2249 trade payable dec 31 2014 dec 31 2013 30 financial instrument financial risk k k payment received account order 31964 14731 general information trade payable third party 36964 43296 section give overview impact payable participation 0 352 financial instrument financial statement payable subsidiary sartorius ag group 12210 7973 sartorius stedim biotech group provides total 81139 66351 additional information balance sheet item contain financial instrument derivative measured fair value determined according marktomarket method financial liability recognized mathematical method used fair value based market data available dec 31 2014 dec 31 2013 k k time value derivative calculated reflect estimate market condition derivative financial instrument 4867 106 end year personnelrelated liability 22437 14631 liability 20774 26392 total 48078 41129 derivative financial instrument refer fair value interest rate swap agreement foreign currency hedging transaction like forward contract mainly related u 138 consolidated financial statement note note individual balance sheet item b class financial instrument following table compare carrying amount fair value category financial instrument reconcile balance sheet item carrying carrying amount fair value amount fair value dec 31 2014 dec 31 2014 dec 31 2013 dec 31 2013 category acc ia 39 k k k k financial asset available sale 1214 1214 1304 1304 trade receivables loan receivables 124787 124787 107199 107199 financial asset loan receivables 6790 6790 6695 6695 derivative financial instrument held trading 12 12 0 0 derivative financial instrument hedging instrument 45 45 2890 2890 financial asset 6847 6847 9585 9585 cash cash equivalent loan receivables 18544 18544 35605 35605 loan borrowing financial liability cost 87643 88976 146989 147659 finance lease liability ifrs 7 18338 21465 18570 18253 trade payable financial liability cost 49175 49175 51620 51620 trade payable ifrs 7 31964 31964 14731 14731 trade payable 81139 81139 66351 66351 derivative financial instrument held trading 3408 3408 0 0 derivative financial instrument hedging instrument 3340 3340 2679 2679 financial liability financial liability cost 63967 66988 61464 67424 financial liability ifrs 7 22088 22088 14324 14324 financial liability 92802 95823 78467 84427 carrying amount financial instrument category shown following table dec 31 2014 dec 31 2013 k k available sale asset 1214 1304 loan receivables 150121 149498 held trading asset 12 0 asset held hedging instrument 45 2890 financial liability cost 200785 260074 held trading liability 3408 0 liability held hedging instrument 3340 2679 fair value financial instrument market price similar instrument level 3 financial determined basis market information instrument calculated basis input factor available balance sheet date allocated derivable observable market data one three level fair value hierarchy accordance ifrs 7 equity investment measured acquisition cost mainly investment nonconsolidated subsidiary level 1 financial instrument calculated basis possible determine fair value reliably due price quoted active market identical asset absence active market applies mainly liability level 2 financial instrument share nonconsolidated subsidiary assumed calculated basis input factor carrying amount correspond fair value derivable observable market data basis balance sheet date consolidated financial statement note note individual balance sheet item 139 financial instrument carried fair value net result financial asset liability held balance sheet date derivative form trading predominantly comprises change forward contract interest rate swap agreement fair value derivative financial instrument well valuation done based quoted foreign interest income interest expense exchange rate available interest rate curve financial instrument taking consideration counterparty risk level 2 net result liability measured amortized calculation fair value financial cost mainly comprises effect foreign currency liability amortized cost especially loan bank translation fair value change finance lease liability done level 3 calculation based market interest rate curve total interest income expense financial asset following zerocoupon method consideration liability measured fair value without expected indicative credit spread recognition profit loss follows pure liability required disclosed 2014 2013 amount present value expected purchase 12 month 12 month k k price payment noncontrolling interest company present value derived interest income 628 362 expected pure sale revenue exercise interest expense 5624 4492 date riskadjusted discount rate presented c capital risk management fair value remaining financial asset liability approximate carrying amount sartorius stedim biotech group capital account predominantly shortterm maturity managed order maximize earnings participating company optimizing ratio equity liability furthermore ensure net gain loss financial instrument group company operate premise goingconcern principle net gain loss various category financial instrument presented following financial liability detailed regarded table managed capital furthermore cash cash equivalent well equity capital 2014 2013 12 month 12 month k k goal financial risk management available sale asset 97 0 loan receivables 2276 3414 treasury department sartorius stedim financial asset biotech group centrally focused sartorius liability held trading 3396 742 corporate administration gmbh subsidiary financial liability cost 3275 1246 sartorius ag centralized treasury department performs service company sartorius group including sartorius stedim biotech group net result financial asset available sale coordinate access national international mainly comprises gain loss equity investment financial market addition treasury dividend gain disposal share department monitor control financial risk internal risk reporting analyzes risk according net result loan receivables mainly degree scope essentially risk entail includes effect currency translation currency interest rate liquidity risk change allowance 140 consolidated financial statement note note individual balance sheet item sartorius stedim biotech group strives previously established exchange rate minimize impact currency interest rate risk generally measured income expense using derivative financial instrument hedging statement profit loss transaction controlling carried different staff member moreover group addition target profit forward internal auditing department regularly monitor concluded optimize hedging transaction use financial instrument trading transaction secure right create obligation derivative financial instrument done hedging swap agreed amount foreign currency purpose corresponding euro amount fixed exchange rate several target date long profit resulting exchange transaction e management exchange rate risk exceed contractually defined limit group exposed currency risk group strategy provides hedging one third sale revenue generated u dollar one half year also hedging measure currency linked u dollar lesser reviewed regular interval order adapt extent foreign currency therefore currency fluctuation derivative financial instrument used hedge net currency exposure resulting currency balance sheet date forward contract translation sale revenue currency hedging carried amount 625 million 2013 foreign currency option forward contract 57 million hedge risk fluctuation used limited extent structured hedge eur usd exchange rate amount cover transaction roughly one third expected net exposure u dollar within period 15 year furthermore forward contract secure right simultaneously japanese yen amount jpy 260 million create obligation sell established foreign hedged jpy 650 million 2013 currency amount exercise date specific exchange rate euro independently following table show forward transaction exchange rate actually valid date profit well target profit forward contract loss resulting difference current balance sheet date fair value dec 31 2013 currency volume maturity k forward contract usd 11500000 q1 2014 749 usd 18500000 q2 2014 687 usd 19500000 q3 2014 552 usd 7500000 q4 2014 11 usd 57000000 1999 forward contract jpy 150000000 q1 2014 551 jpy 100000000 q2 2014 68 jpy 200000000 q3 2014 136 jpy 200000000 q4 2014 136 jpy 650000000 891 consolidated financial statement note note individual balance sheet item 141 fair value dec 31 2014 currency volume maturity k forward contract usd 23000000 q1 2015 1442 usd 14500000 q2 2015 844 usd 12000000 q3 2015 750 usd 8000000 q4 2015 422 usd 5000000 q1 2016 75 usd 62500000 3533 forward contract jpy 50000000 q2 2015 21 jpy 60000000 q3 2015 25 jpy 110000000 47 target profit forward jpy 150000000 q4 2015 15 jpy 150000000 15 derivative financial instrument measured variation swiss franc chf euro time acquisition cost fair value would primarily impact valuation subsequent balance sheet date change value liability connection acquisition derivative financial instrument recognized cell culture medium business lonza 2012 statement profit loss balance sheet denominated chf described note 26 date derivative financial instrument serve increase decrease chf euro 5 hedge cash flow risk qualified hedging would lead impact amounting 19 million relationship exists based criterion ia 39 increase 17 million decrease treasury hedging valuation adjustment recognized directly equity amount recognized equity included profit loss period f interest risk management hedged transaction affect result explained note 26 sartorius stedim biotech 2014 negative amount 3295 k 2013 paid syndicated loan raised 2013 positive impact 2141 k recognized mainly financed parent company comprehensive income cash flow hedging reserve sartorius ag major loan taken variable effective hedging relationship interest rate therefore group continues ineffective portion 201 k posted profit exposed interest rate risk control interest loss period amount 2890 k risk appropriate ratio fixed variable transferred comprehensive income loan maintained furthermore group concluded profit loss period 2013 851 k interest rate hedge form interest swap cover majority loan outstanding u dollar would depreciated 5 variable interest rate result group receives euro equity would increased particular variable interest rate valid 52 million 2013 45 million result would market pay fixed interest rate increased 14 million 2013 04 million following table provides overview interest hedging contract available reporting vice versa u dollar would appreciated date 5 euro resulting impact financial result would 16 million 2013 04 million comprehensive income 58 million 2013 49 million 142 consolidated financial statement note note individual balance sheet item hedging hedging fair value fair value volume volume dec 31 2014 dec 31 2013 hedged dec 31 2014 dec 31 2013 instrument k k end term interest rate k k march swap 60000 60000 2016 237277 1385 2378 march forward swap 40000 40000 2019 168178 1822 195 total 3207 2573 group hedging strategy secure roughly variable interest rate amount approx 70 million 50 70 risk exposure period hedged volume 40 million five year dec 31 2014 raised loan 60 million next five year g liquidity risk management maturity financial liability excluding derivative financial instrument show following pattern carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k loan borrowing 146989 162969 32779 123547 6643 finance lease 18570 37311 1586 7495 28230 trade payable 51620 51620 51620 0 0 liability excluding derivative 67723 71502 26699 16292 28511 financial liability 284902 323403 112685 147333 63384 carrying amount cash flow dec 31 2014 dec 31 2014 1 year 1 5 year 5 year k k k k k loan borrowing 87643 98509 80200 14299 4010 finance lease 18338 35976 1611 8397 25968 trade payable 49175 49175 49175 0 0 liability excluding derivative 63967 73300 21123 23069 29108 financial liability 219122 256959 152109 45764 59086 cash flow shown table include undiscounted expected payment connection respective financial liability including associated interest payment loan borrowing include loan raised parent company sartorius ag see note 26 liability arising sale trade receivables factoring program initiated 2009 liability include liability acquisition cell culture medium business company lonza forward liability acquisition remaining share pure following table illustrate liquidity analysis derivative financial instrument based undiscounted cash flow consolidated financial statement note note individual balance sheet item 143 carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k interest rate swap 2679 3900 1266 2634 0 derivative 2679 3900 1266 2634 0 carrying amount cash flow dec 31 2014 dec 31 2014 1 year 1 5 year 5 year k k k k k gross fulfilment forward contract 3541 3599 3501 98 0 payment obligation 52236 48118 4118 0 payment claim 48637 44617 4020 0 net fulfilment interest rate swap 3207 4418 1231 3187 0 derivative 6748 11616 8233 3383 0 group control liquidity risk maintaining credit line additional facility bank continuously tracking forecasted actual cash flow managing maturity profile financial asset liability table provides overview credit line available reporting date credit line used credit line credit line 1 year 1 5 year 5 year interest rate unused dec 31 2013 k k k dec 31 2013 dec 31 2013 syndicated loan 250000 0 250000 0 variable 100000 150000 bilateral credit variable line 46500 27750 12500 6250 fixed 38200 8300 total 296500 27750 262500 6250 138200 158300 credit line credit line credit line 1 year 1 5 year 5 year interest rate used unused dec 31 2014 k k k dec 31 2014 dec 31 2014 loan sartorius ag 300000 300000 0 0 variable 39511 260489 bilateral credit variable line 67846 52221 12500 3125 fixed 48132 19714 total 367846 352221 12500 3125 87643 280203 market interest rate 10 percentage overall impact profit loss point higher interest expense statement tax would 11 million derivative hedging profit loss would 05 million 2013 instrument classified held trading 10 million higher effect would would impact comprehensive compensated increase fair value income 2013 20 million interest rate swap amount 16 million 144 consolidated financial statement note note individual balance sheet item regard decrease interest rate base dec 31 2014 dec 31 2013 interest rate 0 considered resulting number number option option impact financial result would 03 million 03 million 2013 caused outstanding beginning period 23642 24642 valuation interest rate swap allocated period 0 0 cancelled period 0 0 explained note 26 december 2014 group exercised period 15642 1000 replaced syndicated loan agreement lapsed period 0 0 intercompany loan ultimate parent company outstanding end sartorius ag credit line volume 300 million period 8000 23642 exercisable end period 8000 23642 h risk associated financial instrument reporting date sartorius stedim biotech group exposed risk volatility share price 31 sharebased payment sharebased payment relate stock option plan allocated group personnel various stock option plan outstanding december 31 2013 december 31 2014 summarized follows number number option share number number subject date initial sub number share option target total general date number scribed director number subscribed granted per number meeting board share director initial subscrip exercisable formance beneficiary authorizing granted executive bene tion fiscal year dec 31 dec 31 valid plan approval subscribed executive concerned ficiaries price 2013 2013 2013 option june 23 2000 july 23 2004 140000 0 0 19 923 1000 15642 0 2 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 36 1000 23642 0 4 23642 number number number share number option option date initial sub number share granted subject total general date number scribed director number subscribed target per number meeting board share director initial subscrip exercisable formance beneficiary authorizing granted executive bene tion fiscal year dec 31 dec 31 valid plan approval subscribed executive concerned ficiaries price 2014 2014 2014 option june 23 2000 july 23 2004 140000 0 0 19 923 15642 0 0 0 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 36 15642 8000 0 2 8000 consolidated financial statement note note individual balance sheet item 145 cost fiscal 2014 0 k new additional corresponding item issued capital stock option granted 2014 reserve sartorius stedim biotech share purchase option level sartorius stedim biotech majority allocated group senior shareholder sartorius ag sharebased payment exist managerial employee director fair value form socalled phantom stock unit service performed consideration allocation plan respective board member granted option measured reference fair certain number phantom stock year value option date allocation represent agreed amount money exercise order perform estimate group us stock possible four year binomialtype mathematic model depending certain requirement regarding performance sartorius ag share total fair value plan thus measured stock paid amount based share recognized expense spread full vesting price exercise date payment capped period plan expense recognized amount 25 time share price time personnel cost offset increase reserve virtual option granted detail please cash received group upon exercise refer remuneration report fair value option recognized cash cash equivalent phantom stock unit disclosed follows fair value granted fair value number jan 1 yearend phantom subscription particular dec 31 stock unit price year 2014 paid exercisable k k k tranche phantom stock unit 2010 13469 1578 213 0 531 tranche phantom stock unit 2011 8358 2662 223 556 0 tranche phantom stock unit 2012 7115 3312 235 572 0 tranche phantom stock unit 2013 3686 6936 256 343 0 tranche phantom stock unit 2014 3228 8403 271 291 0 total 35856 1198 1762 531 146 consolidated financial statement note disclosure disclosure consolidated financial statement prepared described structure lead various relation going concern basis transaction related party transaction sartorius stedim biotech sa subsidiary presented note 6 related party material event reporting date company eliminated consolidation disclosed note detail material event occurred reporting date transaction group related party belonging sartorius group disclosed number employee sale purchase commission average workforce employed year 2014 3642 3226 2013 certain business area member sartorius group act contract manufacturer sartorius stedim biotech group vice versa respective 32 related party transaction carried arm length principle disclosed table sale purchase general sale revenue purchase majority shareholder sartorius stedim 2014 2014 k k biotech sa sartorius ag hold either directly indirectly 100 subsidiary vl related party sartorius group 13441 5849 finance sa controlling stake company 743 equity capital 846 voting sale revenue purchase 2013 2013 right k k related party sartorius group organized two division sartorius group 11198 5722 bioprocess solution mainly run sartorius stedim biotech group lab product service mainly run company sartorius certain product group sartorius stedim group structure lead fact group biotech portfolio sold sale force hold two subsidiary country sartorius entity arranging company partially share space staff sale sartorius stedim biotech group resource furthermore german group company paid commission amount 70 million carry various central function accordingly 87 million 2013 commission typically deliver service worldwide entity eg calculated percentage generated sale support company sartorius corporate revenue administration gmbh 100 subsidiary sartorius ag incorporated numerous group function like group finance hr investor relation legal central marketing service charged within group significant extent also sartorius stedim biotech consolidated financial statement note disclosure 147 management fee shareholder cost administration charge shared cost two sartorius stedim biotech sa board member described company also member sartorius ag executive board country share certain function cost paid german parent company underlying contract include mainly sublease service sartorius stedim biotech portion office space central administrative function remuneration charged sartorius accounting controlling human resource stedim biotech sa 07 million 2013 2014 management respect relevant charged sartorius stedim biotech gmbh company charge rent salary social security cost 08 million 2013 2014 expense service well pro rated profit margin service provide shareholder function like group financial reporting compliance investor relation significant contract context one performed mentioned sartorius sartorius stedim biotech gmbh germany corporate administration gmbh germany sartorius corporate administration gmbh service charged sartorius stedim company provides central service biotech sa amount 06 million 2013 administrative function sartorius stedim 07 million biotech gmbh group company calculation service fee typically includes surcharge 3 total cost 3 surcharge shareholder loan compliant arm length principle routine task following oecd eu guideline 2014 service described note 26 sartorius stedim biotech approx 239 million provided sartorius group raised loan parent company stedim biotech gmbh 189 million 2013 sartorius ag credit 300 million amount cover following function current utilization approx 40 million charged interest based variable interest rate plus marketing communication ebusiness business armslength credit margin development environment health security factory maintenance finance human resource information technology central service general organization compensation key management personnel 2013 2014 executive board management received following remuneration shortterm postemployment longterm termination sharebased total benefit benefit benefit benefit payment k k k k k k 2014 1 4173 2823 450 404 0 496 1 2013 3356 2483 118 356 0 418 1 information please refer chapter corporate governance see page 86 93 148 consolidated financial statement note statutory auditor report consolidated financial statement statutory auditor report consolidated financial statement free translation english statutory ii justification assessment auditor report consolidated financial statement issued accordance requirement article l 8239 french language provided solely convenience english speaking user statutory auditor report includes french commercial code code de commerce information specifically required french law report relating justification assessment whether modified information presented bring attention following matter opinion consolidated financial statement includes note 4 accounting policy assumption explanatory paragraph discussing auditor assessment estimate consolidated financial statement certain significant accounting auditing matter assessment made purpose issuing audit refers significant judgment estimate opinion consolidated financial statement taken whole made management particularly concerning provide separate assurance individual account capitalization research development caption information taken outside consolidated expenditure impairment test goodwill financial statement report also includes information relating asset indefinite useful life specific verification information given group management report report read conjunction construed accordance french law periodend company systematically professional auditing standard applicable france performs impairment test goodwill asset indefinite useful life also assesses whether year ended december 31 2014 indication loss value longterm asset according term condition defined shareholder note 16 goodwill intangible asset compliance assignment entrusted u consolidated financial statement annual general meeting hereby report year ended december 31 2014 work consisted assessing data audit accompanying consolidated financial assumption judgment estimate statement sartorius stedim biotech based reviewing test basis calculation justification assessment performed company comparing accounting specific verification required law estimate previous period corresponding consolidated financial statement achievement examining procedure implemented approved board director role management approve estimate verifying express opinion consolidated financial note consolidated financial statement statement based audit provide appropriate disclosure assumption option adopted company opinion consolidated financial statemets assessment made part audit conducted audit accordance professional consolidated financial statement taken whole standard applicable france standard require therefore contributed opinion formed plan perform audit obtain reasonable expressed first part report assurance whether consolidated financial statement free material misstatement audit iii specific verification involves performing procedure using sampling required law also verified technique method selection obtain accordance professional standard applicable audit evidence amount disclosure france information presented group consolidated financial statement audit also includes management report evaluating appropriateness accounting policy used reasonableness accounting estimate matter report fair made well overall presentation presentation consistency consolidated consolidated financial statement believe financial statement audit evidence obtained sufficient appropriate provide basis audit opinion marseille february 19 2015 opinion consolidated financial statement french original signed give true fair view asset liability financial position group december 31 statutory auditor 2014 result operation year ended accordance international financial ernst young audit deloitte associés reporting standard adopted european union xavier senent christophe perrau annual financial statement sartorius stedim biotech sa note 150 annual financial statement ssb sa note annual financial statement annual financial statement parent company balance sheet asset thousand depreciation amortization gross provision net net dec 31 2014 dec 31 2014 dec 31 2014 dec 31 2013 intangible asset 552 4 548 548 property plant equipment 16533 9042 7491 6885 financial investment 128113 128113 189465 total noncurrent asset 145198 9046 136152 196899 inventory work progress 0 0 0 0 receivables trade receivables third party 0 0 0 0 receivables 4663 0 4663 9426 marketable security 0 0 0 0 deposit cash equivalent 6 6 559 total current asset 4669 0 4669 9985 prepaid expense 62 62 45 currency translation adjustment 0 0 0 total asset 149929 9046 140883 206929 parent company balance sheet equity liability thousand dec 31 2014 dec 31 2013 share capital 15359 10396 share premium 16140 59884 reserve 1630 1630 retained earnings carried forward 9032 28969 profit period 24845 20875 regulated provision 4088 4088 total equity 71094 125841 provision liability charge 0 0 total provision liability charge 0 0 loan borrowing 0 0 trade payable 784 1702 tax social charge payable 46 337 liability noncurrent asset 193 0 liability 68767 79049 total liability 69789 81088 currency translation adjustment 0 0 total equity liability 140883 206929 annual financial statement ssb sa note annual financial statement 151 parent company income statement thousand dec 31 2014 dec 31 2013 sale revenue 1465 1501 inventory movement 0 0 capitalized production cost 0 0 depreciation amortization reversal 0 0 operating income expense reallocation 0 0 purchase consumed 0 0 external charge service 2597 2021 tax duty 800 793 personnel cost 0 0 addition amortization depreciation provision 654 598 operating expense 231 223 operating profit ebit 2817 2133 net financing income expense 27194 22716 profit loss ordinary activity 24377 20583 exceptional income expense 0 0 income tax 468 292 net profit loss 24845 20875 152 annual financial statement ssb sa note annual financial statement 1 activity materiel event difference purchase price exercise cancelled share 6132719007 nominal value 103621310 difference equal sixty sartorius stedim biotech sa includes million two hundred ninety thousand nine activity holding sartorius stedim biotech hundred seventysix euro ninetyseven group ownership share subsidiary also cent 6029097697 charged cover real estate related activity holding available premium thirtyseven million eight manufacturing activity site aubagne hundred eightyeight thousand nine hundred therefore sartorius stedim biotech sa present twentynine euro eighteen cent income statement including 3788892918 balance twentytwo million four hundred two thousand fortyseven income expense rental business euro seventynine cent 2240204779 item retained earnings income expense arising holding activity mainly dividend operation reduction share capital le share capital amounted nine million three hundred sixtynine thousand one hundred thirtyfive sartorius stedim biotech sa share capital euro eighteen cent 936913518 divided fifteen million three hundred fiftynine beginning 2014 fiscal year share thousand two hundred thirtyeight 15359238 capital company ten million three share nominal unit value sixtyone cent hundred ninety five thousand eight hundred 061 six euro sixty six cent 1039580666 increase share capital year share capital company rose ten million three hundred ninety 17 july 2014 board director using five thousand eight hundred six euro sixty delegation power granted six cent 1039580666 ten million four extraordinary shareholder meeting 8 april 2014 hundred five thousand three hundred forty decides carry share capital increase eight euro twenty eight cent 1040534828 capitalization five million nine hundred stock option exercised reduced ii ninety thousand one hundred two euro nine million three hundred sixtynine thousand eightytwo cent 599010282 drawn one hundred thirtyfive euro eighteen cent issue premium set forth 936913518 rose iii fifteen million annual account company financial three hundred fiftynine thousand two hundred period closed 31 december 2013 approved thirtyeight euro 15359238 following extraordinay shareholder meeting held condition 8 april 2014 reduction share capital share capital increase carried increase thirtynine cent 039 nominal meeting 17 july 2014 board amount fifteen million three hundred fifty director light authorisation granted nine thousand two hundred thirtyeight 15359238 extraordinary shareholder meeting hold share comprising share capital company 8 april 2014 reduced share capital nominal nominal unit value went sixtyone cent amount one million thirtysix thousand two 061 one euro 1 hundred thirteen euro ten cent 103621310 cancelling entirety share acquired share buyback program 2 accounting principle method authorised extraordinary shareholder meeting held 19 april 2010 ie one million six parent company financial statement year hundred ninetyeight seven hundred ten ended december 31 2014 prepared 1698710 share specified presented accordance french accounting rule amount share represents less ten per cent compliance principle prudence 10 share capital company reporting distinct financial year pre date operation sumption going concern annual financial statement prepared accordance provision french commercial code accounting annual financial statement ssb sa note annual financial statement 153 decree november 29 1983 crc regulation 212 property plant equipment 2014 03 june 5 2014 revision french chart account property plant equipment ppe recognized acquisition value including installation sartorius stedim biotech sa listed compartment cost asset euronext paris stock exchange isin fr code 0000053266 also prepares consolidated financial depreciation calculated standard statement accordance ifrs standard economic life asset using straightline adopted european union december 31 2014 method noncurrent asset depreciated 21 noncurrent asset straightline basis using following indicative period use noncurrent intangible tangible asset valued acquisition cost excluding cost incurred building twenty forty year acquisition improvement fixture fitting ten fifteen year intangible asset property plant equip plant equipment four ten year ment company applied french regulation crc office equipment three five year 2002 10 recodified article 2 4 regulation motor vehicle four five year crc 2004 06 relative amortization depreciation impairment asset according property plant equipment valued component approach acquisition cost less depreciation impairment reported ongoing basis 211 intangible asset 213 financial investment following thus valuated heading incorporation cost patent software investment relate mainly shareholding subsidiary treasury share held within asset amortized straightline basis scope share buyback program using following indicative useful life recorded acquisition cost including fee linked acquisition incorporation cost one five year software one three year writedown provision may established take patent twenty year account particular either stock exchange price underlying asset subsidiary part implementation integrated software financial position prospect direct labor cost concerned included amount capitalized cost function time shareholding subsidiary subject impairment elapsed test intangible asset valued acquisition cost less amortization impairment reported ongoing 22 receivables payable basis receivables payable recorded nominal value receivables whose collection doubtful subject provision doubtful debt 154 annual financial statement ssb sa note annual financial statement 3 noncurrent asset thousand 31 intangible asset gross value dec 31 2013 increase 2014 decrease 2014 dec 31 2014 incorporation cost 4 0 0 4 patent 0 0 0 0 software license 0 0 0 0 business goodwill 548 0 548 intangible asset progress 0 0 0 0 total 552 0 0 552 amortization depreciation 4 0 0 4 net amount 548 0 0 548 32 property plant equipment gross value dec 31 2013 increase 2014 decrease 2014 dec 31 2014 land 496 0 0 496 building 14352 50 0 14402 plant equipment 0 0 0 0 250 893 0 1143 property plant equipment progress 175 317 0 492 total 15273 1260 0 16533 amortization depreciation dec 31 2013 addition release dec 31 2014 building 8363 590 0 8953 plant equipment 0 0 0 0 25 64 0 89 total 8388 654 0 9042 property plant equipment net 6885 606 0 7491 increase tangible asset includes fixture fitting amount 893 k asset construction new building acquired leasing contract 2013 amount 317 k annual financial statement ssb sa note annual financial statement 155 33 financial investment investment dec 31 2013 increase 2014 decrease 2014 dec 31 2014 shareholding 127877 0 0 127877 writedown shareholding 0 0 0 0 deposit guarantee 260 0 25 235 treasury share 61327 0 61327 0 writedown treasury share 0 0 0 0 total 189465 0 61352 128113 following included financial meeting july 17 2014 board investment director light authorization granted extraordinary shareholder meeting held april 8 9999 share capital sartorius stedim 2014 reduced share capital nominal amount bioprocess sarl tunisian company one million thirtysix thousand two hundred thirteen euro ten cent 103621310 100 share capital sartorius stedim cancelling entirety share acquired biotech gmbh company governed german law share buyback program ie one million six following merger sartorius stedim hundred ninetyeight thousand seven hundred ten group june 2007 1698710 share 100 share capital sartorius stedim treasury share item corresponded aseptics sa french company acquired 2004 1698710 share repurchased average price 3610 euro total amount 61327190 100 share capital sartorius stedim fmt therefore reduced amount sa french company created connection contribution asset transfer 2013 investment 01 k 4 trade receivables thousand maturity receivables yearend thousand type receivable net amount less 1 year 1 year deposit guarantee 235 0 235 noncurrent asset 235 0 235 advance payment account 0 0 0 trade receivables 0 0 0 personnel 0 0 0 social security 0 0 0 tax duty 3198 3198 0 group 1434 1434 0 receivables 31 31 0 current asset 4663 4663 0 prepaid expense 0 0 total receivables 4898 4663 235 156 annual financial statement ssb sa note annual financial statement group item receivables group subsidiary 1434 k relates current account cash advance provided sartorius stedim biotech gmbh sartorius stedim fmt sa sartorius stedim france tax duty 3198 k item primarily entail net tax receivable including french tax relief system 3164 k vat receivables 5 maturity liability yearend thousand less 1 type liability net amount 1 year 5 year 5 year loan borrowing credit institution originally less 2 year 0 0 0 0 originally 2 year 0 0 0 0 current bank overdraft accrued interest 0 0 0 0 trade payable 595 595 0 0 including bill exchange 0 0 0 0 advance payment account order 0 0 0 0 tax social security payable 46 46 0 0 liability noncurrent asset 0 0 0 0 group associate 69099 69099 0 0 49 49 0 0 total liability 69789 69789 0 0 accrued expense included account represented 434 k concerned following item type expense dec 31 2014 accrued banking charge 0 supplier invoice received 388 paid vacation including social charge 0 bonus including social charge profit sharing 0 social security payable 41 tax payable 5 employee profit sharing 0 total charge payable 434 6 parent company statement change exercise stock option resulting issue equity thousand 15642 share par value 061 total 9 k 61 equity 135 k share premium associated share capital increase december 31 2014 share capital 15359 k comprising 15359238 share 1 par value reduction share capital cancel treasury share 1698710 amount change equity 2014 result 61327 k please refer part 1 material event following event exercise annual financial statement ssb sa note annual financial statement 157 increase share capital amount allocation retained earnings carried forward 5990 k modify nominal value share 2463 k 061 1 please refer part 1 materiel event exercise paid legal reserve 0 k annual general shareholder meeting april 8 dividend total 18412 k net dividend per 2014 approved appropriation net profit share 120 paid treasury share excluded year 20875 k follows equity appropriation appropriation appropriation appropriation profit profit profit profit 2013 2013 2013 2014 change increase decrease total number share 17042306 17042306 15642 1698710 15359238 share capital 10396 10396 5999 1036 15359 share premium 43744 43744 135 43879 0 merger premium 16140 16140 16140 legal reserve 1040 1040 1040 reserve 590 590 590 balance carried forward 28968 2463 31431 3 22402 9032 dividend paid 0 18412 18412 18412 0 net profit appropriated 20875 20875 0 0 profit reporting year 0 24845 24845 regulated provision 4088 4088 4088 total 125841 0 125841 30982 85729 71095 62 stock option number share subscription option vested exercised date 8000 part policy motivating group senior executive sartorius stedim biotech sa granted potential stock option issued stock option number employee depending achievement future target 7 risk provision thousand 71 provision provision addition release provision type provision dec 31 2013 2014 2014 dec 31 2014 regulated provision accelerated amortization depreciation 4088 0 0 4088 subtotal 1 4088 0 0 4088 provision liability charge exchange risk 0 0 0 0 cost 0 0 0 0 taxation 0 0 0 0 subtotal 2 0 0 0 0 grand total 4088 0 0 4088 158 annual financial statement ssb sa note annual financial statement 72 market risk exposure 2014 net impact according consolidation rule french tax integration operating cash flow risk regime tax relief income 1020 k amount income tax fiscal 2014 settled december 31 2014 net amount sartorius stedim biotech sa 2015 tax foreign currency current asset liability integration regime 2308 k current future tax position thousand future income tax position result january 1 2008 company chose adopt tax paid advance expense recognized french tax integration regime within fiscal year deductible subsequent framework tax group lead company fiscal year group sartorius stedim biotech sa member company tax integration group tax paid advance unrecognized unrealized tax relief sartorius stedim aseptics sa gain sartorius stedim france sa sartorius stedim fmt sa sartorius stedim financière sa deferred tax recognized balance sheet member company report income tax integration tax regime parent temporary difference taxable income corporation benefit tax relief related expense follows consolidating gain loss member company contribution future tax position asset transfer dec 31 increase 2014 solidarity contribution 2 net movement 2014 currency translation difference 0 2014 employee profit sharing 0 depreciation customer inventory 0 total increase 2 decrease 2013 solidarity contribution 2 net movement 2013 currency translation difference 0 2013 employee profit sharing 0 depreciation customer inventory 0 total decrease 2 2014 future tax position 0 0 increase 2013 solidarity contribution 2 net movement 2013 currency translation difference 0 2013 employee profit sharing 0 depreciation customer inventory 0 total increase 2 decrease 2012 solidarity contribution 131 0 net movement 2012 currency translation difference 23 0 2012 employee profit sharing 0 0 depreciation customer inventory 63 0 total decrease 0 2013 future tax position 217 2 annual financial statement ssb sa note annual financial statement 159 8 operating income thousand 81 sale revenue operating segment dec 31 dec 31 operating segment 2014 2013 service 1465 100 1501 100 total 1465 100 1501 100 82 sale revenue geographical region dec 31 dec 31 geographical region 2014 2013 france 1465 100 1501 100 export 0 0 0 eu country 0 0 north american continent 0 0 total 1465 100 1501 100 sale revenue corresponds rent paid entity sartorius stedim fmt sa use premise located aubagne within operational activity 9 breakdown income tax thousand dec 31 2014 dec 31 2013 profit income tax profit profit income tax tax charge tax tax charge profit tax gross taxable income 24377 552 23825 20583 507 20076 exceptional income expense 0 0 0 0 0 0 french tax integration relief 0 1020 1020 0 799 799 net taxable income 24377 468 24845 20583 292 20875 10 information director remuneration remuneration paid member board director director meeting attendance fee amounted 202 k fee related 2013 fiscal year paid 2014 meeting attendance fee paid sartorius stedim biotech sa general management company fiscal 2014 part executive board remuneration recharged sartorius stedim biotech sa amount 746 k 160 annual financial statement ssb sa note annual financial statement 11 offbalance sheet commitment financing group channeled thousand parent company sartorius ag time sartorius ag signed loan agreement dec dec 31 sartorius stedim biotech gmbh secures type commitment comment 31 2014 2013 financing sartorius stedim biotech group commitment given long term credit volume agreement guarantee bilateral 300 million euro interest rate variable credit line 1 2 34500 37375 credit margin based armslength principle see guarantee currency also note 32 hedging contract 1 2 20000 20000 commitment renting leasing 0 0 parallel sartorius stedim biotech group commitment received reimbursed longterm syndicated loan contractual loan 250 million negotiated september 2013 capacity credit institution 0 3000 2 commitment given concern company sartorius stedim biotech gmbh 1 december 2014 sartorius group refinanced commitment connection lease syndicated loan facility led bnp paribas com summarized following table merzbank ag lbbw single 400 million loan facility according loan agreement future 1 year 1 5 year 5 year leasing k k k total buyback value tangible asset building improvments 310 1240 563 2113 0 total 310 1240 563 2113 payment cumulatives depreciation cumulative leasing historical value year payment year depreciation tangible asset building improvments 2391 268 359 0 0 total 2391 268 359 0 0 building operational 1st january 2015 12 information related party thousand affiliate parent company sartorius ag company owned sartorius stedim biotech sa sartorius stedim fmt sa sartorius stedim bioprocess sarl sartorius stedim aseptics sa sartorius stedim biotech gmbh company sartorius stedim biotech sa consoli dated financial statement sartorius ag weender landstrasse 94 108 37075 goettingen germany annual financial statement ssb sa note annual financial statement 161 following find table main amount related party item dec 31 2014 dec 31 2013 investment 127877 127877 trade receivables 440 1771 receivables 994 5672 trade payable 381 1377 liability 68510 78840 income investment 28893 24282 financial income 0 25 finance expense 1698 1437 162 annual financial statement ssb sa note annual financial statement following find table subsidiary shareholding reserve share loan premium change sale retained standing exvat earnings deposit share ownership book value advance financial net dividend dec 31 2014 capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 84232 79949 79949 40070 0 312387 36954 24000 sartorius stedim fmt sa 10000 euro 42940 0 42940 42940 1909 0 91597 1219 1362 sartorius stedim bioprocess sarl 9999 dinar 5950 2743 35389 3666 3379 euro 3132 3132 73 0 15709 1627 1500 sartorius icr 10000 ruble 10 0 70710 2514 0 euro 0 0 0 0 0 1391 49 0 sartorius stedim aseptics sa 448 3277 10000 euro 1848 1848 5002 0 7678 2295 2031 reserve share loan premium change sale retained standing exvat earnings deposit share ownership book value advance financial net dividend dec 31 2013 capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 84232 79949 79949 44611 0 283912 31320 22000 sartorius stedim fmt sa 10000 euro 42940 0 42940 42940 14629 0 84325 2870 0 sartorius stedim bioprocess sarl 9999 dinar 5950 2743 29959 3012 608 euro 3132 3132 2243 0 13880 1395 282 sartorius icr 10000 ruble 10 0 0 677 0 euro 0 0 0 0 0 0 16 0 sartorius stedim aseptics sa 10000 euro 448 3277 1848 1848 4350 0 7448 2061 2000 annual financial statement ssb sa note statutory auditor report financial statement 163 statutory auditor report financial statement free translation english report issued french relating justification assessment provided solely convenience englishspeaking user report read conjunction bring attention following matter construed accordance french law professional auditing standard applicable france note 213 33 financial statement set rule accounting method relative year ended december 31 2014 valuation investment treasury share within scope assessment rule shareholder accounting principle company verified appropriateness accounting compliance assignment entrusted u method specified information annual general meeting hereby report provided note financial statement year ended december 31 2014 made sure correct application audit accompanying financial statement assessment made part audit sartorius stedim biotech financial statement taken whole justification assessment therefore contributed opinion formed specific verification information required expressed first part report law iii specific verification information annual financial statement approved board director also performed accordance professional standard applicable france role express opinion financial specific verification required french law statement based audit matter report fair presentation opinion financial statement consistency financial statement information given management report conducted audit accordance board director document addressed professional standard applicable france shareholder respect financial position standard require plan perform audit financial statement obtain reasonable assurance whether financial statement free material misstatement concerning information given accordance audit involves performing procedure using requirement article l 2251021 french sampling technique method selection commercial code code de commerce relating obtain audit evidence amount remuneration benefit received director disclosure financial statement audit also commitment made favor includes evaluating appropriateness accounting verified consistency financial policy used reasonableness accounting statement underlying information used estimate made well overall presentation prepare financial statement financial statement believe audit applicable information obtained evidence obtained sufficient company company controlling company appropriate provide basis audit opinion controlled based work attest accuracy fair presentation information opinion financial statement give true fair view asset liability accordance french law verified financial position company december 31 required information concerning identity 2014 result operation year shareholder holder voting right ended accordance french accounting properly disclosed management report principle marseille february 19 2015 ii justification assessment original signed statutory auditor accordance requirement article l 8239 ernst young audit deloitte associés french commercial code code de commerce xavier senent christophe perrau 164 annual financial statement ssb sa note statutory auditor report financial statement supplementary information 166 supplementary information information legal nature information legal nature general information issuer corporate purpose france abroad company purpose corporate name purchase develop administrate manage corporate name company portfolio equity security security voting right sartorius stedim biotech social right company regardless activity mean including way legal deed document issued com setting new company contribution kind pany always preceded followed word type social right subscription right société anonyme abbreviation sa merger purchase social right statement share capital heading 1 article 1 incorporation company company bylaw manage conduct coordinate activity subsidiary affiliate applicable registered office provide said company service administrative financial accounting legal registered office aubagne 13400 france nature opinion advise order zi le paluds avenue de jouques study research necessary phone number 33 04 42 84 56 00 development growth office may transferred another location generally financial commercial département french county state industrial personal real property operation adjacent county state simple decision linked directly indirectly abovementioned board director subject ratification next corporate purpose complementary annual general shareholder meeting anywhere related similar purpose may promote else france decision taken extraordinary development accomplishment thereof general shareholder meeting trade commercial register ape code board director decides transfer registered office authorized revise bylaw company registered registre du result heading 1 article 2 company commerce et de sociétés de marseille bylaw number rcs b 314 093 352 economic activity code ape 6420z holding company activity legal form applicable law inspection legal document public limited liability company joint stock company registered office company société anonyme subject french legislation particularly french commercial code reference document may viewed registered office company website website amf validity date incorporation duration present reference document bylaw statutory auditor report financial company incorporated september 28 1978 statement last three fiscal year although société anonyme company duration report mail document historical 99 year effective upon registration french financial information company trade commercial register registre du commerce subsidiary last three fiscal year evaluation et de sociétés unless subject dissolution declaration made expert extension provided present company bylaw document statutory statutory heading 1 article 3 document found registered office supplementary information information legal nature 167 financial year shareholder meeting financial year also referred fiscal year convocation cover period twelve month beginning january 1 ending december 31 year annual ordinary general shareholder meeting convened take decision result revision bylaw extraordinary specific clause company bylaw general shareholder meeting called decide authorize direct indirect revision bylaw special meeting bring together holder form share specific class share consider revision right class share decision made share may nominative bearer form according general meeting binding shareholder shareholder choice share entitled even absent dissenting legally recorded account accordance incapable incapacitated heading 3 article 13 french law bylaw general meeting convened board director default independent auditor person thus empowered general appropriation profit meeting held registered office place stated notice convocation heading 3 income statement summarizes income excerpt article 14 bylaw form expense reporting year discloses timescale notice convocation governed difference deduction amortization depre french law ciation provision profit said reporting year least 5 must deducted annual agenda profit reduced appropriate prior loss heading 3 point 2 excerpt article 14 bylaw set legal reserve deduction cease obligatory legal reserve amount one notice letter call shall indicate tenth share capital obligatory deduction indication required law particularly resume whatever reason legal reserve agenda company electronic address written fall one tenth distributable profit question shareholder may sent eventually comprises profit reporting year less prior mention obligation collect opinion loss amount transferred reserve pursuant prior approval mass security share french law company bylaw increased holder giving access share capital profit brought forward profit distributed among shareholder proportion number meeting may deliberate matter share one hold annual general placed agenda may however remove one shareholder meeting may decide distribute director time amount taken reserve available expressly indicating reserve one shareholder representing percentage transfer made however dividend disbursed share capital required law may way priority annual profit condition time limit set forth law require reporting year except reduction capital inclusion agenda draft resolution distribution may made shareholder equity fall would consequently fall accordance article r 225 71 r 225 74 amount capital together reserve commercial code request made french law company bylaw permit shareholder register draft resolution distribute revaluation surplus distributable agenda written question sent may corporated full part headquarters registered letter recorded company capital however transferring delivery beginning publication meeting amount reserve pursuant french law announcement 25 day general annual general shareholder meeting may transfer meeting delay 20 day beginning amount considers necessary available publication meeting announcement reserve ordinary extraordinary reserve carry one published 45 day general forward meeting date reception request company taken account 168 supplementary information information legal nature request new item agenda must legal representative shareholder motivated request register draft resolution legally incapable incapacitated individual provided text draft resolution may representing corporate shareholder take part short explanation reason request meeting whether shareholder subject justification possession representation required share capital accordance regulatory rule shareholder may also postal voting using registration form sent company according moreover accordance article l 2323 67 law regulation acceptable paragraph 2 labor code request draft registration must received company three resolution made work council added day date meeting agenda sent next 10 day following publication meeting announcement case remote voting using electronic vote proxy vote given electronic signature vote heading 3 point 1 excerpt article 14 bylaw made according condition current regulation meeting unable make valid decision due lack required quorum legal document relative legal information second meeting appropriate second shareholder made available meeting adjourned called least ten day registered office company advance form first meeting provision applicable administration admission meeting power management company heading 3 point 3 excerpt article 14 bylaw board director every shareholder right attend general heading 3 point 3 excerpt article 6 9 bylaw meeting participate discussion person proxy regardless number share 1 subject legal exemption company directed held simple proof identity ownership board director composed minimum share right participate general meeting three member maximum eighteen subject condition share must recorded name shareholder composition board director made shareholder appointed broker either balance number men woman nominative share account held company bearer share account held authorized 2 duration company existence broker zero hour paris time third working director shall appointed renewed office day prior meeting recording registration ordinary general meeting however case share bearer share account held merger director may appointed extra authorized broker must confirmed share ordinary general meeting deciding transaction certificate provided broker share certificate must attached postal voting form 3 director must entire term office proxy form application admission least one share pas issued name shareholder behalf shareholder represented 4 director term office three year appointed broker certificate must also supplied shareholder wish attend general director duty shall cease end ordinary meeting person received general meeting deciding account admission pas zero hour paris time third financial year elapsed held year term working day prior meeting office director concerned expires shareholder may represented another director may renewed office may shareholder spouse partner removed office time ordinary signed civil partnership furthermore general meeting may represented moral physical person choice accordance 5 person may appointed director article l 225 106 106 3 commercial reached age 75 appointment would result code aim representative must present one third member board valid proof proxy director exceeding age proportion supplementary information information legal nature 169 exceeded oldest director shall automatically bound company employment agreement deemed resigned end ordinary may exceed one third director office general meeting approving account financial year exceeded organization management board director 6 director may individual legal entity director legal entity required upon 1 board director elect chairman appointment appoint permanent among member individual representative subject condition determines remuneration set duration obligation incurs liability chairman term office may exceed though personally director without prejudice office director several liability legal entity represented 2 person may appointed chairman board legal entity director terminates director age 75 chairman mandate given permanent representative shall office exceeds age shall deemed promptly notify company registered letter automatically resigned decision well identity new permanent representative applies 3 chairman represents board director event death resignation permanent organizes directs work report representative general meeting ensures proper operation company decisionmaking body ensures 7 one director seat become vacant particular director two general meeting due death position fulfill duty resignation board director may proceed make appointment interim basis fill 4 case absence impediment affecting seat board appointment must made chairman board director appoints acting within three month vacancy number chairman meeting director fallen minimum article association without falling 5 board director appoints secretary statutory minimum may chosen either among director outside secretary shall replaced simple interim appointment made manner decision board board subject ratification next ordinary general meeting failing ratification decision meeting decision board taken act accomplished shall nonetheless remain valid 1 board director meet upon call chairman often required interest number director fall company however director representing least one statutory minimum director remaining office third member board director may required immediately call ordinary meeting precisely indicating meeting agenda call fill vacant seat board board met within last two month director appointed replacement another shall ceo chairing board director may remain office remaining term office request chairman call board meeting predecessor specified agenda 8 director individual cannot concomitantly 2 meeting shall take place registered office hold five seat board director location indicated notice call supervisory board sociétés anonymes call meeting indicating agenda registered office metropolitan france subject sent least 7 day beforehand letter telegram telex exception provided law fax call may verbal meeting may held immediately director agreement 9 company employee may appointed director unless employment agreement corresponds 3 board director validly deliberate effective employment shall lose benefit least one half director required employment agreement number director present represented 170 supplementary information information legal nature board decision taken majority member present represented director shall receive information necessary acting chairman casting vote performance duty may obtain document considers useful general 4 attendance sheet shall held signed management director participating board meeting 3 board director may give delegation 5 internal regulation established board authority representative choice within director may provide director participating limit authority law board meeting videoconference accordance article association applicable regulation deemed present purpose calculating quorum majority board may decide creation review provision shall apply adoption committee charge studying issue following decision board chairman submits appointment remuneration removal general management chairman ceo executive vice president heading 3 article 10 bylaw closing annual account consolidated account mode operation preparation management report report management group accordance article l 225 51 1 commercial code company general 6 board director deliberation recorded management ensured responsibility minute held accordance applicable law either chairman board director minute signed acting chairman individual appointed board one two director director title ceo copy excerpt minute board choice two mode operation director deliberation shall validly certified general management made board chairman ceo director board decision concerning choice mode operation general management taken power board director majority vote director present represented shareholder third party 1 board director determines company informed choice made board director business guideline ensures condition set forth applicable implemented subject power expressly granted regulation law shareholder meeting within limit corporate object deal matter board director may modify option chosen relating proper running company time deliberation governs affair company change mode operation general dealing third party company management shall entail modification bound even act board director article association outside corporate purpose unless prove third party knew act ultra vires depending mode exercise chosen could reasonably unaware thereof board director chairman ceo shall ensure view circumstance specified mere responsibility general management publication article association company suffice establish proof thereof ceo appointed board director 2 board director shall carry control set duration term office determines verification deems appropriate remuneration applicable restriction power supplementary information information legal nature 171 performance duty ceo must also chairman may give rise damage decided age 75 age limit exceeded without valid cause course term office ceo shall deemed automatically resigned new condition exercise voting right ceo shall appointed majority quorum heading 3 article 15 bylaw ceo may removed office time board director removal ceo annual extraordinary general meeting also chairman may give rise damage decided quorum calculated basis share without valid cause comprising share capital special meeting basis share class concerned power ceo net share entitled voting right virtue law ceo vested broadest power act circumstance name company double voting right conferred holder ceo shall exercise power within limit registered share fully paid corporate object subject power expressly registered name holder granted law shareholder meeting least four year board director event postal voting form received ceo represents company dealing company prior meeting third party company bound even act considered calculating quorum ceo outside corporate object condition timeframe set decree unless prove third party knew act ultra vires could reasonably right vote conferred share proportional unaware thereof view circumstance capital represent equal par value specified mere publication article every share capital income right carry right association suffice establish proof thereof one vote executive vice president event share pledged voting right exercised holder security upon motion ceo whether position issuing company may validly vote share filled chairman board director subscribed acquired taken pledge another person board director may name one share taken account calculate individual responsibility assisting quorum ceo title executive vice president voting take place vote cast show maximum number executive vice president hand sitting standing roll may exceed five call decided officer meeting agreement ceo board director information voting right shall determine scope extent power granted executive vice president limit bylaw voting right set remuneration event conversion bearer form converted share immediately forfeit double voting right regard third party executive vice president event capital increase incorporation executive vice president power reserve profit share premium double voting ceo right applies new share issued allocated free charge shareholder basis existing share upon cessation duty case already carry right heading 2 article 3 impediment affecting ceo executive vice company bylaw revision bylaw president shall retain unless otherwise decided unanimously passed general shareholder board director office authority meeting extraordinary session august 24 appointment new ceo 1994 may cancelled general shareholder meeting convened extraordinary session ceo may removed office time ratification special meeting board director removal ceo beneficiary shareholder 172 supplementary information information legal nature december 31 2014 11635635 relevant prior loss amount share double voting right total transferred reserve required french law 15359238 share thus total voting right company bylaw interim dividend may 26994873 exceed profit thus defined reimbursement dividend may required shareholder unless annual general shareholder meeting held distribution made violation legal least year within six month year end provision company determines consider financial statement year subject beneficiary aware illegality extension timeframe legal decision distribution time occurred could ignore annual general shareholder meeting may nature dividend occurs validly deliberate upon first convocation share reimbursement timebarred three shareholder present represented voting post year payment dividend dividend hold least one quarter share right collected within five year payment vote quorum required upon second timebarred convocation meeting decides basis majority vote held shareholder present represented including shareholder voting post liquidity contract excerpt bylaw heading 3 article 16 liquidity contract concluded crossing legal threshold sartorius stedim biotech sa stockbroker gilbert dupont following asset appeared shareholder whose shareholding cross legal liquidity account december 31 2014 threshold defined french law either upwards downwards must declare said crossing notification number share 1502 autorité de marchés financier pursuant law force bylaw company liquidity account cash balance 27390230 provide additional threshold declaration information following asset appeared liquidity account date notification identification shareholder contract implementation issued within legal regulatory framework number share 0 company authorized seek identity bearer shareholder liquidity account cash balance 421860 payment dividend major contract annual general shareholder meeting several service agreement entered power give every shareholder part entity division sartorius group dividend payable option receiving dividend sartorius stedim biotech group order enable share provided french law cash entity division benefit certain general administrative service term term payment dividend cash set general meeting default board among service agreement service agree director cash dividend must paid within ment highest volume importance maximum nine month end place sartorius stedim biotech gmbh reporting year unless timeframe extended sartorius corporate administration gmbh 100 legal authorization however profit may subsidiary sartorius ag sartorius corporate distributed interim dividend prior administration gmbh provides general administrative approval annual financial statement service sartorius stedim biotech balance sheet prepared end entity sartorius group service include financial year certified independent among others accounting treasury management auditor discloses company realized payroll accounting human resource system profit since close previous financial year legal service sartorius corporate administration recognition necessary amortization gmbh invoice service basis internal depreciation provision well deduction external cost incurred plus margin 3 supplementary information information legal nature 173 service invoiced sartorius corporate administration gmbh sartorius stedim biotech gmbh 2014 totaled million 239 apart abovementioned service agreement contract material obligation commitment concluded outside ordinary course company business member sartorius stedim biotech group party strategy sale marketing organization within sartorius stedim biotech group towards customer create valuable longterm relationship therefore example key account management endeavor conclude longterm framework contract customer total solution provider sartorius stedim biotech strives use contract cover entire product portfolio sartorius stedim biotech fit validated process customer 174 supplementary information information legal nature registered trademark trademark application international registration name eu germany france country designated usa australia brazil mexico uk canada 16112007 962279 sartorius 13082007 16112017 17082007 14012008 09112007 stedim 006228019 au ch kr ru sg 3709002 13 trademark 1371410 biotech 13082017 tr vn 10112019 application reg progress 26061985 494574 23102014 04101968 26062015 22071988 16122014 16071988 013398722 873661 bx ch de e 1572999 4 trademark 1246230 biostat reg progress 31102018 fr pt 26122019 application 16072016 12112001 07041983 10122001 28112001 002458461 1065357 2677224 609610 hydrosart 12112021 07042023 21012023 06052019 04101999 15111999 001330885 2450203 maxicaps 04102019 08052021 15022005 16022005 004289724 3195052 midicaps 15022015 02012017 18011979 1107904 09082019 __________ 09081978 26101988 07021979 18011979 980370 1495753 1144895 1107903 minisart 09082018 26102018 30122020 18012020 13061979 17101989 05121979 18112014 20121986 987883 1555685 1200237 908615248 1125952 sartocheck 13062019 17102019 06072022 reg progress 20122020 06061979 17101989 15061982 20121986 988000 1555684 1197792 1125951 sartocon 06062019 17102019 15062022 20122020 02112004 28072004 10112004 004103701 30443764 3178067 virosart 02112024 31072024 28112016 06031985 494396 06032015 bx ch de dz 03061983 eg e fr hu kp 08082007 25101984 1057870 li mc pt ro r 3689721 1228900 sartoflow 30062023 ru sd vn 09292019 25102015 10012000 15022000 18112014 001454461 2429825 2 trademark sartopore 10012020 20022021 application 24011995 630378 24012015 de bx ch ___________________ 31082005 19041993 27022006 879252 31081993 31011995 03092003 31011995 004614038 93465632 27022016 2041550 651778 810249 2009384 flexboy 31082015 19042023 jp 04032017 31012015 03092023 31012015 20021998 02091997 27021998 03092003 000753202 97693975 2414947 810250 flexel 20022018 02092017 26122020 03092023 01071998 000865865 palletank 01072018 31082005 004614046 raft 31082015 15101999 001344266 evam 15102019 05061989 1535354 nutrikit 05062019 05061989 1535352 nutripoche 05062019 22022001 01021995 758706 95556118 22022021 biosafe 01022015 de dk gb ch 16102009 07052009 1028463 06112009 26102009 008285173 16102019 4 trademark 793270 flexact 07052019 au cn jp kr u application 18112026 22102014 22042014 1226740 21102014 012807996 22102024 9084706060 flexsafe 22042024 cn jp kr mx sg tr u reg progress apart trademark mentioned sartorius stedim biotech group owner applicant 315 different trademark various country date indicated daymonthyear supplementary information information legal nature 175 registered trademark trademark application name japan denmark finland ireland malaysia norway sweden china argentina india taiwan 14012008 18012008 sartorius 08112007 11 trademark 12 trademark stedim 5170560 28112007 2 trademark 19112007 1 trademark biotech 03102018 12 trademark application 13 trademark application 22021988 2021770 22022018 __________ 27081986 28061985 05011988 01071985 11071985 27051987 31031988 26042012 17122014 04052012 1880889 233586 100350 116688 8502982 128877 209760 10830519 4 trademark 2326343 biostat 27082016 29082016 05012018 30062016 11072022 27052017 31032018 reg progress application reg progress 21112001 4663672 hydrosart 18042023 15101999 4535058 maxicaps 11012022 25022005 4906540 midicaps 04112015 09021979 1583197 minisart 26042023 29091983 14112014 1618759 3367508 sartocheck 29092023 reg progress sartocon 28012005 24112004 5040228 4379959 virosart 13042017 21062018 sartoflow 02022000 12112014 4495393 2 trademark sartopore 03082021 application 19011995 323347 flexboy 16052017 02031998 4470133 flexel 27042021 28022006 5005301 palletank 24112016 raft evam nutrikit nutripoche biosafe 12112014 30102009 4 trademark 4 trademark flexact application application 21102014 3361996 flexsafe reg progress apart trademark mentioned sartorius stedim biotech group owner applicant 315 different trademark various country date indicated daymonthyear 176 supplementary information special report statutory auditor related party agreement commitment special report statutory auditor related party agreement commitment statutory auditor report related party agreement commitment free translation english report issued french agreement commitment submitted provided solely convenience englishspeaking user report read conjunction con approval general meeting shareholder strued accordance french law professional standard applicable france hereby inform advised agreement commitment authorized general meeting shareholder approve financial course year submitted general statement year ended december 31 2014 meeting shareholder approval accordance article l 225 38 french commercial code shareholder code de commerce capacity statutory auditor company hereby report certain related party agreement agreement commitment already approved commitment general meeting shareholder required inform basis hereby inform advised information provided u term agreement commitment already approved condition agreement commitment general meeting shareholder whose indicated u may identified implementation continued year performance engagement required comment whether beneficial appropriate ascertain existence agreement commitment responsibility marseille february 19 2015 accordance article r 225 31 french commercial code code de commerce evaluate french original signed benefit resulting agreement commitment prior approval statutory audtitors addition required applicable ernst young deloitte associés inform accordance article r 225 31 french commercial code code de commerce xavier senent christophe perrau concerning implementation year agreement commitment already approved general meeting shareholder performed procedure considered necessary comply professional guidance issued national auditing body compagnie nationale de commissaires aux comptes relating type engagement supplementary information resolution submitted annual combined shareholder meeting april 7 2015 177 resolution submitted annual combined shareholder meeting april 7 2015 resolution submitted annual ordinary concerning consolidated account approved shareholder meeting consolidated financial statement year ended 31 december 2014 disclosed net profit first resolution k 73734 presented transaction reflected financial statement summarized approval financial statement year ended report 31 december 2014 discharge director third resolution annual shareholder meeting accordance quorum majority requirement ordinary assignment financial result year ended meeting shareholder considered 31 december 2014 corporate account year ended 31 december 2014 well report board director annual shareholder meeting acting report statutory auditor concerning quorum majority requirement ordinary financial statement approved financial meeting shareholder decided assign statement year ended 31 december 2014 follows income year ended 31 december 2014 disclosed net profit 2484526366 totaling 2484526366 presented transaction reflected financial statement summarized report legal reserve 49634313 result annual shareholder meeting grant balance resulting deduction legal reserve full unreserved discharge director 2434892053 execution management duty said reporting year following added balance year earlier profit carried forward 903234834 annual shareholder meeting approves overall amount expense referred article 394 would yield distributable profit general tax code amounting 757645 well 3338126887 total amount dividend corresponding tax reaching 252548 disbursed shareholder 1996700940 annual shareholder meeting recognizes term balance resulting disbursement 1341425947 report chairman board director composition board remaining amount 1341425947 application principle equal treatment carried forward next year men woman board condition board director prepares share nominal value 1 lead organizes work well proceeding internal payment net dividend valued 130 control risk management introduced company report statutory auditor distributed amount 1996700940 report share eligible allowance 40 applied physical people residing france referred second resolution article 1583 2 general code tax approval consolidated financial statement dividend payed 14 april 2015 year ended 31 december 2014 annual shareholder meeting accordance quorum majority requirement ordinary meeting shareholder considered corporate consolidated account year ended 31 december 2014 well report board director report statutory auditor 178 supplementary information resolution submitted annual combined shareholder meeting april 7 2015 hdistributed amount three last financial seventh resolution year amounted notice element compensation due income eligible tax rebate granted 2014 financial year income mr reinhard vogt executive vice president fiscal year ended dividend distributed dec 31 2013 18412315 0 annual shareholder meeting complying dec 31 2012 16876856 0 243 recommendation afepmedef dec 31 2011 15327238 0 code updated june 2013 deliberating accordance quorum majority requirement ordinary shareholder meeting give favorable fourth resolution opinion element compensation due granted 2014 financial year mr reinhard approval regulated agreement referred vogt executive vice president described article l225 38 subsequent commercial 749 k code eighth resolution annual shareholder meeting accordance quorum majority requirement ordinary notice element compensation due meeting shareholder considered granted 2014 financial year special report statutory auditor concerning mr voleker niebel executive vice president regulated agreement referred article l225 38 subsequent commercial code recognizes annual shareholder meeting complying report conclusion stating absence 243 recommendation afepmedef concluded regulated agreement agreement code updated june 2013 deliberating accordance continued past year quorum majority requirement ordinary shareholder meeting give favorable fifth resolution opinion element compensation due granted 2013 financial year mr volker fixing overall annual amount niebel executive vice president described attendance fee board director member 625 k annual shareholder meeging accordance ninth resolution quorum majority requirement ordinary meeting shareholder approved overall notice element compensation due annual amount attendance fee allocated granted 2014 financial year preceding financial year amounting mr oscarwerner reif executive vice president 207200 annual shareholder meeting complying sixth resolution 243 recommendation afepmedef code updated june 2013 deliberating accordance notice element compensation due quorum majority requirement granted 2014 financial year mr ordinary meeting shareholder give favorable joachim kreuzburg chairman chief executive opinion element compensation due officer granted 2013 financial year mr oscar werner reif executive vice president described annual shareholder meeting complying 622 k 243 recommendation afepmedef code updated june 2013 deliberating accordance tenth resolution quorum majority requirement ordinary meeting shareholder give favorable nomination mr annemarie graffin new opinion element compensation due member board director company granted 2014 financial year mr joachim kreuzburg chairman chief executive annual shareholder meeting accordance officer described 743 k quorum majority requirement ordinary meeting shareholder decides appoint today mr annemarie graffin born 3 may 1961 supplementary information resolution submitted annual combined shareholder meeting april 7 2015 179 french nationality new member board fourteenth resolution director company three year period expiring end annual shareholder meeting nominating salustro reydel deputy statutory acting 2018 related approval financial auditor statement year ended 31 december 2017 annual shareholder meeting accordance eleventh resolution quorum majority requirement ordinary meeting shareholder considered nomination mr susan dexter new member board director report decides appoint board director company today six year period annual shareholder meeting acting 2021 account annual shareholder meeting accordance year ended 31 december 2020 salustro reydel quorum majority requirement ordinary 3 cours du triangle immeuble le palatin 93939 meeting shareholder decides appoint paris la défense cedex deputy statutory auditor today mr susan dexter born 11 octobre 1955 replace auditex audit whose mandate expired american nationality new member board director company three year period resolution submitted expiring end annual shareholder meeting extraordinary shareholder meeting acting 2018 related approval financial statement year ended 31 december 2017 fifteenth resolution twelfth resolution modification article 113 section 3 company bylaw renewing appointment member board director carried mr oscarwerner reif² annual shareholder meeting fulfilled quorum majority requirement pertaining annual shareholder meeting accordance extraordinary meeting shareholder quorum majority requirement ordinary considered board director report meeting shareholder considered board modified bylaw project decides modify article 113 director report decides renew today section 3 company bylaw follows appointment member board director exercised mr oscarwerner reif new three year end article added sentence period expiring end shareholder meeting acting 2018 related approval financial applies agreement intervening statement year ended 31 december 2017 company another one hold entire capital directly indirectly deducting thirteenth resolution minimum number share required satisfying requirement article 1832 civil code nominating kpmg statutory auditor article l 225 1 l 226 1 commercial code annual shareholder meeting accordance rest article unchanged quorum majority requirement ordinary meeting shareholder considered sixteenth resolution board director report decides appoint today six year period annual modification article 143 section 3 shareholder meeting acting 2021 account company bylaw year ended 31 december 2020 kpmg 3 cours du triangle immeuble le palatin 93939 paris la annual shareholder meeting fulfilled défense cedex statutory auditor replace ernst quorum majority requirement pertaining young audit whose mandate expired extraordinary meeting shareholder considered board director report modified bylaw project decides modify article 143 section 3 company bylaw follows 180 supplementary information resolution submitted annual combined shareholder meeting april 7 2015 shareholder right participate annual shareholder meeting vote person proxy regardless number share held upon simple production proof identity ownership share right participate annual shareholder meeting evidenced book registration security name shareholder intermediary acting behalf second business day preceding meeting midnight paris time either registered security account held company bearer security account held authorised intermediary bearer security authorised intermediary must deliver certificate attendance record registration security bearer security account held intermediary must attached postal voting ballot proxy admission card request prepared shareholder name behalf shareholder represented registered intermediary certificate attendance shall also issued shareholder would like physically attend meeting received admission card midnight paris time third business day preceding meeting shareholder may represented another shareholder spouse partner signed civil partnership furthermore may represented moral physical person choice accordance article l 225 106 l106 3 commercial code aim representative must present valid proof proxy legal representative shareholder lacking legal capacity individual representing shareholder legal entity participate meeting whether personally shareholder seventeenth resolution authority formality annual shareholder meeting give full authority bearer original copy extract minute present annual shareholder meeting accomplish necessary procedure supplementary information information reference document annual financial report 181 information reference document annual financial report declaration responsibility reference document 2014 annual financial report hereby certify taken reasonable received completion letter auditor measure effect information stating audited information contained present reference document contained reference document best knowledge accordance financial position financial statement fact make omission likely affect import read document entirety certify best knowledge historical financial information presented financial statement prepared accordance document discussed auditor report applicable accounting standard give fair found page 148 163 reference view asset liability financial position document profit loss company activity included consolidation february 25 2015 management report page 18 68 present fair review development performance business financial position company activity included consolidation well description main risk uncertainty exposed joachim kreuzburg chairman board ceo 182 supplementary information information reference document annual financial report table reconciliation heading note 1 european regulation 8092004 april 29 2004 european order facilitate understanding present commission column right document concerning presentation sartorius corresponding page present document stedim biotech sa table left heading part 1 european regulation n8092004 april 29 2004 page 1 person responsible 11 person responsible information 181 12 certification person responsible registering document 181 2 independent auditor 21 name address independent auditor issuer 100 3 selected financial information 31 presentation selected historical financial information every year period covered 2 22 29 financial information 4 risk factor 46 53 5 information issuer 51 history development company 18 511 corporate name commercial name issuer 166 512 place registration number issuer 166 513 date establishment life issuer 166 514 registered office legal form issuer legislation governing operation country origin address 166 52 investment 25 521 principal investment including amount carried 29 119 120 6 overview operation 61 principal operation 19 22 24 62 principal market 22 23 63 dependence patent license contract 53 174 175 64 competition 20 21 7 organigram organizational chart 71 description group 117 118 72 list subsidiary 118 8 property plant equipment 81 significant existing planned property plant equipment 29 39 126 127 82 environmental issue 30 44 9 analysis financial situation result 91 financial position 25 26 104 106 92 operating profit 22 24 103 121 10 cash position capital 101 issuer capital short longterm 25 27 57 65 106 129 131 156 157 102 cash flow 25 26 105 103 borrowing condition financial structure 25 26 135 142 143 104 expected source financing 119 135 136 142 11 research development patent license 27 28 174 175 12 information trend 20 21 54 56 13 profit forecast estimate applicable 14 governing management supervisory executive body 141 composition governing management body nature family link amongst person 70 78 1411 conviction fraud within last five year least 77 1412 bankruptcy sequestration liquidation member governing body 77 1413 indictment andor official public sanction member governing body 77 142 conflict interest level governing management body 77 15 remuneration benefit 151 remuneration paid benefit kind 66 67 80 82 91 98 152 pension retirement benefit 113 131 134 supplementary information information reference document annual financial report 183 heading part 1 european regulation n8092004 april 29 2004 page 16 operation governing management body 161 expiration date current mandate term office 70 78 162 service agreement member 70 78 163 audit remuneration committee issuer 77 80 82 84 83 164 corporate governance 70 90 17 employee 171 workforce end period covered historical financial information 32 146 172 shareholding capital 65 144 145 173 employee shareholding capital 63 18 principal shareholder 181 crossing threshold 61 62 172 182 double voting right 171 172 183 control business 15 146 19 transaction related party 146 147 20 financial information issuer asset financial situation profit 201 historical financial information result last five year 68 202 20132014 consolidated financial result 22 24 203 2014 statement profit loss 103 204 20132014 consolidated financial statement statement financial position statement profit loss 103 148 statement cash flow statement change equity note consolidated financial statement 205 verification annual historical information independent auditor report 148 163 206 last financial information 3 207 dividend distribution policy 15 131 156 157 208 legal arbitration procedure 56 209 significant change financial commercial situation 19 29 21 additional information 211 share capital 57 2111 amount issued capital number share authorized number share issued fully paid 57 63 129 130 number share issued fully paid par value per share reconciliation number 156 157 share outstanding beginning end year 2112 share representing capital applicable 2113 number book value face value share held behalf issuer 58 58 subsidiary issuer 2114 amount convertible security exchangeable security security warrant 130 144 145 2115 information term acquisition right obligation authorized unissued 57 62 129 130 capital undertaking increase capital 2116 information capital member group option agreed applicable conditionally unconditionally put option 2117 history share capital period covered historical financial information 57 60 212 memorandum article association 166 172 2121 object purpose issuer 166 2122 member administrative management supervisory body 70 88 168 171 2123 right preference restriction attaching class existing share 171 173 2124 action required change right shareholder applicable 2125 condition governing manner annual general meeting extraordinary general 167 168 meeting shareholder called including condition admission 2126 provision issuer article association statute charter bylaw would effect applicable delaying deferring preventing change control issuer 2127 provision article association statute charter bylaw governing ownership 172 threshold shareholder ownership must disclosed 2128 condition imposed memorandum article association statute charter bylaw applicable governing change capital condition stringent required law 22 major contract 172 173 23 information provided third party declaration expert declaration interest applicable 24 document accessible public 3 25 information shareholding 118 184 supplementary information afep medef code afep medef code information implementation provision afep medef code relating corporate governance listed company accordance provision article 251 corporate governance code listed company effect date hereof code listed company referring code required precisely report reference document implementation provision case nonappliance one provision company required provide understandable relevant circumstantial information according rule apply explain recommended amf recommendation n 2014 08 22 september 2014 company indicate specific table provision applied related information general table afep medef code recommendation implemented article disposition code sartorius stedim biotech 1 board director collegial body 13 composition organization yes half organization board work likewise membership must board represented foreign suited shareholder makeup size nature firm director proof group business particular circumstance facing international dimension publication internal rule yes internal rule organization operation described internal rule synthetized document drawn published part full company website reference year entire reference document document published website 2 board director market 212 communication market 213 corporation rigorous policy communication yes press release published analyst market certain practice selective disclosure company website intended assist analyst forecast result transmitted professional prohibited distributor order assure form communication must allow everyone access effective diffusion information time investor board ensure investor receive relevant information balanced enlightens strategy development model longterm strategy corporation 22 offbalance sheet commitment risk listed company must equipped reliable procedure identification monitoring assessment commitment risk provide shareholder investor relevant information area purpose annual report specify internal procedure set yes rating company identify monitor offbalancesheet commitment evaluate published year corporation material risk reference document company must develop clarify information provided sheet commitment shareholder investor regarding offbalancesheet commitment outlined reference material risk disclose company rating financial rating document consolidated agency well change occurred financial year account supplementary information afep medef code 185 implemented article disposition code sartorius stedim biotech 3 separation office chairman board director chief executive officer 31 corporation opts separation office chairman applicable chief executive officer appropriate task entrusted chairman board director addition conferred upon law must described 32 option uniqueness dissociation function yes explaining essential shareholder third party fully informed chairman company choice made separation office chairman chief governance internal control executive officer maintenance position single office report motivation choice governance regard addition form disclosure required regulation company situation reference document annual report may serve medium disclosure shareholder entitled board report ground justification decision 4 board director strategy 4 internal rule board director consider decide upon transaction genuinely strategic importance review ad hoc committee appropriate internal rule board director specify case prior approval board director required yes board director setting related principle may differ according internal rule division group concerned including rule reference document year principle material transaction outside scope firm stated strategy subject prior approval board opposite entire element director integral part board director internal rule rule according board director informed corporation financial situation cash position commitment rule related external acquisition disposal also major investment organic growth internal restructuring action board director informed timely fashion corporation cash position appropriate take decision relating funding indebtedness 5 board director general meeting shareholder 52 communication shareholder yes annual shareholder shareholder meeting decisionmaking body area meeting place open open stipulated law also privileged moment company engage discussion company dialogue shareholder session must occasion strategy past year activity managing body report corporation business also functioning operation board director specialized committee audit governance within company compensation etc also opportunity genuine open dialogue shareholder board director must take care infringe upon specific power shareholder meeting transaction proposes modify fact law corporate purpose company basis contract founding corporation even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business 186 supplementary information afep medef code implemented article disposition code sartorius stedim biotech 6 membership board director guiding principle 63 composition board director yes board director board consider would desirable balance within committee composed membership within committee board member woman foreign director established particular regard representation men group point woman nationality diversity skill take appropriate action willingness pursue assure shareholder market duty international growth performed necessary independence objectivity diversity board publish reference document objective method result director suggests 2015 policy matter shareholder meeting nominate two independent woman director french american within board director 64 woman men representation yes board director give regard representation men woman objective particular attention board shall reach maintain percentage least 20 woman men representation woman within period three year least 40 woman within board period six year shareholder meeting 2010 director suggests 2015 date listing company share regulated market shareholder meeting whichever later director permanent representative legal nominate two independent entity director representing employee shareholder taken woman director french account order determine percentage case american within board director representing employee director board comprises fewer nine member difference end six year number director gender may excess two 65 specific assignment entrusted director applicable board decided confer special task upon director relate governance shareholder relation particular appointing lead director vice president task resource prerogative access must described internal rule 7 representation employee 73 representation employee applicable way director director representing employee company fall shareholder director representing employee entitled vote within scope board director collegial body assigned duty obligation appoint acting time interest company director director may selected board participate committee 74 without prejudice legal provision specific director representing employee shareholder director representing employee right subject obligation particular relation confidentiality take responsibility member board 8 minority shareholder 8 desirable within board representative various yes company main specific group interest board could become shareholder take battleground vested interest instead representing shareholder responsibility conformity whole regard shareholder corporation controlled majority shareholder group direct distinct board shareholder acting concert latter assumes specific responsibility director one monitor shareholder direct separate like conflict interest board director majority shareholder must take particular care avoid possible conflict interest secure transparency information provided market fairly take interest account supplementary information afep medef code 187 implemented article disposition code sartorius stedim biotech 9 independent director 92 independent director yes sartorius stedim biotech although quality board director cannot defined simply company controlled reference percentage independent director director sartorius ag suggests required honest competent active regularly attending nominate additional two involved important board director presence director 2015 significant proportion independent director order shareholder meeting satisfy expectation market also order improve independent director quality proceeding percentage would increase higher 40 independent director account half member board widely held corporation without controlling shareholder controlled company independent director account least third director representing employee shareholder director representing employee taken account order determine percentage 93 qualification independent director discussed appointment committee reviewed every year board director prior publication annual report board director must upon motion appointment yes intendant director committee review individually position member qualification reviewed basis criterion mentioned notify conclusion regularly board shareholder annual report shareholder meeting director nomination director appointed identification independent director additional two independent carried corporation management board director approved 2015 shareholder meeting 4 board director may consider although particular director 10 director meet criterion cannot held independent board director could owing specific circumstance person company thee defined ownership structure reason conversely board may consider director meet criterion nevertheless independent director 94 criterion reviewed committee board order director qualify independent prevent risk conflict interest director management corporation group following employee executive director company yes independent director employee director parent company latter qualification reviewed yearly consolidates position previous board director five year 2015 shareholder meeting approves nomination executive director company corporation additional 2 independent hold directorship directly indirectly employee director 4 10 appointed executive director company currently office held office less five year director director board director could defined customer supplier investment banker commercial banker material company group significant part whose business corporation group account evaluation significant relationship company group must debated board criterion lead evaluation must explicitly stated reference document related close family tie executive director yes independent director qualification regularly auditor corporation within previous five year reviewed board director director corporation twelve year although may executive director chairman board may considered independent company justify based criterion set 188 supplementary information afep medef code implemented article disposition code sartorius stedim biotech 10 evaluation board director 101 assessment board work yes year member sound corporate governance board director evaluate board director formal ability meet expectation shareholder entrusted autoevaluation board authority direct corporation reviewing time time performance based specific membership organization operation implies corresponding criterias functioning review board committee modality effective contribution member accordingly board think desirable balance membership committee created member consider time time adequacy organization operation performance task 11 meeting board committee 11 information board director meeting yes reference document number meeting board director committee indicates number held past financial year mentioned annual meeting level report must also provide shareholder relevant attendance past year information relating director attendance meeting 2014 1 board director frequency duration meeting board director held 8 meeting allow indepth review discussion matter level attendance subject board authority applies meeting board committee audit compensation appointment nomination 98 etc 2 audit committee held 5 meeting proceeding unambiguous minute meeting level attendance summarize discussion specify decision made of100 particular importance since provide necessary record board done order carry duty without 3 remuneration committee held unnecessarily detailed mention briefly question raised meeting level reservation stated attendance 100 12 director access information 12 law recognizes principle chairman chief yes internal rule includes executive officer bound disclose director document modality right information required performance duty information confidentiality manner right disclosure exercised related director confidentiality duty set internal rule board director board responsible necessary determining relevance document requested corporation must also provide director appropriate information throughout life corporation meeting board importance urgency information requires ongoing disclosure also include relevant information including criticism relating corporation article press financial analyst report conversely director bound request appropriate information consider necessary perform duty accordingly director considers able take part proceeding appropriate information bound say board order obtain necessary information director opportunity meet corporation principal executive manager even outside presence executive director latter case given prior notice supplementary information afep medef code 189 implemented article disposition code sartorius stedim biotech 13 director training 13 director training yes start director one major condition appointing director function different training ability cannot expected priori every director session offered order specific prior knowledge corporation organization activity help accomplish director accordingly provided considers mission best applies necessary supplementary training relating corporation specialized member specific feature business market committee audit committee member provided time appointment information relating corporation specific accounting financial operational feature 14 theration director term office 14 time timescale term office yes conformed code without affecting duration current term duration director recommendation duration term office set bylaw status exceed maximum office term 3 year 7 four year shareholder called express director renewed election sufficient frequency 2017 three nomination director agreed next shareholder meeting renewed 2018 term staggered avoid replacement entire body favor smooth replacement director information director yes information annual report detail date beginning expiry iterated director director term office make existing staggering clear biographical presentation also mention director addition list office board director composition position held corporation nationality age principal position list name member board committee meeting shareholder asked appoint director extend term booklet notice calling meeting shareholder must contain biographical notice outlining curriculum vitae addition item required statute even though required law imperative bylaw yes status title iii art 63 internal rule set minimum number share corporation within reference document concerned director must personally hold must appear provides information annual report andor booklet notice calling meeting shareholder 15 committee board 15 existence composition committee yes board director number structure committee determined compensation committee board however addition task assigned audit committee duty select law recommended compensation appointment suggest nomination new director executive director subject preparatory work director specialized committee board director board appointed specialized committee address particular right obligation concern creation committee shall event remove specialized committee matter purview board sole statutory specified internal rule decisionmaking authority allowed cause division within inherent committee board collegial body remain accountable performance duty committee act place board rather extension board facilitating work reason particular quality report committee board inclusion annual report description committee activity stressed committee board may contact exercising duty internal rule complies principal manager corporation informing chairman majority board director subject reporting back board recommendation formulated contact afep medef code committee board may request external technical study relating matter within competence corporation expense informing chairman board director board director subject reporting back board thereon event committee recourse service offered external consultant eg compensation consultant order obtain information compensation system level applicable main market committee must ensure consultant concerned objective 190 supplementary information afep medef code implemented article disposition code sartorius stedim biotech committee must provided internal rule setting duty mode operation committee internal rule approved board may integrated internal rule board set separate provision committee secretariat task shall undertaken person nominated chairman committee agreement chairman existence crossdirectorships committee avoided 16 audit committee 16 existence yes board director board appoint audit committee duty audit committee inseparable board director legally bound approve corporate account prepare consolidated account approving account main occasion board assumes two essential duty review management performance verification reliability clarity information provided shareholder market 161 composition yes referred audit audit committee member competent finance committee chairman financial accounting accountancy competency within description director background proportion independent director audit committee excluding audit committee director representing employee shareholder director representing composed 50 employee taken account least equal two independent director third committee include executive director including chairman appointment extension term office audit committee chairman proposed appointmentsnominations committee specially reviewed board 1621 also desirable time review account yes audit committee committee consider major transaction connection examines least trimestral conflict interest could arisen basis main financial operation analysis time available reviewing account sufficient less two day review board account statutory auditor submit review account audit committee accompanied conclusion twice year presentation statutory auditor stressing essential point audit committee result statutory audit particular adjustment resulting audit significant weakness internal control identified auditor work also accounting method chosen also accompanied presentation chief financial officer describing corporation risk exposure material offbalancesheet commitment 1622 committee must interview statutory auditor regularly including yes audit committee meet interview without executive manager present statuary auditor least twice year statutory auditor must particular interviewed committee meeting dealing evaluation process preparing financial information review account order report execution task conclusion work 1623 committee steer procedure selection statutory yes audit committee pilot auditor submit recommendation board director regarding selection statuary statutory auditor proposed appointment shareholder auditor meeting committee shall suggest board procedure selection particular need make call tender must supervise call tender approve specification choice firm consulted making sure selection result appointment best bidder lowest bidder committee particular receive year following order respond arisen information statutory auditor subject green line european community group statement independence decided anticipate amount fee paid network statutory auditor problematic realizing tender company controlled company entity controlling october november company respect service directly related statutory december 2014 suggesting auditor assignment change statuary auditor information concerning service supplied respect task submitted directly related statutory auditor engagement 2015 shareholder meeting supplementary information afep medef code 191 implemented article disposition code sartorius stedim biotech committee review statutory auditor risk weighing independence protection measure taken order reduce risk committee must particular ensure amount fee paid company group share fee turnover firm network likely impair statutory auditor independence 163 functioning yes audit committee audit committee operating report board director secretary take minute provide board full information thereby facilitating latter meeting summary proceeding deliberation included reference document annual report include statement audit committee activity past financial year yes audit committee working method audit committee interview statutory auditor also intervention person responsible finance accounting treasury matter financial director risk possible hold interview committee wish without director qualified presence corporation executive management people specified within committee review consolidation scope applicable chairman internal control reason excluding certain company report committee able call upon outside expert needed making sure requisite skill independence regard effectiveness internal control risk management system committee ensure system exist implemented corrective action taken event significant weakness flaw end must informed main finding statutory auditor internal audit must interview responsible internal audit risk control give opinion organization service informed program internal audit receive internal audit report regular summary report committee shall examine risk material offbalancesheet commitment assess importance failure weakness communicated necessary inform board 17 committee charge appointment nomination 17 composition yes remuneration appointment nomination committee play essential role committee also charge shaping future company charge preparing nomination order future membership leadership body accordingly board avoid multiplication appoint member committee appointment specific committee nomination director executive director may may separate compensation committee 171 appointment nomination committee separate applicable compensation committee recommendation relating latter membership mode operation also applicable see hereafter however unlike provision governing compensation committee chief executive officer shall associated appointment nomination committee proceeding event office chairman board director chief executive officer separate chairman may member committee 192 supplementary information afep medef code implemented article disposition code sartorius stedim biotech 172 allocation yes compensation committee charge submitting proposal board committee competency reviewing detail factor take account research examine select proceeding desirable balance membership board regard new application makeup change ownership corporation stock nomination board balance men woman board identification director evaluation potential candidate desirability extension term particular organize procedure nomination future independent director perform review potential candidate latter approached way committee selection nomination ad hoc committee established hand plan new member administrator 18 committee charge compensation 181 composition yes member committee include executive director compensation committee nonexecutives composed 50 independent member majority independent director chaired independent director advised employee director member committee 182 committee operating report board director provide yes audit committee board full information thereby facilitating proceeding secretary take minute report proceeding compensation committee meeting summary presented board deliberate issue relating deliberation supplied within compensation executive director without presence latter reference document annual report include statement compensation committee activity past financial year 183 remuneration committee must ensure board director yes remuneration committee given best condition determine compensation working method specified benefit accruing executive director decision made internal control chairman board director report furthermore committee must informed compensation policy applicable principal executive manager executive director company purpose executive director attend meeting compensation committee 19 number directorship executive noexecutive director 19 executive director hold two directorship yes chairman exercise listed corporation including foreign corporation affiliated actually term office within group20 must also seek opinion board surveillance control carl accepting new directorship listed corporation zeiss ag 3 office term within consultative committee case separate chairman board may draw specific recommendation issue taking account particular situation mission conferred himher noexecutive director hold four directorship listed corporation including foreign corporation affiliated group recommendation apply time appointment next renewal term office director keep board informed directorship held company including participation committee board company france abroad supplementary information afep medef code 193 implemented article disposition code sartorius stedim biotech 20 ethical rule director 21 director compensation 211 member board director compensation yes nonexecutives 212 shall recalled method allocation director member committee compensation total amount determined meeting benefit attendance fee shareholder set board director take account take account way shall determine director actual attendance effective participation meeting board committee therefore include significant member different variable portion meeting recommended afep medef additional fee allocated specialized committee member natural director attendance meeting specialized committee give rise additional amount director fee similarly undertaking individual task vice president lead director may give rise additional fee payment extraordinary compensation subject application procedure related party agreement amount director fee reflect level responsibility assumed time need apply duty board must review adequacy level director fee regard duty responsibility placed director 213 rule allocation director fee individual amount yes attendance fee payment thereof made director set annual stated specified clearly report reference document chairman report company corporate governance internal control 22 termination employment contract case appointment executive director 23 compensation executive director 231 principle setting executive director compensation role yes compensation policy board director deliberated remuneration board director supervisory board responsible determining committee submission compensation executive director based proposal made board oscar werner reif compensation committee volker niebel joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech order determine said compensation relevant board committee must take account following principle comprehensiveness balance benchmark consistency understandability rule proportionality 232 compensation policy allocation stock option grant free share yes compensation policy compensation executive director must appropriate balanced deliberated remuneration fair compensation must strengthen sense solidarity committee submission motivation within company board oscar werner reif volker niebel market benchmark may sole one executive director compensation depends work carried result joachim kreuzburg reinhard vogt representing group obtained also responsibility taken executive director bear sartorius ag compensation ultimate responsibility management team warrant higher compensation general policy award stock option policy deliberated decided level mother performance share debated within compensation house sartorius stedim biotech committee basis recommendation committee approved board director 194 supplementary information afep medef code implemented article disposition code sartorius stedim biotech board director must monitor evolution component compensation several year regard corporate performance 2322 fixed compensation yes compensation policy fixed part may calculated differently depending whether deliberated remuneration executive director followed continuous career within company committee submission recruited outside company board oscar werner reif volker niebel unless principle fixed compensation may reviewed relatively exceptional element long interval eg every three year evolution stay moderated increase compensation must linked event affecting one year another one company must take account performance company applies component compensation including fringe benefit afep medef recommendation regard increase however company opts annual increase executive moderation director fixed compensation increase must moderated must respect principle consistency mentioned 231 joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech 2323 variable compensation yes variable compensation board may decide award executive director annual multiannual policy reviewed variable compensation remuneration committee oscar werner reif volker niebel different form variable compensation may cumulative annual variable compensation cumulative amount must decided basis aforementioned multiannual set principle particular comprehensiveness proportionality company unless exceptional variable compensation must determined board director element evolution stay fixed period rule governing determination variable moderated one year compensation must consistent annual multiannual another one company applied assessment executive director performance company afep medef strategy variable compensation reward director recommendation regard performance progress company period increase moderation consideration share price must criterion measuring performance stock market price constitute element compensation variation joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech term variable compensation must understandable shareholder clear complete information must provided year annual report variable compensation must subject achievement precise course predetermined objective quantitative criterion must simple relevant objective measurable suited corporate strategy criterion must regularly reviewed order avoid adhoc adjustment also necessary pay considerable attention possible threshold effect generated quantitative criterion highly specific circumstance may warrant award extraordinary variable component qualitative criterion must defined precisely variable part qualitative criterion used limit must determined qualitative part allowing applicable exceptional circumstance taken consideration variable compensation must set level balanced relation fixed part variable part maximum percentage fixed part adapted business conducted company predefined board except justified case award variable compensation may restricted executive director event executive director leaf completion term envisaged assessment performance criterion payment variable part compensation must ruled unless exceptional circumstance justified board supplementary information afep medef code 195 implemented article disposition code sartorius stedim biotech 2325 benefit taking position yes isnt benefit benefit taking position may granted new executive taking function director come company outside group case amount must made public determined nocompetition benefit yes executive director context implementation procedure related party post contractual non transaction stipulated law conclusion nocompetition competition obligation agreement must subject substantial reflection compensation accordance german law committee due fact sartorius stedim biotech sa controlled german company obligation last two year director left group time noncompetition clause waived terminated director claim half latest remuneration received company board must authorize conclusion nocompetition agreement length requirement nocompetition amount benefit taking account actual effective scope nocompetition requirement decision board must made public board anticipate conclusion agreement mention allows board cancel agreement director leaf board must announce whether nocompetition agreement upheld time director leaf particular director leaf company claim claime²d pension right event nocompetition payment exceed ceiling two year compensation fixed variable termination benefit also paid aggregate two benefit must exceed ceiling see 2326 supplementary pension scheme mentioned article l137 11 yes supplementary pension social security code senior executive executive director must scheme ae according comply condition prevent abuse responsibility executive director company supplementary pension scheme defined benefit must subject condition beneficiary must director employee company claiming pension right pursuant applicable rule order prevent abuse necessary impose certain additional rule without prejudice scheme closed new beneficiary may altered relevant benefit must taken account overall determination compensation basis general principle stated group potential beneficiary must materially broader sole executive director beneficiary must meet reasonable requirement seniority within company least two year determined board director benefit payment pension plan defined benefit year increase potential right shall progressive relation seniority scheme shall account percentage limited 5 beneficiary compensation progression must described benchmark period taken account calculation benefit must cover several year necessary avoid period artificial increase compensation aimed increasing pension benefit necessary exclude scheme giving right immediately time high percentage total compensation end career 196 supplementary information afep medef code implemented article disposition code sartorius stedim biotech addition information individual potential right particular reference income maximum percentage income supplementary pension scheme would confer must made public percentage may 45 reference income fixed variable compensation thee reference period 24 information executive director compensation awarding policy share option performance share 24 law imposes company obligation disclose yes chairman part management report aggregate compensation benefit type company governance paid financial year executive director well internal control report compiles amount compensation benefit type information non director received financial year company executive executive group director compensation comprehensive information must provided shareholder clear view individual compensation paid executive director also policy applied company order determine compensation paid 241 permanent information yes company applies executive director compensation component whether recommendation potential vested must publicly disclosed immediately meeting board approving relevant decision 242 annual report must include chapter drawn support compensation committee informing shareholder compensation received executive director chapter must contain following detailed presentation policy determination yes company indicates compensation paid executive director particular rule information within part governing award annual variable part without jeopardizing dedicated compensation confidentiality may linked certain element within reference document determining variable part compensation presentation must indicate criterion basis variable part determined manner criterion applied financial year compared initial expectation whether individual director personal target attained must also necessary specify payment variable part partly deferred indicate condition method deferred payment finally must necessary specify rule governing award multiannual variable compensation without jeopardizing confidentiality may justified certain element determining variable part compensation must indicate criterion basis compensation determined payment multiannual variable part made manner criterion applied information concerning pension system commitment provided yes company indicates company taking account considerable variety pension information within part scheme necessary indicate whether executive director benefit dedicated compensation pension scheme group senior executive within reference document benefit specific pension scheme describe main feature scheme particular calculation method detailed presentation executive director individual yes company indicates compensation compared preceding financial year personal compensation also broken fixed component variable component although french commercial code impose obligation appears information relevant shareholder consists connecting variable component financial year respect calculated even though compensation paid following financial year therefore recommended disclose priority basis compensation thee respect financial year show summary table amount thee paid current preceding financial year aggregate individual amount director fee paid director yes company indicates rule allocating fee well rule governing total amount individual payment director fee awarded applicable general attendance fee management team respect corporate office held affiliate group supplementary information afep medef code 197 implemented article disposition code sartorius stedim biotech description policy award stock option yes company indicates beneficiary explaining separately applicable specific information within part award policy applicable executive director particular dedicated compensation necessary indicate nature option purchase subscription within reference document option applicable criterion used define category beneficiary periodicity plan condition approved board regard exercise option dilutive impact option award summary table must show data relevant existing option plan used benchmark document description share award policy applicable employee yes company indicates certain category employee executive director information within part condition applicable criterion determined board dedicated compensation director dilutive impact share award within reference document manner stock option summary table must show data particular number performance share awarded executive director total number share awarded main beneficiary employee group valuation stock option performance share awarded yes company indicates executive director time award accordance information within part method used consolidated financial statement fraction dedicated compensation capital awarded executive director within reference document recommended comply standardized presentation attached schedule hereto director compensation item 243 board must present compensation executive director yes company indicates annual general meeting presentation must cover element information within part compensation due warded end closed financial year dedicated compensation executive director within reference document applies afep medef fixed part recommendation annual variable part necessary multiannual variable part objective contribute determination variable part extraordinary compensation stock option performance share element longterm compensation benefit linked taking terminating office supplementary pension scheme benefit presentation followed advisory vote shareholder recommended shareholder vote one resolution presented chief executive officer chairman management board one resolution deputy chief executive officer member management board ordinary shareholder meeting issue negative opinion board acting advice compensation committee must discus matter another meeting immediately publish company website notice detailing intends deal opinion expressed shareholder general meeting 198 supplementary information glossary glossary industrial productspecific term bioreactor freezethaw technology englishspeaking country bioreactor used vessel technology used controlled freezing thawing cultivating animal human cell culture medium non biological liquid liquid biologics englishspeaking country term also used synonymously fermentor system microorganism membrane chromatography bacteria yeast fungi multiply case vessel selective separation mixture substance adsorption used obtain cell part one metabolite specifically modified membrane membrane adsorbers flowing system capsule readytouse filter unit consisting filter housing hose membrane filter connector incorporated filter cartridge connection thin film foil made polymer porous piping structure film used filtration application crossflow monoclonal antibody term taken filtration technology instead directly synthetic antibody increasingly used flowing filter static filtration liquid flow medical diagnosis treatment perpendicularly filter surface prevents filter blockage resulting longer inservice life filter purification important step downstream processing disposable product single use cf singleuse product recombinant protein protein manufactured using genetically modified organism downstream processing example include pharmaceutical protein insulin collective term various step follow fermentation vaccine cell cultivation production biopharmaceuticals example separation purification concentration scaleup transfer scale increase size term used denote fda food drug administration progression process increase range lab u governmental agency responsible monitoring scale pilot scale process scale retaining food biotechnological medical veterinary technology material construction geometry pharmaceutical product throughout fermentation singleuse product see disposable technical process used produce transform intra extracellular substance help microorganism sterile filter sterilizinggrade filter membrane filter whose pore size usually 02 smaller fluid management technology product processspecific validation test required technology system use handling sensitive biological confirm whether filter type selected delivers sterile filtrate liquid example transportation storage medium sterility test sterility testing test verify sample contains living viable substance validation systematic checking essential step facility research development production including testing pharmaceutical ensure product manufactured made reliably reproducibly desired quality supplementary information glossary 199 business economic term amortization ia international accounting standard amortization relates exclusively potential reduction internationally recognized accounting principle value goodwill allocation purchase price intangible asset acquired carried accordance ifrs international financial reporting standard ifrs 3 internationally recognized accounting principle cash flow investment rate short longterm management liquid fund cash ratio capital expenditure sale revenue balance inflow outflow fund pro forma derivative financial instrument pro forma presentation used annual report mean instrument hedging risk change figure include business generated stedim market price foreign currency consolidated first time june 29 2007 full previous year business generated sartorius stedim ebit plastic gmbh consolidated january 1 2007 full earnings interest tax fiscal year 2007 preceding year ebit margin supply chain management ratio ebit see ebit sale revenue setup coordinated control integrated flow material information finance supply chain entire value ebita added process earnings interest tax amortization related business combination amortization item refers tecdax amortization confirmed connection purchase price german stock index transaction service provider allocation ppa intangible asset acquired specified marketplace organizer deutsche börse ag ifrs3 standard treasury ebita margin short mediumterm liquidity management ratio ebita see ebita sale underlying ebita margin ebitda ratio operating ebita see underlying ebita sale revenue earnings interest tax depreciation amortization underlying ebitda ebitda margin ebitda see ebitda adjusted extraordinary item 2013 ratio ebitda see ebitda sale revenue extraordinary item amounted 49 million previous year 37 million essentially cover onetime expense fixed asset strategic group project integration acquisition related sum intangible asset property plant equipment item financial asset underlying ebitda margin free float ratio operating ebitda see underlying ebitda sale share public company freely available revenue investing public underlying consolidated net profit goodwill profit figure yielded adjustment extraordinary represents difference price paid company item amortization business combination refers business net asset goodwill form intangible exclusively purchase price allocation ppa intangible asset asset acquired according revised ifrs 3 200 supplementary information adresses adresses europe france germany austria sartorius stedim biotech sa sartorius stedim biotech gmbh sartorius stedim austria gmbh zone industrielle le paluds augustspindlerstr 11 modecenterstr 22 avenue de jouques c 91051 37079 goettingen 1030 vienna 13781 aubagne cedex phone 495513080 phone 43179657630 phone 33442845600 fax 495513083289 fax 431796576344 fax 33442845619 infosartoriusstedimcom separationaustriasartoriuscom infosartoriusstedimcom sartorius stedim plastic gmbh belgium sartorius stedim fmt sa karlarnoldstr 21 zone industrielle le paluds 37079 goettingen sartorius stedim belgium nv avenue de jouques c 91051 phone 49551504500 leuvensesteenweg 248b 13781 aubagne cedex fax 495515045050 1800 vilvoorde phone 33442845600 infosartoriusstedimcom phone 3227560680 fax 33442845618 fax 3227560681 infosartoriusstedimcom sartorius stedim system gmbh lindreymensartoriuscom robertboschstraße 5 7 sartorius stedim france sa 34302 guxhagen denmark zone industrielle le paluds phone 4956654070 avenue de jouques c 71058 fax 4956654072200 sartorius stedim nordic 13781 aubagne cedex infosartoriusstedimcom hørskætten 6d phone 33442845600 2630 taastrup fax 33442846545 phone 4570234400 infobiotechfrancesartoriusstedimcom fax 4546304030 infodksartoriusstedimcom sartorius stedim aseptics sa zone industrielle de saux 6 rue ampère hungary 65100 lourdes phone 33562427373 sartorius stedim hungária kft fax 33 562420844 kagyló u 5 infosartoriusstedimcom 2092 budakeszi phone 3623457227 fax 3623457147 ssbsartoriushu supplementary information 201 ireland portugal uk sartorius stedim ireland ltd sartorius stedim spain sa sartorius stedim uk ltd unit 41 business centre cisabel colbrand 10 12 oficina 6970 longmead business centre stadium business park polígono industrial de fuencarral blenheim road ballycoolin road 28050 madrid epsom surrey kt19 9qq dublin 11 phone 800855800 phone 441372737159 phone 35318234394 fax 800855799 fax 441372726171 fax 35318089388 biotech_spainsartoriusstedimcom uksartoriussartoriusstedimcom infoirelandsartoriusstedimcom russia sartorius stedim lab ltd italy unit 6 stonedale road sartorius icr ooo saintpetersburg stonehouse gloucestershire gl10 3rq sartorius stedim italy spa rasstannaya str 2 building 2 letter phone 441453821972 via dellantella 76a 192007 st petersburg fax 441453827928 50012 antella bagno ripoli florence phone 78123275327 alanjohnsonsartoriusstedimcom phone 39055634041 fax 78123275323 fax 390556340526 russiasartoriuscom tab biosystems infoitalysartoriuscom york way spain royston herfordshire sg8 5wy netherlands phone 441763227200 sartorius stedim spain sa fax 441763227201 sartorius stedim nl cisabel colbrand 10 12 oficina 6970 infotapbiosystemscom westblaak 89 polígono industrial de fuencarral 3012 kg rotterdamm 28050 madrid phone 31306025080 phone 34913586091 fax 31306025099 fax 34913589623 officenlsartoriuscom biotech_spainsartoriusstedimcom poland switzerland sartorius stedim poland sp zoo ul wrzesinska 70 sartorius stedim switzerland ag 62 025 kostrzyn ringstrasse 24a phone 48616473840 8317 tagelswangen fax 48618792504 phone 41523543636 biuroplsartoriuscom fax 41523543646 biotechswitzerlandsartoriusstedimcom 202 supplementary information africa north america latin america tunisia usa argentina sartorius stedim bioprocess sarl sartorius stedim north america inc sartorius argentina sa km 24 route de zaghouan 5 orville drive int avalos 4251 bourbiâa bp 87 tunisia bohemia new york 11716 b1605ecs munro phone 21679397014 phone 16312544249 buenos aire fax 21679397019 fax 16312544264 phone 541147210505 infosartoriusstedimcom infosartoriusstedimcom fax 541147622333 sartoriusargsartoriuscom sartorius stedim biotech sarl allpure technology inc km 24 route de zaghouan 80 progress avenue brazil bourbiâa bp 87 tunisia new oxford pa 17350 phone 21679397014 phone 17176243241 sartorius brasil ltda fax 21679397019 fax 17176243051 avenida senador vergueiro 2962 infosartoriusstedimcom salesallpureinccom são bernardo campo cep 09600 004 sp sartorius stedim integrated service sarl tap biosystems phone 551143628900 km 24 route de zaghouan 20 montchanin road fax 551143628901 bourbiâa bp 87 tunisia greenville de 19807 sartoriusbrsartoriuscom phone 21679397014 phone 13024789060 fax 21679397019 fax 1 3024789575 mexico infosartoriusstedimcom infotapbiosystemscom puerto rico sartorius de méxico sa de cv circuito circunvalación poniente 149 sartorius stedim filter inc ciudad satélite carretera 128 int 376 53100 estado de méxico barriada arturo lluveras phone 525555621102 po box 6 fax 525555622942 yauco puerto rico 00698 sartoriusmxsartomexcom phone 17878565020 fax 17878567945 marcoslopezsartoriuscom supplementary information 203 asia pacific china singapore australia sartorius stedim biotech beijing co ltd sartorius stedim singapore pte ltd sartorius stedim australia pty ltd 33 yu road tianzhu airport 1 science park road unit 5 7 11 rodeo drive industrial park zone b 05 08a capricorn dandenong south melbourne shun yi district 101300 beijing singapore science park ii victoria 3175 phone 861080426516 singapore 117528 phone 61387621800 fax 861080426580 phone 6568723966 fax 61387621828 enquirycnsartoriusstedimcom fax 6567782494 infoaustraliasartoriusstedimcom chooleepangsartoriusstedimcom india south korea sartorius stedim india pvt ltd 692 693 jakkasandra sartorius korea biotech co ltd kunigal road 8th floor solid space nelamangala bangalore 562123 220 pangyoyeokro phone 918043505250 bundanggu seongnamsi fax 918043505255 gyeonggido 463 400 biotechindiasartoriuscom phone 82316225700 japan fax 82316225798 infosartoriuscokr sartorius stedim japan kk 4th floor daiwa shinagawa north bldg vietnam 1 8 11 kitashinagawa shinagawaku tokyo 140 0001 sartorius representative office phone 81337405407 unit c 17th floor tower big building fax 81337405406 18 pham hung street infosartoriuscojp dinh tu liem hanoi malaysia phone 84437955587 fax 84437955589 sartorius stedim malaysia sdn bhd sartoriusvnhnvnnvn lot l3 e 3b enterprise 4 technology park malaysia bukit jalil 57000 kuala lumpur phone 60389960622 fax 60389960755 ehtansartoriuscommy address visit website internet wwwsartoriuscom 204 supplementary information local presence worldwide local presence worldwide america bohemia ny usa wilmington de usa new oxford pa usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina sale production production sale supplementary information local presence worldwide 205 europe africa dublin ireland barcelona spain royston uk goettingen germany stonehouse uk guxhagen germany epsom uk poznan poland vilvoorde belgium budapest hungary aubagne france vienna austria lourdes france tagelswangen switzerland florence italy mohamdia tunisia asia paciﬁc beijing china shanghai china seoul south korea tokyo japan hanoi vietnam bangalore india kuala lumpur malaysia singapore singapore melbourne australia 206 supplementary information financial schedule analyst conference sfaf paris france march 5 2015 annual general shareholder meeting aubagne france april 7 2015 payment dividends1 april 14 2015 publication firstquarter figure 2015 april 20 2015 publication firsthalf figure 2015 july 22 2015 publication ninemonth figure 2015 october 20 2015 publication preliminary figure fiscal 2015 january 2016 annual general shareholder meeting aubagne france april 5 2016 publication firstquarter figure 2016 april 2016 1 subject approval annual general shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone 495513081686 phone 495513081668 petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius stedim biotech sa michael konrad gmbh corporate communication frankfurt main germany c 91051 13781 aubagne cedex france photography peter ginter editorial deadline lohmar germany february 18 2015 published february 27 2015 translation original frenchlanguage document de référence 2014 sartorius stedim biotech sa sartorius stedim biotech group reference document 2014 zone industrielle le paluds avenue de jouques c 91051 13781 aubagne cedex france phone 33442845600 fax 33442845619 infosartoriusstedimcom wwwsartoriusstedimcom sartorius stedim biotech group reference document 2014 sartorius stedim biotech sa printed germany publication og0043e141201 order 8600000184